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MISSION STATEMENT 
The mission of the European Medicines Agency is to foster scientific excellence in the evaluation and 
supervision of medicines, for the benefit of public and animal health. 
Legal role 
The European Medicines Agency is the European Union body responsible for coordinating the existing 
scientific resources put at its disposal by Member States for the evaluation, supervision and 
pharmacovigilance of medicinal products. 
The Agency provides the Member States and the institutions of the EU the best-possible scientific advice 
on any question relating to the evaluation of the quality, safety and efficacy of medicinal products for 
human or veterinary use referred to it in accordance with the provisions of EU legislation relating to 
medicinal products. 
Principal activities 
Working with the Member States and the European Commission as partners in a European medicines 
network, the European Medicines Agency: 
 provides independent, science-based recommendations on the quality, safety and efficacy of 
medicines, and on more general issues relevant to public and animal health that involve medicines; 
 applies efficient and transparent evaluation procedures to help bring new medicines to the market by 
means of a single, EU-wide marketing authorisation granted by the European Commission; 
 implements measures for continuously supervising the quality, safety and efficacy of authorised 
medicines to ensure that their benefits outweigh their risks; 
 provides scientific advice and incentives to stimulate the development and improve the availability of 
innovative new medicines; 
 recommends safe limits for residues of veterinary medicines used in food-producing animals, for the 
establishment of maximum residue limits by the European Commission; 
 involves representatives of patients, healthcare professionals and other stakeholders in its work, to 
facilitate dialogue on issues of common interest; 
 publishes impartial and comprehensible information about medicines and their use; 
 develops best practice for medicines evaluation and supervision in Europe, and contributes alongside 
the Member States and the European Commission to the harmonisation of regulatory standards at the 
international level. 
Guiding principles 
 We are strongly committed to public and animal health. 
 We make independent recommendations based on scientific evidence, using state-of-the-art 
knowledge and expertise in our field. 
 We support research and innovation to stimulate the development of better medicines. 
 We value the contribution of our partners and stakeholders to our work. 
 We assure continual improvement of our processes and procedures, in accordance with recognised 
quality standards. 
 We adhere to high standards of professional and personal integrity. 
 We communicate in an open, transparent manner with all of our partners, stakeholders and colleagues. 
 We promote the well-being, motivation and ongoing professional development of every member of 
the Agency. 
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FOREWORD BY THE CHAIR OF THE MANAGEMENT BOARD 
Pat O’Mahony 
I am very pleased to introduce the EMEA annual report for 2007. The summaries of activities presented 
here reflect the excellent performance of all EMEA staff and national competent authority experts. 
My role as Chair of the Management Board commenced in June, following my election by the members. It 
is a great honour to be appointed to this post and I look forward to working with the members and all 
partners to advance the important work we undertake on behalf of citizens. I succeeded Professor Hannes 
Wahlroos, who had so successfully chaired the Management Board for the previous three years. I would 
like to express my deep gratitude, and that of the entire network, to Hannes for his important contribution, 
which is greatly appreciated. 
The mission of the EMEA is to foster scientific excellence in the evaluation and supervision of medicines 
for the benefit of public and animal health, and all that we do collectively is focused to that end. 
Throughout 2007, the EMEA worked in close cooperation with others in the European medicines network, 
in particular in the area of risk-management, which is so fundamental to our consumer-protection role. 
Other areas of cooperation included the development of telematics and discussion on common resource 
and competence planning. 
The EMEA experienced yet another year of increases in all of its areas of activity. The new paediatric 
legislation was successfully implemented, and a new scientific committee was established to oversee the 
performance of new tasks for the Agency and for the network. 
The Agency made a substantial contribution in the area of research and development through the work of 
the EMEA/CHMP think-tank on innovative drug development and through the support given to the 
Innovative Medicines Initiative. 
The Agency also contributed to the availability of a number of new medicines on the market, including 
new chemical entities and similar biological and generic medicines. 
I would like to express my gratitude to the Executive Director and all EMEA staff for their commitment 
and excellent contribution during the year. I would like to thank the members of all the scientific 
committees and working parties for their hard work, and also to thank the staff of the European 
Commission for their ongoing support. 
I look forward to continued progress and success in 2008. 
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INTRODUCTION BY THE EXECUTIVE DIRECTOR 
Thomas Lönngren 
I am pleased to report that the European Medicines Agency once again made a strong contribution to EU-
wide efforts in support of making high-quality, safe and effective medicines available for use in human 
and animal populations. 
In this, the thirteenth year of its operation, the EMEA delivered a strong performance in its core activity 
areas relating to the evaluation and supervision of medicines, while also pursuing with good results its 
broader mandate to stimulate innovation within the EU and contribute to European and global cooperation 
on scientific and regulatory practices in the field of medicines. 
An important indicator of the EMEA’s activity during any year is the number of applications it receives 
and processes for the initial marketing authorisation of medicinal products. In 2007, the Agency received 
90 such applications relating to medicines for human use and 15 for veterinary medicines. The number for 
human medicines is higher than in any previous year, and the number of opinions adopted by the 
Agency’s Committee for Medicinal Products for Human Use (CHMP), at 65, was also the highest ever 
recorded. 
The public-health benefit behind these figures is that many new medicines to treat a range of diseases and 
conditions – from cancers to cardiovascular and neurological disorders – are now available for the 
treatment of Europe’s patients. Similarly, new veterinary prevention and treatment options are now 
available for Europe’s food-producing and companion animals. Notably, given recent attention paid in the 
media to the risk of a bird-flu pandemic, two vaccines against avian influenza were made available for use 
in poultry. 
Perhaps the most tangible and significant achievement of 2007 was the Agency’s successful introduction 
of new procedures and creation of a new scientific committee dedicated to implementing the EU’s 
Paediatric Regulation, which came into force on 26 January. With the foundation of this new legislative 
framework and the EMEA’s operation of it, children across Europe will begin to benefit from medicines 
that are developed with their specific needs and best interests at heart. 
The Paediatric Committee – the Agency’s fifth scientific committee – was launched with great enthusiasm 
in July of this year, and immediately began to elaborate scientific and procedural arrangements for the 
assessment of paediatric investigation plans and related regulatory instruments. 
This year also saw Bulgaria and Romania welcomed into the EU family of nations, and they were quickly 
integrated into the work of the EMEA as full members of the European medicines network, while 
preparatory work to integrate Croatia and Turkey was also conducted in advance of these countries’ 
possible accession to the EU. 
Within the existing network, the EMEA worked closely with Member State national competent authorities 
on activities intended to improve the efficiency of the use of available resources and to secure the long-
term availability of appropriate scientific expertise. This latter is particularly necessary given the 
increasing complexity of evaluation procedures and the advent of advanced therapies and other new 
technologies in the medical domain. 
Activities in the area of supporting innovation and improving access to medicines yielded some very 
positive results in 2007. The initial success of the EMEA’s SME Office seen in 2006 was reconfirmed this 
year, with Europe’s smaller innovative companies demonstrating a keen interest in the dedicated support 
on offer to them from the EMEA. Interest in the Agency’s provision of scientific advice and protocol 
assistance also continued to be high, with demand increasing for the third year in a row. 
Further support for increased availability of medicines was also generated through the Agency’s high 
output in relation to medicines for rare diseases – with more positive opinions being adopted in favour of 
orphan designation than in any previous year – and through the continuing work of the Agency’s 
Innovation Task Force and Think-tank on innovative drug development, as well as through its support for 
the European Commission’s Pharmaceutical Forum and Innovative Medicines Initiative. Likewise, 
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innovation and availability remained high priorities in the veterinary area, with input being given from the 
Agency to the Heads of Medicines Agencies (HMA) action plan to promote the availability of veterinary 
medicines and to the European Technology Platform for Global Animal Health, as well as to the further 
development of measures to assist companies seeking to authorise products for limited markets. The 
EMEA also supported the Commission in its work to develop the new Regulation on Advanced Therapies, 
which was published in December and which will usher in further new responsibilities for the Agency in 
2008. 
The EMEA’s cooperation with global partner organisations continued apace in 2007, with the Agency 
playing an active role in the International Conferences on Harmonisation (ICH and VICH); working 
closely with the World Health Organization, in particular on issues relating to medicines for developing 
countries; consolidating its information-exchange programme with the US Food and Drug Administration 
in relation to human and veterinary medicines; and signing confidentiality arrangements to allow closer 
cooperation between the EMEA, the European Commission and the Japanese authorities on regulatory 
issues concerning medicines. 
Cooperation among EU Agencies was intensive too, with the EMEA engaging in activities with the 
European Centre for Disease Prevention and Control, in particular in relation to pandemic-influenza 
preparedness and advanced therapies; with the European Food Safety Authority; with the European 
Monitoring Centre for Drugs and Drug Addiction; and with the European Directorate for the Quality of 
Medicines and HealthCare. 
On an organisational level, the EMEA conducted elections of chairs and vice-chairs for four of its 
scientific committees, including the new Paediatric Committee, and of a new chair for its Management 
Board. The Agency also progressed well with its development and maintenance of information-technology 
services, as well as with its programme to enhance the participation of patients and healthcare 
professionals in EMEA activities. 
In summary, 2007 was a very productive year with intense activity in many areas, as you will note when 
you read the detail of this annual report. For their hard work and dedication throughout the year, I express 
my deep gratitude to all members of the EMEA staff, as well as to all the experts and colleagues of the 
Member State national competent authorities and our partners at the European Commission and European 
Parliament who have contributed greatly to another successful year for the EMEA. 
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1. EMEA IN THE EUROPEAN SYSTEM 
1.1 Management Board 
In 2007, the EMEA Management Board: 
 Adopted the Agency’s work programme, budget and establishment plan for the year 2008 
 Conducted an analysis of the Executive Director’s annual activity report 
 Provided an opinion on the Agency’s final accounts 
 Adopted the Agency’s annual report for 2006. 
 Re-nominated the majority of Board members in May 2007, following expiry of the three-year 
mandate. At its June 2007 meeting, the Board elected Pat O’Mahony as Chair and Lisette Tiddens-
Engwirda as Vice-chair. 
 
1.2 European medicines network 
The European medicines network, a partnership of more than 40 medicines regulatory authorities in the 
European Union (EU), is the basis of the EMEA’s success. The network gives the EMEA access to a pool 
of more than 4,000 experts, allowing the Agency to source the best-available scientific expertise for the 
regulation of medicines in the EU. Experts participate in the work of the EMEA as members of the 
scientific committees, working parties, scientific advisory groups and related groups. 
 Bulgaria and Romania joined the EU on 1 January 2007. The transition from observer status to full 
participation in the European medicines network and in the work of the Agency was facilitated as a 
result of careful preparations. 
 In view of the possible accession of Croatia and Turkey to the EU, the Agency organised a conference 
in each of these countries to prepare the groundwork for their potential future integration into the 
European medicines network. 
 Resources in the network are scarce and work began to develop planning processes leading to 
improved use and better efficiency of the available resources. 
− EMEA participated in the planning process at the level of the Heads of Medicines Agencies 
(HMA). 
− The EMEA started an exercise to improve the organisation of working parties, aimed at achieving 
more efficient meetings and a better distribution of tasks to the members of the scientific 
committees and their working parties. 
− Vitero-based audioconferencing was introduced for some meetings, reducing the need for experts 
to travel to the EMEA. 
 In light of the growing complexity of evaluation procedures, and the advent of emerging therapies and 
new technologies, the EMEA continued to extend the involvement of scientific experts and 
stakeholders in its work. 
− The Agency held a number of workshops and conferences to address critical scientific areas, 
involving academia, regulatory authorities and, where appropriate, pharmaceutical industry. 
Topics covered included: first-in-man clinical trials, biosimilars, immunogenicity of therapeutic 
proteins, adaptive design in confirmatory clinical trials, process analytical technology for 
biological medicinal products, and cell- and tissue-engineered products. 
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− The Agency also organised a number of training sessions for assessors from the national 
competent authorities. Topics covered included: gene therapy products, diagnostics, oncology 
development, new approaches to quality assessment, and influenza pandemic. 
− Principles and processes for advanced education exchanges between regulatory authorities, 
academia and, where appropriate, industry were established. As a result of this, the Agency held 
regular contacts with relevant learned societies, in particular in the areas of cardiology, diabetes, 
central nervous system and oncology. 
− With a view to participating in educational programmes for regulatory scientists, in conjunction 
with academia and the national competent authorities, the EMEA contributed to the initiative 
started by Italy for a European school for regulatory assessment of medicines. 
 Experts from academia and university hospitals on secondment to the EMEA contributed to the work 
of the European medicines network, ensuring the availability of complementary expertise. 
 The Agency successfully organised a conference with a wide range of stakeholders to examine the 
operation of the Clinical Trials Directive after three years of operation, and published a report on the 
outcome. 
 
1.3 Transparency and communication 
In 2007, the Agency’s activities in relation to transparency and communication concentrated on the 
consolidation of its existing activities. 
 Good progress was made with the implementation of the Agency’s rules on access to documents. A 
functioning internal system is now in place to handle the increasing demand for access to documents. 
More information about activities in relation to access to documents can be found in section 6.4. 
 Further improvements were made in relation to the provision of information on medicines. Some 
highlights include: the systematic publication of assessment reports for withdrawn or refused 
marketing-authorisation applications; the publication of press releases and question-and-answer 
documents to provide better information in cases where there were safety concerns with medicines; 
the provision of product-related information in all EU languages. More information about activities in 
relation to the provision of information about medicines can be found in section 2.10. 
 Representatives of patients’ organisations and healthcare professionals were actively involved in and 
made valuable contributions to a number of EMEA activities. More information about the work of the 
EMEA with patients’ organisations and healthcare professionals can be found in section 2.10. 
 
1.4 Support for innovation and access to medicines 
The Agency remained committed to the objectives of the Lisbon agenda. 
Recognising that micro, small and medium-sized enterprises (SMEs) are often a motor for innovation, in 
particular in the field of new technologies and emerging therapies, the EMEA’s SME Office continued to 
implement the policy to support SMEs. 
 The number of companies requesting SME status in 2007 was 212, exceeding the forecast by more 
than 50%. 
 The number of companies assigned SME status was 172, bringing the total number of companies with 
assigned SME status up to 246 at the end of 2007. Of the assigned companies, the majority are 
developing medicinal products for human use, 9 are veterinary companies, 8 are developing medicinal 
products for human and veterinary use, and 19 are regulatory consultants. 
 A total of 81 applications for fee reduction or deferrals were received – 70% over forecast. 
 A total of 66 fee-reduction or deferral requests were granted. 
 
EMEA annual report 2007 
EMEA/MB/17464/2008 2.4, CURRENT 
Page 10/138 
 A total of 47 requests for administrative assistance were received – over three times more than the 
initial forecast. 
 Two SMEs benefited from translation support for the product information of their medicines. 
 The EMEA provided guidance and training for SMEs. 
−  The SME User Guide was updated in 2007 to reflect the experience gained during the course of 
2006. 
−  A news bulletin for SMEs was initiated in 2007. 
−  The first SME workshop was held on 2 February 2007. 
 The Agency further facilitated electronic reporting of adverse drug data by SMEs through the 
EudraVigilance system (EudraVigilance web-based system). This was achieved by providing training 
for SMEs at the EMEA and by providing free access to the system, thus allowing SMEs to fulfil their 
pharmacovigilance reporting obligations. Twelve training courses took place during the course of 
2007. 
−  The first workshop on analysis of data in the Eudravigilance Veterinary datawarehouse was held. 
 In addition to the other EMEA core activities relating to stimulation of innovation – such as the 
provision of scientific advice to companies developing medicinal products, support to the orphan 
medicinal products policy, and the activities of the EMEA Innovation Task Force (ITF) – the Agency 
participated in the Innovative Medicines Initiative, which aims to address bottlenecks in the 
development of medicines. 
 In the context of the 7th Framework Programme, the EMEA worked with the Directorate-General 
(DG) Research of the European Commission to define project objectives in the field of rare diseases 
and collaborated on calls in the field of medicines for children. 
 The final report from the EMEA/CHMP think-tank group on innovative drug development, titled 
‘Innovative Drug Development Approaches’, was published in 2007. The work of the think-tank 
focused on identifying scientific bottlenecks and emerging science in the development of medicines – 
both in industry’s R&D and in the academic environment – and on generating recommendations for 
future EMEA actions. 
 The EMEA and its Committee for Medicinal Products for Veterinary Use (CVMP) maintained priority 
measures aimed at improving the availability of veterinary medicines, which are detailed in section 
3.2.2. 
 The EMEA was a member of the Steering Committee of the European Technology Platform for 
Global Animal Health, which aims to accelerate the development of novel animal-health products, for 
both major and minor markets, within the context of the 7th Framework Programme. The Agency 
participated in the preparation of the Action Plan that was released in August 2007 to implement the 
Strategic Research Agenda. 
 
1.5 European public-health activities 
 The EMEA worked closely with the European Commission and other EU bodies on the preparation of 
the new legislation on advanced therapy medicinal products. The final text of Regulation (EC) No 
1394/2007 was adopted on 13 November 2007. 
 Patients’ and consumers’ organisations became involved in the review of Package Leaflets at the time 
of renewal of a medicinal product and in the preparation of the EPAR summaries aiming at providing 
quality information to patients. 
 The development of a database on biological warfare agents and treatment/prevention options was 
completed in 2007. The database is expected to be rolled out during the first half of 2008. 
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 The Agency continued its activities to maintain readiness for a potential influenza pandemic. As part 
of this, the Agency organised trainings for assessors and staff on the assessment procedures for 
pandemic-influenza vaccines. 
 Availability of effective vaccines for control of avian influenza in birds is a key measure to reduce the 
likelihood of a pandemic in man. The Agency adopted positive opinions for two vaccines against 
avian influenza in birds. 
 The Agency developed a procedure for sharing of information between the Committee for Medicinal 
Products for Human Use (CHMP) and the Committee for Medicinal Products for Veterinary Use 
(CVMP) in relation to initiatives for complementary activities in the field of zoonosis (any disease that 
can be transmitted to humans from animals). In this context, a revision of the joint CHMP/CVMP 
‘Note for guidance on minimising the risk of transmitting animal spongiform encephalopathy agents 
via human and veterinary medicinal products’ is ongoing. 
 The EMEA continued its contribution to the work of the European Commission’s Pharmaceutical 
Forum, particularly in the working group on added therapeutic value and on information for patients. 
 The Agency continued to participate in activities in support of the EU programme to reduce the use of 
animals in testing of medicines and develop other modern approaches to safety-assessment of 
medicines. 
−  The Agency participated in the European Partnership for Alternative Approaches to Animal 
Testing, a joint Commission/industry initiative which has the intention to promote the 
development of new ‘3R’ methods (refine, reduce, replace) as modern alternative approaches to 
safety-testing. 
−  The CVMP completed a review by its working parties of the use of animals in regulatory testing 
of veterinary medicinal products and will reflect on the scope for further application of the ‘3Rs’ 
during 2008. 
 The CVMP maintained as a high priority its work to minimise the risk of development of 
antimicrobial resistance through the use of antibiotics in animals, developing guidance on post-
authorisation monitoring and the use of fluoroquinolones. 
 The CVMP produced guidance on how applicants should meet the technical requirements of VICH 
guidelines on environmental risk-assessment (ERA) and assisted the Commission with the production 
of guidance on meeting the legal requirements of Directive 2001/82/EC with respect to ERA. 
 Cooperation continued with the European Centre for Disease Prevention and Control (ECDC), in 
particular in relation to pandemic-influenza preparedness, advanced therapies and biological warfare 
agents. 
 The EMEA and the European Centre for Disease Control and Prevention (ECDC) made preparations 
for the establishment of a joint working group to produce a technical report setting out the medical 
needs in the area of antimicrobial resistance – an initiative arising from the EMEA-CHMP think-tank 
report. 
 Further cooperation continued with the European Food Safety Authority (EFSA), in particular on 
genetically modified organisms, with the European Monitoring Centre for Drugs and Drug Addiction 
(EMCDDA), and with the European Directorate for the Quality of Medicines and HealthCare 
(EDQM). 
 
1.6 Preparations for future enlargement 
 The Agency organised conferences in Croatia and Turkey to prepare the groundwork for the possible 
accession of these two countries to the European Union. The conferences were held in the context of a 
multi-beneficiary programme dedicated to supporting the participation of Croatia and Turkey in 
certain Community agencies. 
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1.7 International cooperation 
These activities cover cooperation at international level, namely: coordination of EU experts’ participation 
in the International Conference on Harmonisation (ICH and VICH); work with the World Health 
Organization, including on medicinal products for use in developing countries; the Codex Alimentarius; 
the World Organisation for Animal Health (OIE); and work with the US Food and Drug Administration 
(FDA), the US Department of Agriculture (USDA) and Health Level 7 (HL7). 
 Within the ICH framework, the EMEA was rapporteur for ICH M5 EWG (Data elements and 
Standards for Drug Dictionaries) and EU Topic Leader for ICH E2B (Clinical Safety Data 
Management: Data Elements for Transmission of Individual Case Safety Reports). The EMEA also 
provided input on behalf of the Eudravigilance Expert Working Group (EV-EWG) to the topic ICH-
M1 (Medical Dictionary for Drug Regulatory Activities (MedDRA)) and contributed as editor to the 
ICH Rapporteur for ISO Task Force 215, Work Group 6 (Pharmacy and medication). In addition, the 
EMEA participated in the working groups of the Council for International Organizations of Medical 
Sciences (CIOMS) on signal detection, vaccines and Standardised MedDRA Queries (SMQ). 
 Confidentiality arrangements were signed between the European Commission, the EMEA, the 
Japanese Ministry of Health, Labour and Welfare (MHLW) and the Japanese Pharmaceuticals and 
Medical Devices Agency (PMDA) at a bilateral meeting in Tokyo held in February 2007. 
 Confidentiality arrangements were also signed between the European Commission, the EMEA and the 
Health Products and Food Branch of Health Canada at a bilateral meeting in Brussels held in 
December 2007. 
 The Agency’s cooperation with the US Food and Drug Administration (FDA) was strengthened in 
accordance with the revised EU/FDA Confidentiality Arrangements Implementation Plan. 
 The Agency also provided scientific support to the Commission on EU cooperation with India, in 
particular in the area of traditional herbal medicinal products. Representatives from the Commission 
and the EMEA, including from the Agency’s Committee on Herbal Medicinal Products (HMPC), 
participated in a fact-finding mission to India with a view to explore technical issues concerning the 
potential application of the EU legal framework for traditional herbal medicinal products to Ayurvedic 
products. 
 The Agency continued to promote the effective operation of mutual-recognition agreements (MRAs) 
with Australia, New Zealand, Switzerland, Canada and Japan. 
1.8 Integrated management at the Agency 
 The Agency continued the process-improvement exercise it begun in 2006. The objective of the 
exercise is to optimise key processes of the Agency, improve cost-effectiveness of the Agency’s 
operations, improve performance, and achieve higher satisfaction of its stakeholders. Improvement 
actions that were identified have started to be implemented and the process is expected to continue 
into 2008. 
 A programme of 11 internal audits was carried out in 2007, looking at key processes such as 
procurement, information technology, outsourcing of infrastructure services, the functioning of orphan 
product designation and of the Committee on Orphan Medicinal Products (COMP), Quality Review of 
Documents, management and running of the Veterinary Unit, and processing of access-to-documents 
requests. 
 The level of implementation of standards for internal control, as well as the overall effectiveness of 
the Agency’s IQM system, was reviewed. A number of improvement actions were proposed and 
implementation of some of them started in 2007. 
 The Agency introduced an environmental policy for its internal and external operations. As part of the 
policy, the EMEA endeavours to conduct procurements giving priority, where possible, to 
environment-friendly products, and is introducing various environment-friendly practices across the 
Agency. 
2. MEDICINES FOR HUMAN USE 
2.1 Orphan medicinal products 
Orphan medicinal products are intended for the diagnosis, prevention or treatment of life-threatening or 
chronically debilitating conditions affecting not more than five in 10,000 persons in the European Union, 
or where for economic reasons such medicines would not be developed without incentives. 
2.1.1 Core activities 
Orphan designation 
 For the fourth consecutive year, more than one hundred applications were received for the designation 
of orphan medicinal products: a total of 125 applications were submitted. 
 The number of withdrawn applications (19) was the lowest in the past seven years. 
 The Committee for Orphan Medicinal Products (COMP) adopted 97 positive opinions – the highest 
number ever – and one negative opinion. 
 As in previous years, cancer treatment was the most-represented therapeutic area for which the COMP 
adopted positive orphan-designation opinions. 
 Almost half of the positive opinions for orphan designation were for conditions affecting children. 
 The average time taken by the COMP to evaluate applications was 65 days, slightly higher than in the 
previous two years. 
Orphan medicinal product designation procedures (2005 - 
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Designated orphan medicinal products for the treatment of 
children and adults (2005-2007)
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Performance indicators 
Performance indicator Target Outcome 2007 
Percentage of applications 
evaluated within the 90-day 
timeline 
100% of applications 98% 
Percentage of summaries of 
COMP opinions published within 
1 month of the European 
Commission’s decision on 
designation 
70% of summaries of opinion 27%. This was because effort 
focused on clearing the backlog 
from 2006 which was created due 
to staff shortages 
Number of COMP guidelines 
released or revised on topics as 
planned 
80% 100%. All COMP guidelines 
were released or revised as 
planned 
 
EU special contribution for orphan medicines 
 A total of €4.89 million from the EU special contribution was used to grant fee reductions for orphan 
medicines in 2007. 
 The Agency amended its policy on fee reductions for orphan medicines in 2007 to continue to focus 
on incentives to support protocol assistance, marketing-authorisation applications and other pre-
authorisation activities, and to support SMEs in the first year after granting of a marketing 
authorisation. 
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Use of EU special contribution for orphan medicines  (2007)
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2.1.2 Specific objectives in 2007 
 Work to integrate global development for orphan medicinal products in collaboration with the US 
Food and Drug Administration (FDA) is ongoing. 
−  The European Commission, EMEA and FDA adopted a common application form for sponsors 
seeking orphan designation of medicines in the EU and USA in December 2007. This initiative 
aims at simplifying the process of obtaining orphan status for medicines intended for rare diseases 
in both jurisdictions. 
−  No requests for parallel advice for protocol assistance with the FDA were received in 2007. 
2.2 Scientific advice and protocol assistance 
The Agency provides scientific advice and protocol assistance to sponsors during the phase of research 
and development of medicinal products. Scientific advice is provided on any aspect of research and 
development relating to quality, safety or efficacy of medicinal products. In addition, the Agency provides 
advice to sponsors of designated orphan medicines in the form of protocol assistance, which can include 
advice on the significant benefit of a product. 
Scientific advice and protocol assistance are key areas of activity for the Agency, in particular with respect 
to fostering new innovative technologies and therapies. The Agency considers scientific advice as a means 
to facilitate and improve earlier availability of medicinal products to patients and healthcare professionals, 
and as a means to promote innovation and research. 
2.2.1 Core activities 
 Interest in scientific advice and protocol assistance from the EMEA remains high. 213 requests for 
scientific advice were received in 2007. 
 A marked increase in the number of requests for protocol assistance was registered in 2007, with 17% 
more requests received than in 2006. 
 As in previous years, the Agency and the Scientific Advice Working Party (SAWP) have yet again 
shortened the timelines for the delivery of scientific advice. 
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Scientific-advice and protocol-assistance requests received 
(2005-2007)
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Scientific-advice and protocol-assistance requests finalised 
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Mean duration of scientific-advice procedures in days (2005-
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Scientific-advice requests by topic (2007)
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Scientific-advice requests by product type (2007)
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Scientific-advice requests by therapeutic area (2007)
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2.2.2 Specific objectives in 2007 
 Review of scientific-advice and protocol-assistance procedures with a view to improving them for the 
benefit of fostering innovation in all procedures is ongoing. 
−  A questionnaire, developed together with EFPIA, was distributed to users of scientific-advice and 
protocol-assistance procedures. 
−  A procedure was set up to ensure effective coordination between the Scientific Advice Working 
Party (SAWP) and the Paediatric Committee (PDCO). 
 In the context of the European Risk Management Strategy, the EMEA considers the risk-management 
plans early on in a medicine’s lifecycle. Changes were introduced to the scientific-advice/protocol-
assistance procedure to prepare for risk-management plans. 
 
EMEA annual report 2007 
EMEA/MB/17464/2008 2.4, CURRENT 
Page 17/138 
 
EMEA annual report 2007 
EMEA/MB/17464/2008 2.4, CURRENT 
Page 18/138 
Performance indicators 
Performance indicator Target Outcome 2007 
Scientific-advice and protocol-
assistance requests evaluated 
within the procedural timelines 
100% of requests 99.7% 
Percentage of pre-submission 
meetings for orphan and non-
orphan products 
60% of protocol assistance and 
80% of scientific advice 
respectively 
41% of protocol assistance and 
33% of scientific advice 
External experts involved in 
procedures 
at least 70% of scientific-advice 
and protocol-assistance requests 
53% 
Percentage of marketing-
authorisation applications for 
new technology products having 
received scientific 
advice/protocol assistance 
50% of applications 50% 
 
2.3 Initial evaluation 
Initial evaluation covers activities relating to the processing of applications for medicinal products 
(orphan, non-orphan, similar biological (biosimilar), generic, etc.) from pre-submission discussion with 
future applicants, through evaluation by the CHMP, to the granting of a marketing authorisation by the 
European Commission. These activities culminate in the production of the European public assessment 
report (EPAR). Applications for certification of compliance with Community legislation of plasma master 
files (PMF) are processed in a similar manner but without the production of an EPAR. Opinions are also 
provided on ancillary medicinal substances and blood derivatives used in medical devices. The Agency 
provides regulatory advice to industry during pre-submission meetings.  
2.3.1 Core activities 
New applications 
 The total number of new applications was higher than in any other year. However, the number of 
initial applications by active substance, i.e. without double applications, was 19% lower than in 2006. 
 Applications for new products for use in the treatment of cancer once again represented the highest 
proportion by therapeutic area in 2007. Neurology and the central nervous system followed by anti-
infectives were the next most-represented therapeutic groups. 
 The number of marketing-authorisation applications for orphan designated medicines was lower than 
in 2006 but close to the 7-year average since the introduction of orphan legislation. 
 With the legal and regulatory framework for similar biological medicines now firmly established, 10 
applications for these were received in 2007. 
 One application was received for a scientific opinion on medicinal products intended for non-EU 
markets. 
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Initial-evaluation applications by type of application (2005-2007)
26
47
59
15
18
11
4
109 10
2 1 1
0
10
20
30
40
50
60
70
2005 2006 2007
New medicinal products (non-orphan) Orphan medicinal products
Similar biological products Generics, hybrid products, etc.
Scientific opinions for non-EU markets  
 
Initial marketing-authorisation applications per therapeutic area 
(2007)
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Opinions 
 In 2007, the EMEA’s Committee for Medicinal Products for Human Use (CHMP) adopted 58 positive 
opinions on initial-evaluation applications, the highest number ever. 
 Seven out of the total number of 65 opinions adopted were negative, recommending that the 
marketing authorisation for these medicines be refused. 9 applications were withdrawn. 
 The highest number of positive opinions adopted was for cancer products, followed by anti-infectives 
and alimentary-tract products. 
 Two positive opinions were adopted for medicines that were reviewed under accelerated assessment. 
 Three opinions were adopted recommending granting of a conditional marketing authorisation. 
 Four opinions were adopted recommending granting of a marketing authorisation under exceptional 
circumstances. 
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 The first ‘live’ marketing-authorisation application using the PIM (product information management) 
system was successfully finalised with the adoption of a positive CHMP opinion in July 2007. PIM 
increases the efficiency of the management and exchange of product information by all parties 
involved in the evaluation process, using electronic means. In addition, it helps improve the quality 
and consistency of the published product information. 
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Public-health benefits of medicines recommended for authorisation in 2007 
 
Medicines of notable public-health interest that received a positive opinion from the CHMP in 2007 
included: 
 A designated orphan medicinal product intended to reduce haemolysis (destruction of red blood cells) 
in patients with paroxysmal nocturnal haemoglobinuria (PNH), a rare blood disorder in which the red 
blood cells are destroyed more rapidly than normal, causing the urine to turn dark. This was the first 
medicine for which an accelerated assessment procedure was concluded successfully. It was also the 
first medicine submitted by a company benefiting from incentives for SMEs. 
 A second vaccine for prophylaxis against high-grade cervical intraepithelial neoplasia (CIN grades 2 
and 3) and cervical cancer causally related to human papilloma virus (HPV) types 16 and 18. 
 A medicine belonging to a new class of antiretrovirals (CCR5 inhibitors) that reduce the amount of 
HIV in plasma (viral load) and increase the number of T cells (specifically CD4 cells) in heavily 
experienced patients with CCR5-tropic HIV-1, when used in combination with other anti-retroviral 
medicines. 
 Two mock-up pandemic-influenza vaccines intended for the prevention of influenza during an 
officially declared pandemic situation. Marketing authorisations under exceptional circumstances 
were granted subject to certain specific obligations to be reviewed annually. (A mock-up pandemic 
vaccine is not intended for stockpiling, but can be used to speed up the availability of a final vaccine 
in the event of a pandemic, once the pandemic strain has been identified.) 
 A medicine with a chemical structure resembling that of thalidomide. It is approved in multiple 
myeloma, where it works by blocking the development of tumour cells and by stimulating some of the 
specialised cells of the immune system to attack the cancerous cells. 
 The first two dipeptidyl peptidase 4 (DPP-IV) inhibitors, both indicated for type II diabetes. They 
work by blocking the breakdown of incretin hormones in the body, thereby stimulating the pancreas to 
produce insulin when blood-glucose level is high, and also decreasing the levels of the hormone 
glucagon. They bring about a reduction in blood-glucose levels and help to control type II diabetes. 
 The first renin inhibitor indicated for treatment of hypertension. It blocks the activity of renin, an 
enzyme which is involved in the production of angiotensin I that is subsequently converted into the 
hormone angiotensin II, a powerful vasoconstrictor (it narrows blood vessels and consequently raises 
the blood pressure). By blocking the production of angiotensin I, levels of both angiotensin I and 
angiotensin II fall. 
 A medicinal product for the treatment of metastatic carcinoma of the colon or rectum after failure of 
oxaliplatin- and/or irinotecan-containing chemotherapy regimens. 
 A medicinal product for the treatment of patients with advanced soft-tissue sarcoma (namely 
liposarcoma and leiomyosarcoma), after failure of anthracyclines and ifosfamide, or who are unsuited 
to receive these agents. 
 An antidote medicinal product used for treating cyanide poisoning. 
2.3.2 Specific objectives for 2007 
 Review of the outcome of the first year from implementation of new procedures contributing to 
availability of medicines and their safe use (including procedures reducing regulatory times and those 
dealing with risk-management plans) was completed. 
− Preparations for a monitoring system were made. 
− An assessment of procedures for early access to medicines was completed. 
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 Re-engineering exercise of the processes for the pre-authorisation phase of marketing authorisation 
and PMF certification, and reinforcement of scientific-secretariat input from pre-filing to opinion, are 
ongoing. 
− Following review of its processes from the pre-filing stage through to the adoption of the opinion, 
EMEA prepared improvement plans which are currently under discussion. 
− A system was piloted for reviewing scientific-advice requests in order to strengthen the link 
between scientific advice and the initial-evaluation phase. 
− A process for the rolling review of defined packages of applicants’ responses to lists of questions 
will be developed as part of the EMEA-CHMP think-tank plan. 
 Development and improvement of the peer-review process advanced well. 
− A pilot peer-review was successful: all new marketing-authorisation applications, including 
similar biological medicinal products, generics and influenza vaccines, were peer reviewed in 
2007. The pilot phase was extended to 2008. 
− The Biologics Working Party peer-reviewed quality aspects of marketing-authorisation 
applications for biologics. 
 There was further extension of the use of the European medicines network in the areas of advanced 
therapies through the establishment of specialised contact points in national competent authorities. 
 
Performance indicators 
Performance indicator Target Outcome at end of 2007  
Percentage of applications 
evaluated within regulatory 
timeline of 210 days 
100% compliance 100% 
Percentage of accelerated-
assessment applications 
evaluated within regulatory 
timeline of 150 days 
90% compliance 100% 
Percentage of marketing-
authorisation applications 
including risk-management plans 
(RMP) peer reviewed by the 
EMEA as part of the assessment 
of the initial marketing-
authorisation application 
80% of applications that include 
an RMP 
92% 
Percentage of opinions sent to the 
European Commission within the 
regulatory timeline of 15 days 
95% compliance 98% 
Number of opinions for 
compassionate use given by 
procedural deadline 
80% compliance None received in 2007 
Percentage of plasma-master-file 
applications evaluated within the 
regulatory timeline 
100% of applications 100% 
 
2.4 Post-authorisation activities 
Post-authorisation activities relate to variations, line extensions and transfers of marketing authorisations. 
Variations to marketing authorisations can be either minor (type-IA or IB) or major (type-II) changes. 
These variations concern quality- and (non-)clinical-related aspects, including extensions of indications. 
2.4.1 Core activities 
 The number of applications for variations and line extensions of marketing authorisations continues to 
rise. A total of 2,045 applications were received in 2007 – an increase of almost 30% compared to the 
previous year. 
 For adopted post-authorisation opinions or notifications, the increase was even more pronounced. The 
number rose by 37% over the previous year. The Agency was able to cope with the increased 
workload partly due to process improvements for the handling of variation applications that led to 
efficiency gains in the handling of certain types of variations. 
 CHMP adopted 41 opinions for new indications, providing additional treatment options for patients. 
 The CHMP adopted two negative opinions, recommending the refusal of two applications for an 
extension of indication. The CHMP also restricted the indication for a number of products for efficacy 
or safety reasons. 
 The CHMP recommended new contra-indications or the removal of contra-indications for a number of 
products, as well as concluded more than 100 type-II variations pertaining to warnings and 
precautions for use. 
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Public-health impact of the EMEA’s post-authorisation activities in 2007 
Positive opinions for new indications 
The CHMP adopted 41 opinions on new indications, providing additional treatment options for patients. 
 Most of the new indications related to medicinal products approved for the treatment of various forms 
of cancer, such as hepatocellular carcinoma, locally advanced squamous cell carcinoma, metastatic 
breast cancer, advanced gastric cancer, advanced or metastatic renal cell cancer, metastatic colorectal 
cancer, non-small cell lung cancer, relapsed multiple myeloma and B-cell chronic lymphocytic 
leukaemia, and follicular non-Hodgkin’s lymphoma. 
 Several extensions of indication were also granted for the treatment of diabetes (providing more 
options for the combined use of oral antidiabetics and insulins). 
 New indications were also approved in the fields of cardiovascular, infectious, rheumatoid and 
inflammatory-bowel diseases and central nervous system disorders. 
 Six medicinal products had their use extended to include the treatment of children and adolescents 
having Crohn’s disease, anaemia associated with chronic renal failure, or HIV, or to include 
immunisation against additional infections caused by streptococcus pneumoniae. 
Negative opinions for new indications 
The CHMP adopted two negative opinions, recommending the refusal of two applications for an extension 
of indication: 
 one for NutropinAq (recombinant somatropin) to add the long-term treatment of children with severe 
idiopathic short stature, due to the lack of evidence that the benefits of NutropinAq in the long-term 
treatment of children with severe idiopathic short stature did not outweigh its possible risks; 
 one for Zavesca (miglustat) to add the treatment of the ‘neurological’ symptoms of Niemann Pick type 
C disease. Although the CHMP acknowledged that there are no alternative treatments for Niemann 
Pick type C disease, it was concerned that a benefit of Zavesca in the proposed indication had not been 
sufficiently demonstrated. 
Restriction or deletion of indications 
The CHMP also recommended the restriction or the deletion of the indications of some centrally 
authorised medicines. 
 Visudyne (verteporfin): the indication in patients with age-related macular degeneration with occult 
subfoveal choroidal neovascularisation with evidence of recent or ongoing disease progression was 
deleted, as the results of a confirmatory study failed to support the efficacy of the use of Visudyne in 
these patients. The benefit/risk balance of Visudyne in the other approved indications remained 
positive. 
 Ketek (telithromycin): three of the four approved indications were restricted. For the treatment of 
bronchitis, sinusitis and tonsillitis/pharyngitis, Ketek should only be used for infections caused by 
bacterial strains that are suspected or proven to be resistant to, or cannot be treated with, macrolide or 
beta-lactam antibiotics. No such restrictions were recommended for the remaining indication, the 
treatment of community-acquired pneumonia. 
 The safety of epoetins – both centrally authorised (Aranesp, Nespo, Dynepo, Mircera, NeoRecormon, 
Binokrit, Epoetin Alfa Hexal, Abseamed) and nationally authorised (Eprex) – was reviewed because 
data from recent clinical trials showed a consistent unexplained excess mortality in patients with 
anaemia associated with cancer who have been treated with epoetins. The CHMP concluded that the 
benefits of these products continue to outweigh their risks in the approved indications. However, the 
indication in the treatment of anaemia was restricted to anaemia associated with symptoms. 
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Contra-indications, warnings and precautions for use 
The CHMP recommended new contra-indications for 20 centrally authorised medicinal products, and in 
some instances for the entire classes of centrally authorised medicinal products (class labelling), including: 
 Viracept (nelfinavir mesilate): co-administration with omeprazole; 
 Acomplia (rimonabant): ongoing major depressive illness and/or ongoing antidepressive treatment; 
 Agenerase, Aptivus, Crixivan, Invirase, Kaletra, Norvir, Prezista, Reyataz, Telzir, Viracept (protease 
inhibitors): concomitant use with oral midazolam (while further directions concerning co-
administration with parenteral midazolam are provided in the SPC) (class labelling); 
 Pegintron (peginterferon alpha 2b), Viraferonpeg (peginterferon alpha 2b) and Rebetol (ribavirin): 
initiation of treatment of hepatitis C in patients with hepatitis C and HIV co-infection who have 
cirrhosis and a Child-Pugh score of 6 or higher. 
The CHMP recommended the deletion of contra-indications for 12 centrally authorised medicinal 
products, and in some instances for the entire class of centrally authorised medicinal products (class 
labelling), including: 
 Pioglitazone- (Actos, Glustin, Competact, Tandemact) and rosiglitazone- (Avandia, Avandamet, 
Avaglim) containing medicinal products: deletion of the contra-indication for their combined use with 
insulins (class labelling); 
 Stocrin and Sustiva (efavirenz): deletion of the contra-indication for their co-administration with 
voriconazole. 
The CHMP concluded more than 100 type-II variations relating to special warnings and precautions for 
use, including: 
 a new safety warning for Tamiflu (oseltamivir phosphate) and the risk of neuro-psychiatric adverse 
events; 
 a new warning for recombinant factor VIII medicinal products regarding the possible recurrence of 
inhibitors after switching from one recombinant factor VIII product to another in previously treated 
patients with more than 100 exposure days who have a history of inhibitor development (class 
labelling); 
 a new warning for pioglitazone- and rosiglitazone-containing medicinal products regarding the 
increase of bone fractures in women; and for rosiglitazone-containing medicinal products only 
regarding a possible risk of ischaemic heart disease; 
 a new warning with an urgent safety procedure (USR) concerning the rare but serious risk of drug rash 
with eosinophilia and systemic symptoms (a severe type of allergic reaction) with strontium-ranelate-
containing medicinal products (used to treat osteoporosis in women who have been through 
menopause). 
Safety review of Viracept 
 The CHMP conducted a review of Viracept (nelfinavir) further to contamination during the 
manufacturing process of several batches of the active substance with ethyl mesilate, a known 
genotoxic substance. The CHMP first recommended the suspension of the marketing authorisation and 
the recall of Viracept from the market. Following the assessment of the corrective and preventive 
measures put in place by the marketing-authorisation holder and the inspection of the manufacturing 
site – which provided reassurance that the cause of the contamination had been eliminated and that 
future production of Viracept would meet the required quality standards – the CHMP subsequently 
recommended the lifting of the suspension of the marketing authorisation and the re-introduction of 
the medicine onto the market in the European Union. 
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2.4.2 Specific objectives in 2007 
 The EMEA continued its process process-improvement-exercise activities related to the processing of 
type-I and II variations. 
− Reports on process improvement for type-I and II variations were finalised. Implementation of the 
improvement actions was begun. 
 The EMEA supported the European Commission’s review of the Variations Regulation (Regulation 
(EC) No 1085/2003). 
 Building on the operational improvements introduced in 2006, the EMEA continued its exercise to 
strengthen the quality and the regulatory and scientific consistency of CHMP opinions and assessment 
reports. 
− Staff received scientific, regulatory and procedural training in order to reinforce the EMEA’s role 
as scientific secretariat. 
− The input of specialist advice was further strengthened in 2007, building on the work already 
undertaken in 2006, through a re-enforcement of the participation of the Pharmacovigilance 
Working Party (PhVWP) co-opted members in safety safety-related issues. 
 
Performance indicators 
 
Performance indicator Target Outcome 
Percentage of applications for 
post-authorisation procedures 
evaluated within the regulatory 
timelines 
100% of applications 100% 
Percentage of applications 
meeting the legal timeline of 27 
days for the linguistic post-
opinion check 
100% of applications 41% between January and June. 
45% between July and November 
 
2.5 Parallel distribution 
A Community marketing authorisation is valid throughout the EU and a centrally authorised medicinal 
product is by definition identical in all Member States. Products placed on the market in one Member 
State can be marketed in any other part of the Community by a ‘parallel distributor’ independent of the 
marketing-authorisation holder. Typically, this is done to benefit from price differentials. The EMEA 
checks compliance of such products distributed in parallel with the appropriate terms of the Community 
marketing authorisation. 
2.5.1 Core activities 
 The number of initial parallel-distribution notifications and the number of notifications of change have 
exceeded the expected number. 1,937 initial notifications were received this year, 8% more than 
forecast. 3,518 notifications of change were received, 45% more than forecast. 
 The timelines set out in the procedures were not adhered to due to the high number of notification 
requests received, a backlog from previous years, and a lack of resources. 
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2.5.2 Specific Objectives in 2007 
 Review and update of the EMEA guidance on parallel distribution was postponed to 2008. 
 Efforts were undertaken to increase parallel distributors’ compliance with the checking process. 
−  An overview of notices for parallel distribution issued by the EMEA has been published monthly 
since 1 January 2007. 
−  A discussion on proposals aimed at improving efficiency of the parallel-distribution-notification 
process was initiated in 2007. 
 
Performance indicators 
Performance indicator Target Outcome at end of 2007 
Percentage of notifications 
checked for compliance within 
the regulatory timeline of 35 
working days (validation and 
regulatory check) 
70% of applications checked 
within 35 working days 
46% of applications were handled 
in 35 working days. 
Average handling time was 72 
working days. 
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2.6 Pharmacovigilance and maintenance activities 
Pharmacovigilance activities include the management of suspected adverse drug reactions in the pre- and 
post-authorisation phases (individual case safety reports (ICSRs)), periodic safety-update reports (PSURs) 
and risk-management plans (RMPs). Maintenance activities relate to post-authorisation commitments 
(specific obligations, follow-up measures), renewal applications and annual reassessments. 
Safety of medicines is a priority area for the EMEA and the Agency will continue to strengthen its efforts 
in order to ensure the safe use of medicinal products authorised in accordance with the centralised 
procedure. 
 
The wide range of activities undertaken in the field of pharmacovigilance and maintenance (and which, to 
an important extent, come within the scope of the EMEA Road Map and the ERMS), have allowed a more 
proactive approach to safety of medicines to be taken, hence protecting public health. 
2.6.1 Core activities 
Pharmacovigilance 
 The EMEA received 381,990 adverse-drug-reaction (ADR) reports in 2007 – an increase of more than 
25% compared to the previous year. 40% of ADR reports received related to centrally authorised 
medicinal products. 
 The EMEA received 63,393 reports concerning investigational medicines, i.e. adverse drug reactions 
observed during clinical trials. This is an increase of 18% compared to 2006. 
 A total of 762 suspected signals concerning 139 intensively monitored products, and 349 suspected 
signals concerning 162 routinely monitored products, were identified. Following further investigation, 
22% (132) of suspected signals required follow-up for intensively monitored products, including 
involving the rapporteur for 43 signals. About 10% (33) signals were followed up for routinely 
monitored products, with involvement of the rapporteur in 21 cases. 
 The Agency reviewed 92% of the risk-management plans (RMPs) submitted as part of new 
applications. This review was undertaken in the context of the peer-review process prior to day 120 
and continued up to finalisation of the scientific review by the CHMP. 
 The number of periodic safety update reviews conducted during 2007 was 15% higher than in 2006. 
 The number of follow-up measures (FUMs) and specific obligations (SOs) submitted increased 
slightly (5%) in 2007. It should be noted that the high number submitted in 2006 was partly explained 
by submissions following a reminder to marketing-authorisation holders to submit any data (including 
paediatric data) that might be available and which had not previously been submitted to the EMEA. 
 
EU and non-EU ADR reports transmitted to the EMEA
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Periodic safety update reports (PSURs) and follow-up measures (FUMs)/specific 
obligations (SOs) (2005-2007)
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2.6.2 Specific objectives in 2007 
 Considerable efforts were made to apply a proactive approach to safety of medicines, with particular 
emphasis on the establishment of an intensive drug-monitoring system. Activities undertaken come 
within the scope of the EMEA Road Map and the implementation of the European Risk Management 
Strategy (ERMS), in collaboration with the national competent authorities of the Member States. 
−  A new rolling two-year work programme for 2008-2009 was prepared and adopted by the Heads 
of Medicines Agency, together with the ERMS status report. 
−  A review and learning project for risk-management plans submitted to the EMEA as part of an 
application is ongoing at the level of the CHMP and the PhVWP. 
−  The European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) 
project is progressing very well. The first phase, i.e. the identification of centres across the EU, 
was concluded, resulting in the establishment of an inventory. A kick-off meeting with academic 
centres was organised at the end of June. Discussions have started on the development of a 
structure and model for the future network. 
−  The topic ‘Relative safety of NSAIDs’ was included in the 2007 work programme for the Health 
theme of the 7th Framework Programme as a result of discussions with the European Commission 
(DG Research). In addition, a list of the top five public-health issues in drug safety was developed 
by the CHMP/PhVWP in view of a reply to subsequent calls for proposals in the context of the 7th 
Framework Programme. 
 
 Activities to strengthen EudraVigilance to support proactive pharmacovigilance continued in 2007, 
and resulted in the following: 
−  the number of national competent authorities and pharmaceutical companies reporting 
electronically to Eudravigilance has increased. However, 100% compliance has still not been 
achieved; 
−  the EMEA prepared a EudraVigilance action plan, which was subsequently agreed by the Heads 
of Medicines Agencies and the EMEA Management Board. The plan addresses implementation 
problems related to the quality of the submitted data and the legal reporting deadlines; 
−  the EudraVigilance Datawarehouse and Analysis System (EVDAS) was rolled out to the national 
competent authorities on 6 July 2007. It is designed to support signal-detection and the assessment 
of adverse-drug-reaction reports; 
−  the EMEA made efforts to improve the efficiency of its operation in the area of signal detection 
and assessment of adverse drug reactions. Quantitative signal-detection methodologies were 
included in EVDAS and new functionalities facilitating the review of signals were added to 
EudraVigilance; 
 
EMEA annual report 2007 
EMEA/MB/17464/2008 2.4, CURRENT 
Page 29/138 
 
EMEA annual report 2007 
EMEA/MB/17464/2008 2.4, CURRENT 
Page 30/138 
−  delays have occurred in the introduction of other additional functionalities, re-coding activities 
and the implementation of the EudraVigilance access policy, because efforts had to be directed to 
the roll-out of EVDAS; 
−  progress was made in the field of international standardisation activities concerning the 
finalisation of ICH step 4 guidelines and standards in the area of clinical-data management and 
multidisciplinary topics (i.e. E2B( R), M5); 
−  with a view to integrate additional healthcare data, the THIN database – a medical research 
database of anonymised patient records from information entered by general practices – was 
integrated at the EMEA and a research project initiated. 
 
Performance indicators 
Performance indicator Target Outcome at end of 2007 
Percentage of RMPs that are 
peer-reviewed by the EMEA as 
part of the assessment of 
variations and line extensions that 
result in a significant change to a 
marketing authorisation 
70% of RMPs 90% for line-extension 
applications and 86% for 
extension-of-indication 
applications 
Percentage of ICSRs reported 
electronically for centrally 
authorised products (CAPs) 
100% of ICSRs 93% of MAHs are compliant 
with the electronic reporting of 
CAPs 
Review of post-authorisation 
commitments (PACs) within the 
agreed timeframe 
80% of PACs 68% of all PACs were reviewed 
within a 60-day timeframe (80% 
for quality PACs only and 63% 
for clinical PACs) 
Delays have occurred and the 
extent of these delays will be 
monitored in 2008 
Submission of outcome reports 
for PACs to applicants/MAHs 
within 2 weeks of the CHMP 
meeting 
100% of reports 95% 
 
2.7 Arbitration and Community referrals 
Arbitration procedures (either under Article 29 of Directive 2001/83/EC as amended or Articles 6(12) and 
6(13) of Commission Regulation (EC) No 1084/2003) are initiated because of disagreement between 
Member States or because of disagreement of the marketing-authorisation holder with the Member States 
in the framework of the mutual-recognition or decentralised procedures. 
Article 30 referrals are mainly initiated in order to obtain harmonisation of authorisations for medicinal 
products authorised in the Community by the Member States. 
Article 31 and 36 referral procedures are mainly initiated in case of Community interest and generally for 
safety-related issues. 
Article 16(1) and 16(4) referrals are initiated by Member States regarding herbal medicinal products with 
a traditional use longer or shorter than 15 years respectively. 
Article 107 procedures under Directive 2001/83/EC, as amended, are initiated to obtain a CHMP opinion 
further to the suspension or revocation of the marketing authorisation of a medicinal product in a Member 
State as a result of pharmacovigilance data. 
Article 5(3) procedures under Regulation (EC) No 726/2004 require a CHMP opinion on any scientific 
matter raised by the EMEA, the European Commission or a Member State. 
2.7.1 Core activities 
 The number of referrals submitted to the EMEA continues to rise. A total of 57 referrals were received 
in 2007, 40% more than in 2006. 
 A new referral procedure – the procedure following Article 107(2) of Directive 2001/83/C as amended 
– was used for the first time in 2007. Altogether, five referrals were carried out under this procedure. 
 Nine out of the 36 finalised referral procedures related to safety concerns. In 3 cases the CHMP 
recommended withdrawal and in 2 cases temporary suspension of the involved marketing 
authorisations. 
 According to revised Community legislation, Member States can initiate referrals regarding herbal 
medicinal products. Up to December 2007, however, no referrals regarding herbal medicinal products 
were received. 
 The CHMP adopted 2 opinions on scientific matters in the context of Article 5(3) procedures: 
−  opinion on the adequacy of guidelines on medicinal products for human use in the context of the 
elderly; 
−  opinion on the potential risk of carcinogens, mutagens and substances toxic to reproduction 
(CMRs) when used as excipients in medicinal products for human use. 
 
Procedure Type 2005 2005 2006 2006 2007 2007
Started Finalised Started Finalised Started Finalised
Article 6(12) of Commission Regulation (EC) 
No 1084/2003
3 1 0 2 6 2
Article 6(13) of Commission Regulation (EC) 
No 1084/2003
4 0 0 4 0 0
Article 29 of Directive 2001/83/EC 7 5 20 12 22 18
Article 30 of Directive 2001/83/EC 3 0 1 4 14 1
Article 31 of Directive 2001/83/EC 2 0 3 1 4 4
Article 36 of Directive 2001/83/EC 0 0 7 7 4 4
Article 5(3) of Regulation (EC) No 726/2004 3 2 2 2
Article 16(1) Herbal 0 0 0 0
Article 16(4) Herbal 0 0 0 0
Article 107(2) of Directive 2001/83/EC 0 0 5 5
Article 29 of Regulation (EC) No 1901/2006 0 0
Totals: 19 6 34 32 57 36
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Procedures of high public-health interest finalised in 2007: 
 Review of mifepristone-containing medicinal products, following safety and efficacy concerns 
regarding the use of the approved dose of 600 mg mifepristone, as compared to the use of a 200 mg 
dose, in the medical termination of developing intra-uterine pregnancy in sequential use with 
prostaglandin analogue. The CHMP concluded that the available data support the effectiveness of a 
600 mg dose of mifepristone, followed by the use of prostaglandin analogues, for the termination of 
pregnancy up to 63 days of amenorrhoea (absence of menstrual periods). In pregnancies up to 63 days, 
comparative studies between 200 mg and 600 mg mifepristone in combination with 1 mg gemeprost 
delivered vaginally suggest that 200 mg mifepristone may be as effective as 600 mg mifepristone. 
However, in pregnancies up to 49 days, comparative studies between 200 mg and 600 mg 
mifepristone in combination with 400 μg misoprostol delivered orally cannot exclude a slightly higher 
risk of continuing pregnancies with the 200 mg dose. Based on the available published data, the 
benefit/risk profile of mifepristone in combination with oral misoprostol for pregnancy from 50 to up 
to 63 days is unfavourable due to poor efficacy (Article 31 procedure). 
 Review of medicinal products containing bicalutamide 150 mg, triggered by safety concerns, in 
particular heart problems, when the medicinal product is used in the treatment of early prostate cancer. 
The CHMP concluded that the benefits of these products outweigh their risks, but only in those 
patients who are at high risk of their disease getting worse (Article 31 procedure). 
 Review of piroxicam-containing medicinal products, triggered by safety concerns over gastrointestinal 
side effects and serious skin reactions. The CHMP concluded that piroxicam should no longer be used 
for treatment of short-term painful and inflammatory conditions. Piroxicam can still be prescribed for 
the symptomatic relief of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis. However, it 
should not be the first choice of non-steroidal anti-inflammatory drug (NSAID) treatment in these 
conditions (Article 31 procedure). 
 Review of veralipride-containing medicinal products following the withdrawal of veralipride form the 
Spanish market because of reports of serious side effects affecting the nervous system and by a 
number of regulatory actions in other EU Member States where veralipride was authorised. The 
CHMP concluded that the risks outweigh the benefits and recommended the withdrawal of the 
marketing authorisation for all veralipride-containing medicines (Article 31 procedure). 
 Review of systemic formulation of nimesulide-containing medicinal products, following the 
suspension of the marketing authorisation for these medicines in Ireland, due to concerns over serious 
liver problems. The CHMP concluded that the benefit-risk of nimesulide continues to be positive and 
recommended the maintenance of the marketing authorisation but that there is a need to restrict its use 
(Article 107(2) procedure). 
 Review of clobutinol-containing medicinal products, following the suspension of the marketing 
authorisation for these medicines in Germany, due to concerns regarding side-effects affecting the 
heart. The CHMP concluded that the benefits of these medicines do not outweigh their risks and 
therefore recommended that the marketing authorisations for clobutinol-containing medicines be 
withdrawn throughout the EU (Article 107(2) procedure). 
 Review of carisoprodol, following the plan to withdraw the marketing authorisation for this medicine 
in Norway, due to risks of intoxication, psychomotor impairment, addiction and misuse due to off-
label prescribing. The CHMP concluded the risks of these medicines outweigh their benefits and 
recommended the suspension of the marketing authorisations (Article 107(2) procedure). 
 Review of lumiracoxib-containing medicinal products, intended for the treatment of osteoarthritis 
further to the notification by the UK which was considering the suspension of the marketing 
authorisation due to possible increased risk of hepatotoxic adverse events at the 100 mg dose. The 
CHMP recommended the withdrawal of the marketing authorisations for all lumiracoxib-containing 
medicines, because of the risk of serious side effects affecting the liver (Article 107(2) procedure). 
 Review of aprotinin-containing medicinal products, used for the prophylactic use to reduce 
perioperative blood loss and the need for blood transfusion in those patients undergoing 
cardiopulmonary bypass in the course of coronary artery bypass graft (CABG) surgery. This was 
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further to the decision by Germany to suspend all nationally authorised products containing aprotinin 
for intravenous use due to an increased risk of mortality in the aprotinin arm of the BART study 
(Article 107(2) procedure). 
 Review of medicinal products containing 30 μg ethinyl estradiol + 2 mg chlormadinone acetate, 
because of differences among Member States on whether the indication of these two products should 
be extended to include the treatment of women suffering from moderate acne. The CHMP 
recommended the refusal of the new indication because the data submitted were considered 
insufficient to demonstrate efficacy in the applied indication (Article 6(12) procedure). 
 Review of generic medicinal products containing cetirizine because of concerns over their 
bioequivalence. Further to a CHMP review conducted in 2006, the concerned national marketing 
authorisations were suspended by the European Commission because of concerns regarding good 
clinical and laboratory practices (GCP/GLP) compliance that impacted on the quality and reliability of 
bioequivalence studies supporting the marketing authorisations. Due to GCP concerns still identified 
in a further study, the CHMP recommended the revocation of the marketing authorisations for these 
generic medicinal products (Article 36 procedure). 
Procedures of high public-health interest started but not yet finalised in 2007: 
 Review of medicinal products containing ergot-derived dopa agonists, triggered by safety concerns in 
relation to fibrotic disorders and cardiac valvulopathy (Article 31 procedure). 
 Review of methylphenidate-containing medicinal products triggered by safety concerns related to 
cardiovascular events and cerebrovascular disorders (Article 31 procedure). 
 Review of oral formulation of norfloxacin-containing medicinal products to re-assess the balance of 
benefits and risks of these medicinal products (Article 31 procedure). 
 Review of etoricoxib-containing medicinal products triggered by cardiovascular safety concerns when 
these medicinal products are used in the long-term treatment of ankylosing spondylitis and rheumatoid 
arthritis: Article 6(12) procedures for Arcoxia (centrally authorised medicinal product) extension of 
indications and Article 31 procedure for all etoricoxib-containing medicinal products. 
 Review of moxifloxacin-containing medicinal products because of differences among Member States 
on the extension of the therapeutic indication of moxifloxacin to include pelvic inflammatory disease 
(Article 6(12) procedures). 
 
2.7.2 Specific objectives in 2007 
 An external guidance document on referral procedures was published. 
 With a view to ensuring transparency and appropriate information for patients and the public, 
question-and-answer documents were systematically published at the time of the adoption of the 
CHMP opinions for procedures conducted in accordance with Article 31 and Article 107(2). 
 
Performance indicators 
Performance indicator Target Outcome at end of 2007 
Percentage of arbitration and 
referral procedures managed 
within the legal timeline 
100% of procedures 100% 
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2.8 Medicines for children 
This covers EMEA activities relating to the assessment and agreement of, and verification of compliance 
with, paediatric investigation plans (PIPs) and waivers by the Paediatric Committee of the EMEA. An 
agreed paediatric investigation plan may lead to information on the paediatric use of medicines being 
included in a centralised or a national marketing authorisation for new medicinal products and in a 
paediatric-use marketing authorisation for off-patent products. It also includes agreement on the strategy 
for the establishment of the European network of paediatric research and the provision of information on 
clinical trials performed in children. 
 
The Agency received entirely new responsibilities with the entry into force of Regulation (EC) No 
1901/2006 on medicinal products for paediatric use (the Paediatric Regulation) on 26 January 2007. These 
activities received a high level of support from the network of Medicines Agencies, in particular for the 
Paediatric Committee activities. 
2.8.1 Core activities 
Applications for PIPs and waivers received 
 The EMEA received applications for PIPs and waivers relating to 202 indications. These correspond 
to 85 applications with an average of 2-4 indications per application. The assessment of each 
indication may extend to several age groups, each of which requires a separate scientific evaluation. 
 The applications also include PIPs where a full and/or a partial waiver may be sought for one or more 
indications in addition to the PIP. 
 Seventeen per cent of applications were requests for full waivers, where for every indication a full 
waiver is sought. 
 While the number of applications was lower than announced by pharmaceutical companies, the high 
number of PIPs for medicines authorised at the level of the Member States and the complexity of the 
applications due to multiple indications and several age groups per application resulted in a much 
higher workload than expected. Since applications forecast by companies have been delayed, their 
submission is now planned for early 2008. A high workload has resulted from these complex 
applications; the workload was shared between the EMEA secretariat and the Paediatric Committee 
members.  
Opinions and decisions adopted 
 The PDCO adopted 10 opinions on PIPs and waivers, covering 15 indications. Eight of the 10 
opinions were adopted for full waivers and 2 for PIPs. 
 The EMEA had adopted a decision on 4 of the 10 opinions by the end of 2007. 
 The number of opinions is lower than the forecast, since in most cases the PDCO adopts opinions at 
day 120 of the procedure, due to the complexity of applications and the related discussions. Therefore, 
as a result of the need for full procedural timelines and associated clock-stops requested by applicants, 
more opinions on applications submitted in 2007 are expected in 2008. 
List of class waivers 
 Following the opinion of the PDCO, the EMEA issued a decision on a ‘list of class waivers’ on 3 
December 2007. The list includes 17 symptomatic conditions relating to different types of cancer 
(lung cancer, basal cell carcinoma, breast and ovarian cancer, multiple myeloma, etc.), 
neurodegenerative conditions (Alzheimer’s disease, Parkinson’s disease) and other conditions that 
occur only in the adult population (age-related macular degeneration, menopausal disorders, etc.). 
These conditions do not affect children and the requirement to submit a paediatric investigation plan 
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can therefore be waived. Further guidance to applicants who intend to develop a medicinal product for 
treatment of a condition that appears on the above-mentioned list is under preparation. 
 
2.8.2 Specific objectives in 2007 
 The implementation of the regulation on medicinal products for paediatric use, including the 
establishment of the new Paediatric Committee (PDCO), was one of the EMEA’s top priorities in 
2007. 
−  The PDCO was established within the required legislative timing and held its first meeting on 4-5 
July 2007. 
−  Committee members nominated by the CHMP and the Member States were identified before the 
July 2007 deadline. Representatives of patients’ and healthcare professionals’ organisations had 
not yet joined the PDCO by year’s end. The European Commission launched selection procedure 
for the appointment of these members. 
−  The EMEA established the necessary procedures and guidance to ensure timely decision-making. 
This included preparation of templates for opinions, decisions and summary reports, as well as 
practical and procedural guidance for the PDCO and applicants. 
−  The PDCO prepared a proposal for an implementing strategy for the European network of 
paediatric research, which was adopted by the EMEA Management Board during its December 
2007 meeting. 
−  The new legislation requires that transparency of EudraCT, the database on clinical trials in the 
European Union, be increased with respect to clinical trials conducted in children. The PDCO, 
together with the EU Member States and the European Commission, contributed to a draft 
guideline on the EudraCT fields that include data on clinical trials in children and fields to be 
made public. 
−  The PDCO provided the European Commission with its recommendation on a symbol for use on 
medicinal products granted a marketing authorisation for a paediatric indication. 
−  The EMEA published a guidance document on the survey of all existing paediatric-use medicines. 
−  The EMEA, together with the CMD(h), prepared for the coordination of paediatric data to be 
received early in 2008 on centrally and nationally authorised medicines. 
−  The EMEA contributed to the European Commission guideline on ‘Ethical considerations on 
clinical trials in paediatric populations’. 
−  The EMEA organised training for assessors of national competent authorities on the new 
paediatric legislation and workshops for the pharmaceutical industry. 
−  The EMEA organised workshops with DG Research in relation to its 7th Framework Programme 
for products to be developed in paediatrics. 
 Improving the safety of medicines for children is an important aspect of the new legislation. The 
EMEA undertook a number of activities in 2007 to support paediatric pharmacovigilance in the 
context of the new legislation. 
−  A final guideline on paediatric pharmacovigilance was published in 2007 and the implementation 
of its practical implications was started, notably in the area of signal detection, PSURs and 
product information. 
−  The ENCePP project included paediatric networks in order to ensure the availability of 
appropriate expertise in paediatric pharmacovigilance and investigated new sources and methods 
for intensive monitoring of paediatric use of medicines. 
 
Performance indicators 
Performance indicator Target Outcome at end of 2007  
Number of PIP or waiver 
opinions or decisions adopted 
within the legal timeframe 
100% of procedures 100% 
 
2.9 Herbal medicinal products 
The Agency’s activities in the area of herbal medicines include: the provision by the Committee on Herbal 
Medicinal Products (HMPC) of scientific opinions on questions relating to herbal medicines; the 
establishment of Community herbal monographs for traditional and well-established herbal medicinal 
products; the establishment of a draft list of herbal substances, preparations and combinations thereof for 
use in traditional herbal medicinal products; the provision of opinions on herbal substances at the request 
of the CHMP; and the evaluation for referral and arbitration procedures concerning traditional herbal 
medicinal products. 
2.9.1 Core activities 
 The HMPC released for consultation 13 draft Community herbal monographs for traditional and well-
established herbal medicinal products. 
 Sixteen Community herbal monographs for traditional and well-established herbal medicinal products 
were finalised. 
 The HMPC adopted 2 entries to the list of herbal substances, preparations and combinations thereof 
for use in traditional herbal medicinal products. The number of list entries is limited because the 
HMPC has concerns about the availability and quality of genotoxicity data for some herbal 
substances. 
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2.9.2 Specific objectives in 2007 
 The first three-year mandate of the Committee on Herbal Medicinal Products (HMPC) expired in 
2007. Review of the first mandate and reconstitution of the new HMPC were important objectives for 
the year. 
− The ‘HMPC Status report on the implementation of the provisions of Chapter 2a of Directive 
2001/83/EC as amended by Directive 2004/24/EC as regards traditional herbal medicinal 
products’ was published in August 2007. 
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− Revised HMPC rules of procedure were adopted in May 2007. 
 Operation of the HMPC’s working parties and drafting groups, in particular their cooperation with the 
CHMP, were also reviewed and proposals for modifications were made. 
− Mandate, objectives and rules of procedure of the Working Party on Community Monographs and 
Community List were revised. 
 Relations with the HMPC’s interested parties were strengthened by updating them on the Committee’s 
operations and future challenges. 
− The HMPC met representatives of Interested Parties to discuss the Community herbal monographs 
adopted by the HMPC, as well as the process of preparation of and public consultation on such 
monographs, in March 2007. 
 
Performance indicators 
Performance indicator Target Outcome at end of 2007  
Number of Community herbal 
monographs established 
20 Community herbal 
monographs 
13 
Number of entries to the list of 
herbal substances, preparations 
and combinations thereof 
10 entries to the list 2 
 
2.10 Emerging therapies and new technologies 
This area relates to the activities undertaken by the EMEA to support the scientifically sound development 
of advanced-therapy medicinal products, including gene therapy, somatic cell therapy or human tissue 
engineered products, and other emerging therapies and new technologies that are not within the scope of 
the regulation on advanced therapies. 
2.10.1 Core activities 
 The EMEA’s Innovation Task Force (ITF), a multidisciplinary group that includes scientific, 
regulatory and legal competences, continued its activities. 
−  The ITF held 18 briefing meetings with companies developing medicines in the area of emerging 
therapies and new technologies. 
−  Sponsors may request advice on whether their product can be considered a medicinal product, 
thus being eligible for EMEA procedures. Thirty-one requests for classification were received. 
−  The CHMP adopted 18 classification reports drafted by the ITF that describe the scientific and 
regulatory criteria for the definition of a medicinal product. 
2.10.2 Specific objectives in 2007 
 The Agency made good progress in promoting and encouraging early dialogue with sponsors of 
potential applications for advanced therapies and emerging products and technologies. 
−  Implementation of new procedures to facilitate early dialogue with sponsors resulted in an 
increased number of requests for regulatory eligibility and briefing meetings. 
−  The EMEA organised meetings to address scientific and regulatory matters arising from new 
products and approaches. Meetings included the EMEA-Infarmed-Expertissues joint workshop on 
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cell-based medicinal products, held in Lisbon in October 2007, and the EMEA-EFPIA joint 
workshop on methodology for adaptive designs in confirmatory clinical trials, organised in 
December 2007. 
 Identifying expertise, expectations and bottlenecks related to the area of new treatment solutions was 
another EMEA objective for 2007. 
−  Several meetings with learned societies and industry were held in order to extend the dialogue 
with academia and society at large. Meetings included joint sessions with the European Society of 
Human Genetics and CHMP Pharmacogenetics Working Party (PGWP); with ESGCT (European 
Society of Gene and Cell Therapy) and CHMP Gene Therapy Working Party (GTWP); with 
CliniGene (European Network for the Advancement of Clinical Gene Transfer and Therapy) and 
GTWP; and a joint workshop with ESGCT and CliniGene. 
 
Performance indicators 
Performance indicator Target Outcome at end of 2007  
Briefing meetings organised 
within 60 days from receipt of a 
request 
80% of meetings 95% 
Regulatory advice on new-
technology, emerging-therapy 
and borderline medicinal 
products given within 60 days 
80% of requests 85% 
 
2.11 Provision of information to patients and healthcare professionals 
The Agency has implemented processes and procedures aimed at the provision of targeted, understandable 
and accessible information for patients and healthcare professionals. In addition to summaries of opinions, 
European public assessment reports (EPARs), and information on arbitrations and referrals, the Agency 
provides a wider range of information. This includes information on withdrawals of applications prior to 
Commission Decision and on negative decisions, for both new applications and extensions to existing 
indications, as well as EPAR summaries for the public. 
2.11.1 Core activities 
 A summary of opinion was published at the time of the adoption of the opinion by the CHMP for all 
medicines that were recommended for initial authorisation or for which changes to the indications or 
contraindications were recommended. 
 Sixty-two summaries of EPARs written in a manner understandable to the public (EPAR summaries 
for the public) were prepared for new marketing authorisations. In addition, the EMEA also started to 
publish these in cases of major variations. 
 Efforts to provide product-related information in all EU languages continued throughout 2007. 
Compliance by Member States with the translation-checking process was very good overall, in both 
pre-authorisation and post-authorisation phases. In addition, feedback from the Member States 
indicated good quality overall of the translations provided by pharmaceutical industry. 
 The EMEA coordinated the post-opinion linguistic review for 76 new applications and line 
extensions. 
 The first two small- and medium-sized enterprises benefited from translation support for the product 
information of their medicines. 
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2.11.2 Specific objectives for 2007 
 Interaction with and participation of the Agency’s stakeholders (healthcare professionals, patients and 
consumers) was further developed and reinforced. 
−  The publication of a monthly electronic newsletter providing information on medicines for human 
use to the patients’ and consumers’ organisations involved in the Patients’ and Consumers’ 
Working Party (PCWP) was trialled in a pilot phase in 2007. 
−  A status report on the progress of the implementation plan of the framework of interaction with 
patients and consumers was presented to the PCWP during its December 2007 meeting. 
−  The development of recommendations of the EMEA/CHMP Working Group with Healthcare 
Professionals (HCP WG) was started in 2007. 
−  The development of a framework of interaction between the EMEA and healthcare professionals 
was started in 2007. 
−  The first joint meeting with patients and healthcare professionals was held on 1 June 2007. 
Following this meeting, it was concluded that joint meetings would be held at least once a year, 
and that representatives from both groups would attend meetings of the PCWP and HCP WG 
respectively. 
 In 2007, the Agency made efforts to improve the provision of up-to-date and understandable 
information targeted at patients and the general public on all products subject to scientific review by 
the Agency, thus promoting the appropriate use of medicines and further contributing to patient safety. 
−  The guideline on summary of product characteristic was revised in order to introduce new 
requirements in accordance with the new Paediatric Regulation. A draft was published for a three-
month public consultation in December 2007. 
−  Consultation of target patient groups on product information has been a mandatory element of 
marketing-authorisation applications for medicines since 2005. The EMEA reviewed the 
experience gained with ‘user-testing’ reports submitted in the context of new marketing 
authorisations with the aim to provide an overview of how companies and CHMP members deal 
with the legal requirement to perform user-testing. A document outlining a number of 
recommendations is currently under preparation. 
−  The translation framework was reviewed in 2007. Based on information collected from various 
Member States, the EMEA will propose amendments to the framework policy and eventually the 
service contracts in terms of general handling and financial compensation. Discussions with 
Member States are ongoing. 
−  Guidance for the assessment of user-testing results by the CHMP was prepared and adopted in 
agreement with the Coordination Group for Mutual Recognition and Decentralised Procedures 
(CMD(h)). 
−  Following expiry of the derogation in May 2007, Maltese was smoothly phased in to the 
translation framework for product information for human and veterinary medicines. A linguistic-
review process was established. Ninety-nine medicines for human use and 20 medicines for 
veterinary use went through this process in 2007. 
−  Bulgaria and Romania were successfully included in the translations framework. 
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Performance indicators 
Performance indicator Target Outcome at end of 2007  
Percentage of summaries of 
opinions published at the time of 
the CHMP press release 
90% of summaries of opinion 100% 
Percentage of initial EPARs 
published within 2 weeks of the 
Commission decision 
80% of marketing authorisations 
granted 
44% 
Percentage of EPAR summaries 
in a language understandable to 
the public, published together 
with the EPAR 
80% of EPARs 100% 
Percentage of assessment reports 
published within 2 months of 
withdrawal of a marketing-
authorisation application 
70% of assessment reports None were published within 2 
months of withdrawal of the 
marketing authorisation 
application 
Percentage of refusal assessment 
reports published within 2 weeks 
of the Commission decision 
70% of assessment reports None were published within 2 
weeks of the Commission 
decision 
Publication of ‘question and 
answer’ documents for 
Community-interest referrals and 
Article 107(2) procedures at the 
time of CHMP opinion 
100% of ‘question and answer’ 
documents 
Community interest referrals: 
100%* 
Article 107(2): 100% 
 
*In one instance a decision was 
taken not to publish a Q&A 
document 
 
2.12 Scientific committees, working parties and scientific advisory groups 
Committee for Medicinal Products for Human Use 
The Committee for Medicinal Products for Human Use (CHMP) is responsible for the scientific 
evaluation and provision of scientific opinions to the European Commission for the authorisation and 
maintenance of medicinal products. The CHMP provides scientific advice and protocol assistance to 
pharmaceutical enterprises during the process of medicines development. The CHMP also provides 
scientific opinions on medicinal products involved in arbitration and referral procedures, on medicinal 
products intended for use outside the European Union, and on any scientific matter at the request of the 
European Commission or the Executive Director of the Agency. Furthermore, the CHMP is involved in 
work undertaken in the fields of harmonisation of technical requirements for pharmaceutical regulation, 
pharmacovigilance and public-health threats. 
 
 The composition of the CHMP was renewed in June 2007, following expiry of the three-year mandate 
of most CHMP members. 
 The CHMP elected Eric Abadie as new Chair and Thomas Salmonson as Vice-chair at its June 2007 
meeting. 
 The CHMP co-opted four new members in September 2007. 
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 The CHMP rules of procedure were revised in March 2007. 
 An electronic meeting-documents system was introduced in order to move towards paperless CHMP 
meetings. 
 The CHMP held 11 meetings in 2007, each of them lasting four days. 
 
Committee for Orphan Medicinal Products 
The Committee for Orphan Medicinal Products (COMP) is responsible for making recommendations to 
the European Commission for the designation of orphan medicinal products for rare diseases. The COMP 
is also responsible for advising the European Commission on the development of a policy on orphan 
medicinal products, and for assisting the liaison with international partners and patients’ organisations on 
this issue. For more information, refer to section 2.1. 
 
 The COMP met 11 times in 2007, with each meeting lasting up to two days. 
 
Committee on Herbal Medicinal Products 
In addition to the tasks described in section 2.8, the Committee on Herbal Medicinal Products (HMPC) 
helps to harmonise procedures and provisions concerning traditional herbal medicinal products laid down 
in the Member States, and helps to further integrate herbal medicinal products in the European regulatory 
framework. 
 
 Following completion of its three-year term and subsequent renomination of the majority its members, 
the HMPC met for the first time in its new composition on 31 October 2007. Dr Konstantin Keller was 
re-elected as Chair; Dr Ioanna Chinou was elected as Vice-chair. 
 The HMPC met 6 times in 2007, with each meeting lasting one and a half days. 
 
Paediatric Committee 
The Paediatric Committee (PDCO) conducts assessment and agreement of, and verification of compliance 
with, paediatric investigation plans. The PDCO also establishes lists of waivers of specific or classes of 
medicinal products that are not suitable or necessary for the treatment of children. The PDCO advises the 
EMEA on the development of a European network of paediatric research. For more information, refer to 
section 2.7. 
 
 The first meeting of the PDCO took place on 4-5 July 2007. 
 Daniel Brasseur, former Chair of the CHMP and the former Paediatric Working Party, was elected 
Chair; Gérard Pons was elected as Vice-chair. 
 The PDCO met 7 times in 2007, with each meeting lasting up to three days. 
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Standing and temporary working parties and scientific advisory groups 
The working parties of the EMEA scientific committees responsible for medicinal products for human use 
are involved in the development and revision of guidelines, and the provision of recommendations and 
advice on medicinal products for which applications are made. In addition, they contribute to marketing-
authorisation, traditional-use registration, post-authorisation and post-registration activities, according to 
the specific area of responsibility of each group. This includes providing advice and recommendations on 
general public-health issues relating to medicinal products. 
Scientific advisory groups are established by the CHMP to evaluate and advise on specific types of 
medicinal products or treatments. They are composed of experts from academia and university hospitals, 
representing various schools of thought and medical practices in the EU. 
 
 The Agency discussed with the Member State competent authorities and the CHMP the mandate of 
the Pharmacovigilance Working Party (PhVWP). Implementation of the PhVWP mandate for non-
centrally authorised medicines is ongoing, as is an exercise to optimise the interaction between the 
CHMP and the PhVWP. 
 The EMEA Human Scientific Committees’ Working Party with Patients’ and Consumers’ 
Organisations (PCWP) replaced the EMEA/CHMP Working Group with Patients’ and Consumers’ 
Organisations. 
 An EMEA/CHMP Working Group with Healthcare Professionals’ Organisations was established in 
2007. 
 Work continued on improving the cost-effectiveness of the arrangements for working parties. A 
review of the mandates of the working parties, the distribution of work, and support provided to them 
by the secretariat was begun, in order to improve the effectiveness of the arrangements for working 
parties. 
 As a result of the new legislation on paediatric medicines and the establishment of the Paediatric 
Committee, the CHMP Paediatric Working Party ceased its activities during 2007. 
 Eleven meetings of scientific advisory groups (SAGs) were held in 2007. The oncology and 
cardiovascular issues SAGs each held 3 meetings. The latter SAG was established in 2007. 
 
2.13 Coordination Group for Mutual-Recognition and Decentralised Procedures–
Human 
The Agency provides secretarial support to the Coordination Group for Mutual-Recognition and 
Decentralised Procedures–Human (CMD(h)) and its sub-groups/working groups, in accordance with the 
approved rules of procedure. The work of the CMD(h) is essential for the effective authorisation and 
maintenance of more than 90% of medicines entering the EU market. The mutual-recognition procedure 
(MRP) and the decentralised procedure (DCP) are the primary authorisation routes for generic 
applications within the EU. Through its work on referral procedures and the identification of SPC 
harmonisation lists, the CMD(h) supports the entry of such products into the EU market. 
 
A full report on the CMD(h)’s activities in 2007 is available here: 
http://www.hma.eu/uploads/media/CMDh_2007.pdf 
 
 The CMD(h) met 11 times in 2007, with each meeting lasting two to three days. 
 Forty-four MRP applications and 25 DCP applications were referred to the CMD(h) in 2007. 
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 Agreement was reached for 51 MRP and 12 DCP applications (applications submitted in 2006 or 
2007). 
 Fifteen MRP and 7 DCP applications were referred to the CHMP in accordance with Article 29(4) of 
Directive 2001/83/EC, as amended. 
 The EMEA facilitated liaison of the CMD(h) with other scientific forums and with Interested Parties. 
−  A document on interaction between PhVWP and CMD(h) was endorsed. 
−  A meeting of the CMD(h) and the EMEA with representatives of Interested Parties, on the 
submission of paediatric studies in accordance with Articles 45 and 46 of the Paediatric 
Regulation, was held in May 2007. 
−  A meeting between the CMD(h) and representatives from the European Generic Medicines 
Association (EGA) was held in June 2007 to discuss proposals for a work-sharing initiative for 
patient consultation across Europe. 
 The EMEA provided support to CMD(h) sub-groups and working groups, including the 
Communication Tracking System (CTS) Working Group; the Sub-group on Harmonisation of SPCs; 
the Joint CMD(h)-PhVWP WG, in cooperation with the PhVWP Secretariat; the CMD(h)/EMEA Sub-
group on Paediatric Regulation, in cooperation with the EMEA Paediatric Team; the Sub-group with 
GCP Inspectors; the Ad hoc Working Group on Validation issues/National requirements; the Ad hoc 
Working Group on work-sharing for patient consultation; and the Ad hoc Working Group on 
decentralised procedure. 
 The CMD(h) agreed a new list of medicinal products for which a harmonised summary of product 
characteristics should be drawn up. 
 
 Total started in 2007* Under evaluation in 
2007* 
Ended 
positively 
in 2007* 
Referrals 
to 
CMD(h) 
in 2007 
Referrals 
to 
CHMP 
in 2007 
New applications 
MRP 
396 159 441 44 15 
New applications 
DCP 
1,033 1,038 386 25 7 
Type-IA variations 5,864 134 5,640 N/A N/A 
Type-IB variations 2,355 236 2,298 N/A 2 
Type-II variations 2,461 1,130 2,167 N/A 6 
 
*The numbers include multiple procedures as stated at 31 December 2007. 
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2.14 Regulatory activities 
The Agency provides regulatory and procedural advice to the pharmaceutical industry during the lifecycle 
of medicinal products, from scientific advice and pre-submission meetings with applicants through to 
post-authorisation and annual meetings with marketing-authorisation holders. It develops and updates 
guidance documents focusing on the key steps of the centralised procedure, as well as on issues of quality, 
safety and efficacy of medicinal products, to facilitate use of the centralised procedure and support the 
submission of applications of the required quality. 
The Agency also works to continuously address regulatory and procedural issues affecting the EMEA 
committees, standing and temporary working parties, and associated groups. 
Regulatory support was provided in various ways in 2007. 
 Regular training was continuously provided to EMEA staff on topics stemming from the 2004 2005 
Community legislation. 
 Various guidance documents were updated to better reflect the new legislative tools, including in the 
field of SMEs. 
 Extensive preparatory work went into the implementation of the paediatric legislation, including the 
setting-up of the new Committee (PDCO). 
 Preparations for the implementation of the advanced therapies legislation began in 2007. 
 A revision of the guideline on invented names was finalised, following extensive discussions with the 
European Commission and pharmaceutical industry, and a public consultation. 
  
3. MEDICINES FOR VETERINARY USE 
3.1 Scientific advice 
Scientific advice is a priority area for the EMEA. The provision of scientific advice helps companies with 
their development programmes, and thus contributes towards bringing innovative medicines to the market 
more quickly. 
The Agency provides advice on specific questions that typically arise during the research and development 
of medicinal products, relating to quality, safety or efficacy, or to the establishment of maximum residue 
limits. 
3.1.1 Core activities 
 The level of activity in relation to scientific advice was lower in 2007 than expected: 7 requests for 
scientific advice were received in contrast to the original, optimistic forecast of 16. By comparison, 14 
requests were received in 2006, which was a very active year. 
 At this stage, there is no suggestion that there is a general trend for decreasing activity in this area, but 
the level of activity will continue to be monitored. 
 The average time required to finalise procedures for provision of scientific advice in 2007 was 48 
days, which is a reduction from 55 days for 2006. 
 Two marketing authorisations were issued in 2007 that had previously had scientific advice from the 
Committee, one a pharmaceutical for dogs to treat congestive heart failure and one a vaccine for pigs 
against porcine circovirus infection. 
 
 Scientific-advice requests received 
(2005 - 2007)
10 
14
7
0 
2 
4 
6 
8 
10 
12 
14 
16 
2005 2006 2007
 
 
Free scientific advice for minor uses and minor species 
 Free scientific advice was granted in 2007 under the provisions of the programme for minor uses and 
minor species for 2 applications, one related to development of a vaccine for sheep, goats and cattle 
and one concerning a live vaccine for wild rabbits. There is therefore continued interest in this 
measure designed to promote authorisation of products indicated for limited markets. 
3.1.2 Specific objectives for 2007 
 The EMEA completed an exercise to measure the level of satisfaction of applicants with the quality 
and conduct of scientific advice. 
− A survey was conducted on the views of applicants as to the quality of the scientific advice 
provided and the efficiency of the procedures. A total of 15 questionnaires were returned, out of 
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21 sent out, and these were analysed. The results indicated a very high level of satisfaction with 
the procedure (87% of applicants were either very satisfied or satisfied). Satisfaction was due to 
the clarity of the advice given, timely assessment of documentation, the smooth procedure and 
good guidance provided. In all, 87% of applicants indicated they would consider scientific advice 
in the future. 
− Some improvements have been implemented already, such as amendments to the web guidance 
document to indicate the quality of advice is improved if applicants take a position and provide 
their reasoning rather than ask completely open questions. 
 
Performance indicators 
Performance indicator Target Outcome at end of 2007 
Scientific-advice requests 
evaluated within the procedural 
timelines 
100% of applications 100% 
 
3.2 Initial evaluation 
Applications for new medicines are reviewed by the Agency by means of assessment carried out by the 
Committee for Medicinal Products for Veterinary Use (CVMP). The CVMP assesses the quality, safety 
and efficacy of every new veterinary product that is subject to the Community or centralised procedure 
and, based on the overall balance of the benefits and risks of the medicine, gives its opinion on whether or 
not the European Commission should grant a Community-wide marketing authorisation. 
3.2.1 Core activities 
Applications received 
 The Agency received a total of 15 initial marketing-authorisation applications, 8 of which were for 
pharmaceutical products and 7 for immunologicals. 
 Of the 8 pharmaceutical applications, 1 was a generic application. Five concerned medicinal products 
for companion animals, principally dogs, and the other 3 concerned medicines indicated for pigs, 
cattle and rabbits. 
 All 7 immunological applications were indicated for food-producing animals: 2 for poultry, 2 for pigs, 
1 for cattle, 1 for both cattle and sheep, and 1 for horses. 
 Two applications were made for medicines that had received free scientific advice under the 
programme for minor uses and minor species.  
 Overall, these figures are consistent with a trend towards the introduction of immunological methods 
of control for disease problems in food-producing animals and an emphasis on companion-animal 
products in the field of veterinary pharmaceuticals. 
 
New applications for veterinary medicines
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Opinions adopted 
 In 2007, the CVMP adopted a total of 9 positive opinions for initial marketing-authorisation 
applications; 4 less than in 2006. 
 Two opinions were adopted following accelerated assessment of the application. 
 The CVMP recommended a marketing authorisation under exceptional circumstances for 2 medicines. 
 Assessment of new applications by the CVMP took an average of 200 days. This increase from 183 
days in 2006 arose due to fewer accelerated procedures being completed in 2007. 
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Animal-health benefits of medicines recommended for approval in 2007 
The CVMP recommended authorisation of 2 vaccines against avian influenza in poultry, mainly chickens. 
Applications for these 2 vaccines were evaluated on an accelerated timetable, with opinions adopted in 90 
and 120 days, taking into account the epidemiological situation within the EU and the contribution of the 
Agency to pandemic preparedness. The vaccines were authorised under exceptional circumstances and are 
subject to specific obligations and follow-up measures, including enhanced pharmacovigilance measures, 
to ensure the safe use of the products. 
The CVMP adopted positive opinions for 2 vaccines for pigs against porcine circovirus type 2. Porcine 
circovirus is involved in the aetiology of porcine multisystemic wasting syndrome (PMWS), which is 
considered one of the most significant challenges facing the pig industry in the EU, and the authorisation 
of these products should assist with control of this disease. 
Other medicines that were recommended for approval included: a medicine to treat heart failure in dogs; a 
medicine to obtain temporary infertility in male dogs; a medicine for treatment of overweight and obese 
dogs; a generic medicine for treating musculoskeletal disorders in dogs. 
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3.2.2 Specific objectives in 2007 
 The EMEA and its scientific committees have been extremely active in relation to preparing measures 
aimed at promoting the availability of products for limited markets, including products for minor use 
and minor species (MUMS). 
− The CVMP produced internal reflection papers on the criteria to be used for defining a limited 
market and on the procedure whereby the committee formally classifies a product as indicated for 
a limited market. 
− The CVMP endorsed a set of proposals for measures that could be provided by the EMEA to 
assist companies with the submission of applications through the centralised procedure relating to 
limited markets in line with the requirements of Article 79 of Regulation 726/2004. These 
proposals require contributions from both the Agency and national competent authorities. They 
form part of the overall response of the European regulatory network to the problem of the lack of 
availability of veterinary medicines. 
− Promoting access to vaccines against the major epizootic diseases of domestic livestock has 
remained a high priority for the Agency, in particular with respect to avian influenza and 
bluetongue. Bluetongue is an insect-borne disease of domestic ruminants, principally sheep, 
whose geographical range has now spread to include much of the EU. Vaccination is seen as an 
important method of control and there is therefore an urgent need to make available to competent 
authorities vaccines authorised through the centralised procedure for use in Commission-approved 
vaccination campaigns. To facilitate this procedure, the CVMP adopted a reflection paper on 
minimum data requirements for an authorisation under exceptional circumstances for vaccines for 
emergency use against bluetongue. 
− The Agency continues to give a high priority to authorisation of vaccines against avian influenza 
in chickens on the basis that control of the disease in chickens reduces the likelihood of a 
pandemic developing due to transfer from birds to man. In this context, the CVMP adopted a 
positive opinion for an H7 avian influenza vaccine. 
− In collaboration with IFAH-Global, the EMEA hosted a Global Animal Health Conference on 15-
16 November 2007. This two-day meeting brought together all of the major stakeholders in animal 
health, including industry, academia, international animal-health organisations and regulators 
from around the world. The meeting considered the major challenges facing the development of 
new medicines and the continued availability of existing ones. A series of conclusions were 
reached that will assist decision-makers in the relevant organisations. 
 The CVMP continued its efforts to ensure high-quality assessments and improvement of information 
to the public. In particular, the CVMP and the secretariat started work to develop a revised approach 
on peer-review of assessments with the intention of further enhancing the quality and consistency of 
the work of the CVMP. 
 A prototype scientific-memory database related to veterinary applications was completed but a 
decision was taken not to progress to an operational version due to limited functionality. Further work 
to develop a scientific-memory database for veterinary applications will be progressed in parallel with 
future development of the corresponding human database. 
 
Performance indicators 
Performance indicator Target Outcome at end of 
2007 
Percentage of products evaluated within the 
regulatory timeline of 210 days 
100% of 
applications 
100% 
Percentage of opinions sent to the European 100% of 0%* 
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Commission within the regulatory timeline of 15 
days 
applications 
 
* Compliance with this target requires timely action by applicants and Member States to enable EMEA to 
meet the 15-day deadline, which was not forthcoming in 2007. However, EMEA achieved 100% 
compliance with submitting the opinion to the Commission in English (only). 
 
3.3 Establishment of maximum residue limits 
If food-producing animals are treated with medicines, residues may remain in the food produced by or 
from them. To obtain a marketing authorisation for a veterinary medicinal product intended for use in a 
food-producing species, so-called maximum residue limits (MRLs) for all pharmacologically active 
substances must be established in advance for the animal species concerned and for its tissues or products, 
e.g. meat, milk, honey, etc. An MRL is the safe level of residue in food that can be consumed by a person 
every day over a lifetime without it causing a harmful effect. 
3.3.1 Core activities 
Applications for MRLs 
 In 2007, the EMEA received and validated 2 new applications for MRLs – 1 fewer than was forecast 
for the year. 
 The small number of new MRL applications is of concern as it clearly shows that very few new 
molecules are being introduced onto the veterinary market. The ongoing decrease in MRL 
applications is consistent with the comparatively greater interest currently seen for the development of 
new pharmaceutical products for companion animals rather than for food-producing animals, and with 
the trend to develop more immunological products, as in both of these cases there is no requirements 
to establish an MRL for the active principle thereby reducing the cost and time of bringing a product 
to market. 
 There was also a shortfall in the number of applications submitted for extension or modification of 
MRLs, with only 1 of the forecast 5 being submitted. 
 The lack of uptake  of extension applications is possibly related to the fact that many extensions that 
are of interest to companies have already been undertaken by the CVMP as free-of-charge 
extrapolations over recent years in the CVMP’s efforts to facilitate authorisation of products for 
MUMS. 
 However, concerns remain that this decrease of interest in MRL applications and extensions could 
mean that, despite the efforts of facilitating the marketing authorisations for MUMS products and 
establishing specific guidelines allowing reduced data requirements to cater for these specific 
products, an adequate incentive to develop products for minor species and minor uses has yet to be 
established. The matter will require further analysis. 
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Opinions on maximum residue limits 
 The CVMP adopted 3 positive opinions for the establishment of new MRLs. 
 One positive opinion related to the establishment of final MRLs further to previous provisional MRLs 
for a new substance. 
 Four positive opinions related to the extension of existing MRLs to other species. 
 All applications for new MRLs and for extension or modification of MRLs were processed within the 
120-day legal timeframe. 
Opinions for extension applications and extrapolations of 
maximum residue limits (2005 - 2007)
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3.3.2 Specific objectives in 2007 
 Strengthened MRL review process. 
 No actions were ultimately considered necessary in this area. 
 Following a review of the MRL review process, the EMEA considered that no actions are necessary in 
this area. 
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 The Agency provided technical and scientific advice to the Commission in its work to revise the MRL 
Regulation (Council Regulation (EEC) No 2377/90) in line with ‘Better Regulation’ principles. 
Further input will be required during 2008 in this highly complex area. 
 
Performance indicators 
Performance indicator Target Outcome at end of 
2007 
Percentage of applications evaluated within the 
120-day timeline 
100% of 
applications 
100% 
 
3.4 Post-authorisation activities 
Changes to the terms of marketing authorisations are made frequently during the life of a medicine. 
Marketing authorisation holders may want to change the manufacturing process, alter or improve the 
medicinal product, or introduce additional warnings and contraindications. These changes, known as 
variations, require formal approval. Variations can involve either minor (type IA or IB) or major (type II) 
changes. 
Besides variations, post-authorisation activities also include line extensions and transfers of marketing 
authorisation. 
3.4.1 Core activities 
 The overall number of applications for variations to marketing authorisations received in 2007 was 
significantly higher than in 2006, in part accounted for by the greater number of centrally authorised 
products on the market. It is therefore likely that this trend for an increase in post-authorisation 
activity will increase in coming years. 
 A total of 53 type-I variation applications were received, relating to 29 type-IA and 24 type-IB 
variations. 
 There were also 47 applications relating to the more complex type-II variations. Of these, 13 
concerned pharmaceutical products and 34 concerned immunological products. 
 Six of the variations concerning pharmaceuticals related to changes in quality, 5 related to clinical 
changes and 2 related to updates of summary of product characteristics (SPC) and the package leaflet 
(PL). 
 Twenty variations concerning immunologicals related to quality changes, 8 related to clinical changes 
and 6 related to updates of SPC and PL. 
 There were 9 applications for extension of marketing authorisation. Of these, 5 concerned 
pharmaceutical products (3 for a new pharmaceutical form, 1 additional target species and 1 deletion 
of a route of administration), whilst 4 concerned immunologicals (all relating to a quantitative change 
to the active substance). 
 The total number of type-II opinions adopted in 2007 was 45. Of these, 11 were received in 2006 (2 
for new indications, 1 for update of product literature and 8 quality changes), and 34 were received in 
2007 (8 updates of SPC and PL, 1 new presentation, 7 new indications and 18 other quality changes). 
 All variation applications were evaluated within the regulatory time limits. 
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3.4.2 Specific objectives in 2007 
 EPAR summary updates for line extensions. 
 EPAR summaries are now updated on a regular basis for line extensions. 
 Assist Commission with revision of the regulation governing variations. 
 Input was provided to the Commission with respect to how proposed revision of the variations 
regulation would affect processing of variations to centrally authorised veterinary medicinal products. 
 Procedures for monitoring the actual placing on the market of medicines. 
 A simplified reporting procedure for ensuring that marketing-authorisation holders meet the 
requirements of the ‘sunset clause’ was endorsed by the CVMP. This procedure is appropriate for the 
needs and resources available in the veterinary sector. 
 
Performance indicators 
Performance indicator Target Outcome at end of 
2007 
Percentage of applications for type-I and II 
variations and line extensions evaluated within the 
regulatory timelines 
100% of 
applications 
100% 
Percentage of applications meeting the legal 
timeline of 27 days for the linguistic post-opinion 
checking procedure 
100% of 
applications 
0%* 
 
* Compliance with this target requires timely action by applicants and Member States to enable EMEA to 
meet the 27-day deadline, which was not forthcoming in 2007. However, EMEA achieved 100% 
compliance with submitting the opinion to the Commission in English (only). 
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3.5 Pharmacovigilance and maintenance activities 
This activity relates to pharmacovigilance information, including adverse-drug-reaction reports (ADRs) 
and periodic safety-update reports (PSURs). Pharmacovigilance remained a high priority for the Agency 
in 2007, to ensure that effective risk-management was continuously applied to post-authorisation 
monitoring of veterinary medicines throughout the EU. 
 
Pharmacovigilance in the veterinary sector in the EU continues to undergo changes triggered by the new 
legislation. The electronic exchange of pharmacovigilance information within the EU is improving, as are 
active surveillance, harmonisation and risk management. 
3.5.1 Core activities 
 A marked increase in expedited reporting of suspected adverse reactions was observed. The number of 
reports received was almost double the number of reports received in 2006. It is believed to result 
from, among other factors, the Agency’s efforts to promote awareness of expedited reporting. 
 For centrally authorised veterinary products, a total of 1,424 expedited spontaneous reports of 
suspected adverse reactions were reported within the 15-day legal timeframe in 2007. 
 1,212 of the 1,424 reports received related to suspected adverse reactions in animals and 213 to 
reactions in humans following exposure to a veterinary medicinal product. 
 133 reports received related to food-producing animals (mainly cattle, pigs and horses), following 
treatment of 17,459 animals, of which 4,428 showed suspected adverse reactions: 
− 659 related to suspected adverse reactions in dogs; 
− 389 related to suspected adverse reactions in cats; 
− 569 originated within the EU. 
 81 periodic safety-update reports (PSURs) were received in 2007 for centrally authorised products. 
 Following its review of PSURs, the CVMP recommended in 6 cases that variations be submitted for 
the products concerned, mainly for the addition of new adverse-reaction information to the product 
literature. 
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3.5.2 Specific objectives in 2007 
 The preparation of guidance documents is a continuous activity for the CVMP and its 
Pharmacovigilance Working Party. In 2007, this activity focused on the preparation of a new Volume 
9B of the Rules Governing Medicinal Products in the European Union. Guidance prepared included: 
− pharmacovigilance of medicinal products for veterinary use, a guideline for marketing 
authorisation holders for monitoring of compliance with pharmacovigilance regulatory obligations 
and pharmacovigilance inspections; 
− guidance for regulatory authorities concerning the assessment of PSURs. 
 Further to the publication of the Simple Guide to Veterinary Pharmacovigilance in the EU in English 
in 2006, several Member States made this guide publicly available in their national language(s) as part 
of efforts to promote pharmacovigilance and safety reporting. 
 Development of EudraVigilance Veterinary (EVV) continued in 2007. 
− EudraVigilance Veterinary became the main reporting tool used by national competent authorities, 
now containing a total of 11,000 case reports in the database. 
− Only a few reports were submitted electronically by marketing-authorisation holders, with the 
majority of the large veterinary pharmaceutical companies still being in the implementation and 
testing phase. 
− Development of EVV was delayed for a period of some 6 months during 2007 due to re-
prioritisation of resources to further development of the Eudravigilance (human) data warehouse. 
Following resumption of activity on EVV, the Agency and the Vet Joint Implementation Group 
developed the EudraVigilance Veterinary Action Plan, which was endorsed by the EMEA 
Management Board and the Head of Medicines Agency. This plan now gives the required 
predictability to future development of EVV that is necessary for national competent authorities to 
commit the necessary resource to ensure its full and timely implementation. 
− Good progress was made on developing the DataWarehouse tool to facilitate continuous 
monitoring and signal detection of pharmacovigilance data in EudraVigilance Veterinary. The tool 
is now being tested by a subgroup of the Pharmacovigilance Working Party. The DataWarehouse 
is expected to become fully operational in 2008. 
− Following training sessions on the use of EudraVigilance Veterinary in previous years, a first 
training on scientific DataWarehouse queries took place. Assistance is provided on a day-to-day 
basis to Member States for the import of product-related data in the product dictionary of 
EudraVigilance Veterinary. 
 Major milestones in the discussions for international standards outside the EU were reached, in 
particular with an agreement between Japan, the US and Europe within the VICH initiative on the 
required data elements for reporting and exchanging adverse-events data related to veterinary 
medicinal products. 
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 During the year, a refined action plan was established for the European Surveillance Strategy, now 
including priorities for promotion of adverse-reaction reporting, implementation of electronic 
reporting of these reactions, data analysis, and worksharing between Member States. Communication 
on safety issues between all stakeholders is also considered a high priority. 
 
Performance indicators 
Performance indicator Target Outcome at end of 
2007 
Percentage of PSURs evaluated within the 
established timeline of 60 days 
80% of PSURs 49%* 
 
* This target was not met in 2007 due to a higher than usual proportion of PSURs requiring follow-up and 
of PSURs associated with renewals, both of which extend the timeline for completion of the evaluation. 
 
3.6 Arbitration and Community referrals 
Arbitration procedures are initiated because of disagreement between Member States within the 
framework of the mutual-recognition procedure (Article 33 of Directive 2001/82/EC, as amended). 
Referrals are initiated either in order to obtain harmonisation within the Community of the conditions of 
authorisation for products already authorised by Member States (Article 34 of Directive 2001/82/EC) or in 
cases involving the interests of the Community or concerns relating to the protection of human or animal 
health or the environment (Articles 35 and 40 of Directive 2001/82/EC). 
3.6.1 Core activities 
Procedures started in 2007 
 The number of referrals made to the CVMP in the framework of the mutual-recognition procedure 
was considerably lower than estimated. 
 This is was in part due to the efforts made by the Coordination Group for Mutual-Recognition and 
Decentralised Procedures-Veterinary (CMD(v)) in cooperation with the CVMP to solve contentious 
issues between Member States before they become the subject of arbitration. 
 A total of 6 referral procedures were initiated, in contrast to the 13 forecast, of which 1 related to 
safety concerns for existing products. 
 Three of the referrals were made under Article 33 and 3 were made under Article 35 of 
Directive 2001/82/EC. 
Referral procedures concluded in 2007 
 The CVMP completed the assessment and issued opinions on 3 of the referral procedures started in 
2007 and on 7 of the referral procedures started in 2006. 
 All referrals were processed within the legal timeframe. 
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A list of referral procedures can be found in Annex 18. 
3.6.2 Specific objectives in 2007 
 Joint efforts continued between the CVMP and the Coordination Group for Mutual-Recognition and 
Decentralised Procedures-Veterinary (CMD(v)) to promote efficient cooperation in order to ensure 
harmonised and consistent scientific and regulatory approaches; to avoid duplication of efforts; and to 
ensure that arbitrations referred to the CVMP relate to scientific rather than regulatory or procedural 
issues. 
− The Chair of the CMD(v) attends meetings of the CVMP and its Strategic Planning Group to 
ensure effective liaison between the two Committees. 
− In consultation with the Commission, the CVMP made progress on the appropriate procedures for 
handling referrals that relate to the safety and efficacy of generic products. It is hoped that this 
will ultimately lead to fewer, but more appropriate, referrals to the Committee. 
Performance indicators 
Performance indicator Target Outcome at end of 2007  
Percentage of arbitration and 
referral procedures managed 
within the legal timeline 
100% of procedures 100% 
 
3.7 Committee for Medicinal Products for Veterinary Use 
 The Committee for Medicinal Products for Veterinary Use (CVMP) met 11 times in 2007. 
 The Committee completed the exercise to renew or replace the nominations of members following the 
expiry of the first mandates under the revised legislation. 
 Gerard Moulin was re-elected Chair of the CVMP and Anja Holm was elected Vice-chair. 
 The Committee reviewed the expertise available to it and appointed co-opted members to provide 
additional expertise as needed. A similar exercise was conducted where necessary for working parties. 
Methodology for benefit-risk assessment 
 The CVMP developed a methodology for the systematic assessment of the benefit-risk balance of 
medicines for veterinary use. The Committee considered in detail how to ensure that the analysis of 
the benefit-risk balance is conducted in a systematic and scientifically robust manner. A guideline on 
the evaluation of benefit-risk balance was prepared and published for consultation during 2007. Close 
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liaison was maintained with the CHMP, which is likewise developing a methodology in this area in 
relation to products for human use. 
Environmental risk assessment 
 The CVMP, with the support of its Working Party on Environmental Risk Assessment, continued to 
provide advice for the implementation of the requirements of the amended Veterinary Directive 
regarding environmental risk assessment. This is a high-profile and difficult area in which the 
requirements for a thorough environmental risk assessment need to be weighed against the impact that 
excessive data requirements could have on the availability of veterinary medicines. Detailed practical 
guidance to applicants and competent authorities that will facilitate carrying out the environmental 
risk assessments for veterinary medicinal products and allow for a harmonised approach was 
completed in 2007. Guidance aimed at clarifying the legal requirements has also been further 
advanced, in cooperation with the Commission, and is expected to be finalised in 2008. 
Activities relating to antimicrobial resistance 
 The CVMP, together with the Scientific Advisory Group on Antimicrobials (SAGAM), continued its 
activities in relation to antimicrobial resistance. 
− On the basis of recommendations from the SAGAM, the CVMP finalised its position statement on 
the use of quinolones and fluoroquinolones in the EU, critically reviewing recent data on their use 
and their potential impact on human and animal health. 
− Efforts continued to implement, together with Heads of Agencies of EU Member States, risk-
management actions for (fluoro)quinolone-containing veterinary medicines. 
− The CVMP developed a proposal for antimicrobial-resistance surveillance as a post-marketing 
authorisation commitment. 
− The CVMP drafted a reflection paper on third- and fourth-generation cephalosphorins, similarly 
addressing their use and potential impact on resistance-development in relation to human and 
animal health. 
Liaison with other scientific committees and EU institutions 
 The committee maintained close working relationships with a number of other scientific committees 
of EU institutions to ensure consistency and relevant exchange of information. Notably, there were 
numerous exchanges with the scientific panels of the European Food Safety Authority. 
− The Committee provided input to the opinions of the Animal Health and Welfare Panel on 
bluetongue, avian influenza, echinococcus, ticks and fish vaccines. 
− There were exchanges with the Scientific Panel on Additives and Products or Substances used in 
Animal Feed to ensure consistency between scientific opinions for veterinary medicines and feed 
additives. 
− The CVMP and CHMP both provided input into a review of an opinion from the Panel on 
Genetically Modified Organisms on the use of an antibiotic-resistance gene as a marker in a 
genetically modified plant. 
Working parties and scientific advisory groups 
 The working parties to the CVMP were extremely active during 2007, developing a wide range of 
guidelines and guidance documents. 
 Focus-group meetings and workshops were organised involving external stakeholders on the topics of 
fibrosarcomas at sites of injection of veterinary medicines in cats, anticancer treatments for dogs and 
cats, the CVMP guidance on user safety, and the description of pharmacovigilance systems and 
pharmacovigilance inspections. 
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 Training of assessors with the aim of ensuring a consistent level of knowledge and promoting 
harmonisation of assessments throughout the Community was provided by the CVMP working parties 
on environmental risk assessment, efficacy, pharmacovigilance and safety. 
 
3.8 Coordination group 
Heads of Medicines Agencies–Veterinary website: http://www.hma.eu/veterinary.html 
The Coordination Group for Mutual-Recognition and Decentralised Procedures–Veterinary (CMD(v)) met 
on a monthly basis in 2007. One informal meeting was held in Helsinki, Finland. 
Procedures started and concluded in 2007 
 Eighty-four mutual-recognition procedures (MRPs) were started for a total of 75 products, and 80 
decentralised procedures (DCPs) were started for a total of 65 products. 
 Ninety mutual-recognition procedures were finalised for a total of 76 products, including 1 referral 
carried over from 2006. Thirty decentralised procedures were finalised for a total of 26 products, 
including 1 referral carried over from 2006. 
 Four MRP products and 3 DCP products were referred to the CMD(v) and 4 products were referred to 
the CVMP for arbitration. One product did not reach Day 60 in 2007. 
 
 Started 
products (procedures)  
Finalised 
products (procedures)  
CMD(v) 
referrals 
CVMP 
referrals 
MRP 75 (84) 76 (90) 4 2 
DCP 65 (80) 26 (30) 3 2 
 
 The CMD(v) addressed a number of questions from industry and from Member States, most of them 
in relation to the appropriate legal base for new applications and for variations to veterinary medicinal 
products. The administrative handling of products containing diluents was agreed and communicated, 
thus preventing unnecessary invalidation of applications. With regard to the availability of medicines, 
an ad hoc working group was set up to address industry’s proposals to modify the label requirements 
for packaging texts. 
 In consultation with the Heads of Medicines Agencies for veterinary medicines, the CMD(v) agreed 
on the principles for handling generic applications, in particular with regard to the European reference 
product and the situation where indications, withdrawal periods and target species have not been 
authorised for the reference product in a Member State. 
 The group also drafted various best-practice guides, standard operating procedures and Q&A 
documents. 
 Three meetings were held – with IFAH-Europe, the European Group for Generic Veterinary Products 
(EGGVP) and the Association for Veterinary Consultants (AVC) – to discuss regulatory issues. 
 The EMEA provided full secretariat and administrative support to the CMD(v). 
4. INSPECTIONS 
4.1 Inspections 
The EMEA coordinates the verification of compliance with the principles of good manufacturing practice 
(GMP), good clinical practice (GCP) and good laboratory practice (GLP), and with certain aspects of the 
supervision of authorised medicinal products in use in the European Community. It does this through 
inspections requested by the CHMP or CVMP in connection with the assessment of marketing-
authorisation applications and/or the assessment of matters referred to these committees in accordance 
with Community legislation. 
Similarly, the EMEA coordinates pharmacovigilance inspections requested by the scientific committees 
and inspections of blood establishments within the plasma-master-file (PMF) certification framework. 
Communication and action by Member States in response to suspected quality defects and counterfeit 
medicines relating to centrally authorised medicines are also coordinated by the EMEA. 
4.1.1 Core activities 
Inspections 
 GMP inspection numbers (including inspections in the context of plasma master files (PMFs) were 
higher than expected (145), showing a 32% increase compared with 2006 (110). This reflects the 
increasing number of authorised products requiring re-inspection, increasing numbers of variations 
and some unanticipated PMF inspections. 
 GCP and pharmacovigilance inspection figures were also significantly over forecast, with more than 
double the number of inspections requested in 2006. This reflects an increase in the number of routine 
inspection requests in line with the policy on GCP inspections adopted in 2006, as well as in 
increasing focus on inspections in countries where there is little European experience. 
 GLP (non-clinical) inspections are on target. 
 All inspections were managed within the legislative deadlines. 
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Product defects and deviations 
 Coordination work on quality defects and counterfeits also increased significantly during 2007, 
although actual numbers of defects were in line with figures from 2005 and 2006. 
 66 quality defects were successfully coordinated, 22 of which resulted in recalls. 
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 6 of these were class-1 recalls, compared with 0 during all of 2006. 
 One of the class-1 recalls (Viracept) led to a substantial amount of follow-up activities to prevent 
reoccurrence of similar issues (critical GMP failure leading to high-level contamination with 
genotoxic impurities) for any similar centrally authorised, MRP, decentralised or national products in 
the EU (mesilate and related active substances). 
 Four out of the 6 class-1 recalls related to counterfeited centrally authorised products. 
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4.1.2 Specific objectives in 2007 
 The first phase of the EudraGMP database on manufacturing authorisations and GMP certificates was 
launched on 27 April 2007; the second phase went into production on 6 December 2007, five months 
later than anticipated. 
 A survey on the impact of the new legislation and procedural requirements on GMP for active 
substances was completed and the results analysed for the consideration by the European Commission 
of new approaches. The Commission published an online questionnaire to assess the approach on 
GMP for certain excipients and concluded that no legislative action was necessary in this area. 
 Work on implementation of the new legislation continued, with publication of draft guidelines on 
good manufacturing practice for radiopharmaceuticals and medicinal gases. 
 The EMEA coordinated activities relating to the joint audit programme for GMP inspectorates. 
 Significant progress was made on implementing the ICH guidelines on quality risk management, with 
the publication of a revised text on quality management, training and qualification of inspectors, and 
the elaboration of a document for assessment purposes. 
 In the area of pharmacovigilance inspection, a section on the pharmacovigilance system and on 
pharmacovigilance inspections was published in Volume 9 of EudraLex in February 2007. 
 Revised SOPs on coordination of GxP pre-approval inspections and coordination of product defects 
were published, successfully harmonising practices in these areas. 
 A report on major deficiencies found during GMP inspections performed in 2006 and an analysis of 
defects reported during 2006 and 2007 were completed and published. 
 Cooperation between the Member States on inspection performances and outcomes continued to be an 
important aspect in 2007. Specific bilateral meetings with three competent authorities were held as 
part of the work towards improving cooperation within the European network. One of these focussed 
on GMP, while the two others also addressed GCP and pharmacovigilance inspections. 
 Issues relating to bioequivalence studies for generic applications were addressed by a joint group 
involving GCP inspectors and members of the CMD(h). 
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Performance indicators 
Performance indicator Target Outcome at end of 2007  
Management of inspections 
within legislative timelines 
100% of inspections 100% 
 
GMP, GCP, GLP Inspectors Working Groups and Joint CHMP/CVMP Quality Working 
Party 
 The three main working parties (GMP, GCP and Quality Working Party) under the responsibility of 
the Agency’s inspection sector each met four times in 2007. 
 A meeting of the ad hoc group of GLP inspectors took place in September 2007. 
 Two meetings of pharmacovigilance inspectors took place, in February and September respectively, in 
conjunction with meetings of the GCP Inspectors Working Group, addressing compliance with 
Community procedures and information sharing. 
 A number of training activities took place in the second half of 2007, including a GCP training event, 
a workshop on quality risk management (jointly organised with PIC/S) and a workshop on specialised 
quality-assessment issues. 
 Cooperation between inspection and assessment functions continued to be developed, through the 
work of the Process Analytical Technology (PAT) team and a joint meeting of GMP inspectors and 
quality assessors in June, as well as through meetings between GCP inspectors and representatives of 
the CMD(h). A first joint workshop of the PAT team in cooperation with the Biologicals Working 
Party (BWP) was also organised. 
 New names, mandates and terms of reference were agreed and published for the GMP/GDP and the 
GCP Inspectors Working Groups. 
 
4.2 Mutual-recognition agreements 
Mutual-recognition agreements (MRAs) between the European Community and partner (third) countries 
include specific annexes relating to medicinal products and GMP. These allow EU Member States and the 
MRA partner to mutually recognise conclusions of inspections of manufacturers carried out by the 
respective inspection services of the other party, and to mutually recognise the manufacturers’ certification 
of conformity to specifications for each batch without re-control at import. The EMEA is responsible for 
implementation and operational aspects of these MRAs. MRAs with Australia, New Zealand, Switzerland, 
Canada and Japan are currently operational, but with slightly different provisions as to scope and 
applicability. 
 
 The internal evaluation of new Member States in the context of the mutual-recognition agreements 
continued, despite delays encountered due to new legislative frameworks in some of the Member 
States concerned. 
− The Commission requested that Bulgaria and Romania indicate their readiness for evaluation. 
 With the successful launch of the first phase of EudraGMP in May 2007, initial steps to extend it to 
MRA (and other international) partners were made and technical discussions are ongoing. 
 The remaining external evaluation work in the context of the EC-Canada MRA is ongoing. 
− External evaluations of Malta and Cyprus by Canada were successfully completed. 
 Dedicated discussions with the European Commission and Australian representatives on rewording of 
the MRA agreement took place, successfully facilitating the inclusion of new Member-State 
authorities within the scope. 
 Although a number of observed inspections in the context of the Japanese MRA took place, there was 
little progress on the implementation of the full scope of the GMP Annex of the EC-Japan MRA. 
 Analysis of the changes to GMP in view of the implementation of quality risk management 
discussions with MRA partners was postponed. 
 
4.3 Certificates of medicinal products 
The purpose of the EMEA scheme for certificates of medicinal products is to support the work of health 
authorities outside the European Union, in particular in developing countries. EMEA certificates are 
issued by the Agency, on behalf of the European Commission, to confirm the marketing-authorisation 
status of products authorised by the European Commission through the centralised procedure or products 
for which a centralised application has been submitted to the EMEA. The certificates also confirm 
compliance with good manufacturing practice (GMP) at the manufacturing site(s) where the medicinal 
product is produced in bulk pharmaceutical form. 
 
 The number of certificate requests increased by 28% relative to 2006, compared with an expected 
increase of 16%. 
 Certificates within the framework of cooperation with the WHO and certificates for SMEs also 
increased. 
 The Agency did substantial work on rationalisation of the certification process, including staff re-
allocation and IT developments, continuing to make the process more resource-efficient despite the 
increasing workload. A web-based application form was launched in October 2007, thus facilitating 
incorporation of requests into the database and helping to avoid errors. However, due to the increase 
in workload (50% increase since 2005), without a corresponding increase in resources, it was not 
possible to consistently meet the timelines indicated in the performance measures. 
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Performance indicator Target Outcome at end of 2007  
Percentage of certificates 
issued to requesting parties 
within the timeline 
95% compliance 90% compliance 
 4.4 Sampling and testing 
The objectives of the sampling and testing programme, derived from the legal requirements, are to 
supervise the quality of centrally authorised medicinal products placed on the market and to check 
compliance of these with their authorised specifications. This ensures that the products actually on the 
market continue to meet public and animal health requirements. Sampling from the market in different 
countries is carried out by national inspectorates and testing is performed by official medicines control 
laboratories coordinated through the European Directorate for the Quality of Medicines and HealthCare 
(EDQM). A selection of centrally authorised products is included in each annual programme. 
 
 The EMEA, the EDQM and the national authorities in the programme continued their close 
collaboration in 2007, with a view to assure effective and continued post-marketing surveillance of the 
quality of medicines. 
 Forty products were tested as part of the 2007 sampling and testing programme. 
 A new risk-based approach to the selection of products and parameters for testing was discussed and 
agreed by the relevant working parties/groups for medicinal products for human use. Specific criteria 
for veterinary medicinal products require further development. 
 The move to ‘one laboratory testing’ for chemical products was completed in 2007. A corresponding 
stepwise introduction for biological products remains under discussion. 
 In the context of the considering the most appropriate way for generic medicinal products to be 
included in future programmes, associated selection criteria and the possibility of including packaging 
and labelling details were further investigated. 
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Performance indicators 
Performance indicator Target Outcome at end of 2007  
Percentage of planned 
products (40) actually tested 
95% of planned products 100% 
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4.5 Implementation of the Clinical Trials Directives 
The Agency provided continuing support for the implementation of Directive 2001/20/EC and Directive 
2005/28/EC in 2007. 
 The Agency organised a highly successful conference with a wide range of stakeholders, examining 
the operation of the Clinical Trials Directive after three years of practical experience, and published a 
report on the feedback provided. 
 GCP-inspection-related procedures and guidelines progressed as planned, with finalisation of 
procedures relating to the conduct of inspections and the exchange of information. 
 A number of joint sessions with the CMD(h) on issues relating to bioequivalence trials were 
organised, resulting in one targeted inspection of a bioequivalence site within the centralised 
procedure and several others relating to non-centrally authorised products. 
 Work on the interpretation of GMP in the context of investigational medicinal products resulted in the 
finalisation of a number of documents, including a clarification of the respective responsibilities of the 
Qualified Person and the investigator. 
 The EMEA continued to support the Clinical Trial Facilitation Group, particularly in relation to the 
EudraCT database. 
− Increasing transparency of some parts of EudraCT was addressed in the context of EudraPharm 
and the Paediatric Regulation. 
− Work in the context of the Paediatric Regulation focussed on communication and awareness 
raising, as well as on contributing to the development of a guideline. 
 The EMEA also contributed to preparation of the ‘Guideline on strategies to identify and mitigate 
risks for first-in-human clinical trials with investigational medicinal products’ 
(EMEA/CHMP/SWP/28367/07). 
 
4.6 GMP harmonisation 
Work continued on the preparation of guidelines and Community procedures associated with 
implementation of GMP-related aspects of the new legislation. 
 GMP annexes on sterile medicinal products (Annex 1), herbal medicines (Annex 7) and 
radiopharmaceuticals (Annex 3) were finalised. 
 Draft annexes on GMP for biological medicinal products (Annex 2) and medicinal gases (Annex 6) 
were released for consultation. 
 A meeting with interested parties discussed: feedback on the published reflection paper on compliance 
with the requirements of the marketing authorisation; GMP requirements for substances whose main 
use is not in the pharmaceutical area (atypical actives); and the proposed ICH approach to 
Pharmaceutical Quality Systems (Q10). 
 A survey on experience with the operation of the 2004 legislative requirements in relation to GMP for 
active substances was also completed and analysed. 
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5. EU TELEMATICS STRATEGY 
The EU telematics strategy for pharmaceuticals is agreed between Member States, the EMEA and the 
European Commission. In order to implement European pharmaceutical policy and legislation, the various 
telematics initiatives aim to increase efficiency and enhance transparency, and to support and facilitate the 
operation of procedures established by legislation. 
The implementation strategy concentrates on a number of projects with high European added value. The 
projects that have been agreed are EudraNet, EudraVigilance, EudraPharm, electronic submissions, and 
the clinical-trials and good-manufacturing-practice databases. In addition, the Telematics Steering 
Committee has endorsed a set of horizontal services that are necessary to support the implementation of 
the systems mentioned. 
 
2007 was the fifth year of implementation of the EU telematics projects by the Agency. 
The majority of EU telematics systems were in use at the beginning of 2007. These systems are evolving 
in line with communicated requirements. The table below provides an overview of the development of 
systems in 2007. 
 
System or process 
(Status in 2006) 2007 milestones 
EudraNet 
(In production) 
High performance of EudraNet was achieved both in terms of 
system availability and quality of management, development and 
operation of EudraNet applications (EudraNet II, EudraLink, ECD, 
Experts Database, etc.). 
Inspections agencies that are not part of the national medicines 
agencies have been added into the EudraNet. Further, advanced 
network-management and performance services were implemented. 
EudraPharm 
(In production) 
EudraPharm was updated in 2007. The new features include: 
‘Advanced Search’, product information available in a number of 
EU languages in test; a new site map offering an improved 
navigation experience; and the inclusion of maximum residue limit 
(MRL) information for veterinary products. 
EudraVigilance 
(In production) 
The EudraVigilance DataWarehouse and Analysis System 
(EVDAS) was rolled out to the national competent authorities on 6 
July 2007. It is designed to support signal-detection and the 
assessment of adverse-drug-reaction reports. 
Quantitative signal-detection methodologies were included in 
EVDAS and new functionalities facilitating the review of signals 
were added to EudraVigilance. 
Eudra DataWarehouse 
(In pre-production) 
Development of the Eudra DataWarehouse was ongoing. However, 
work on the interim DataWarehouse solution for EudraVigilance 
Human had severe impact on work in this area. A first version for 
use by national competent authorities was released in September 
2007. 
EudraCT 
(In production) 
In addition to preliminary specification work for the next major 
upgrade, technical upgrades were implemented on the system. 
EudraCT Paediatrics Work on this has barely started, as guidelines fundamental to the 
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Database 
(At inception) 
determination of the scope and functionality of the proposed system 
are not yet available in final form. 
EudraGMP 
(In production) 
The first version of EudraGMP was launched in April 2007, and 
version 1.1 was released into production in December 2007. 
European Review System 
(Installation) 
The roll-out across the NCAs has resulted in the majority of NCAs 
having an installation or having opted for a different tool. Work 
remained to be done in respect of a small number of NCAs. 
PIM (Product Information 
Management) 
(In pilot production) 
Pilot activities were undertaken in respect of both new and post-
authorisation applications. A decision was taken to extend the pilot 
phase into 2008. 
EU Telematics Controlled 
Terms 
(In pilot production) 
Definition and implementation of EU Telematics controlled terms 
continued. The first pilot was released in September. 
 
Operations 
Operational support was put in place to complement the investment in systems and infrastructure over the 
past four years. The Eudra Service Desk provides assistance to users, and may be accessed by e-mail or 
telephone. Appropriate structures are maintained to provide support in accordance with the stated service 
levels, elements of which are set out below in the performance indicators. 
 
Performance indicator Target Outcome 
2007 
Project management in EU telematics 
Project delivery in accordance with stated timelines All projects 5 out of 8 
projects 
Project delivery in line with the anticipated budget All projects 2 out of 8 
projects 
Project deliverables perceived as being in line with expectations All projects 7 out of 8 
projects 
Provision of service in EU telematics 
Availability of services (excluding planned maintenance downtime) 
(during EMEA office hours) 
98% 99.8% 
Response-time to 80% of EU telematics IT ServiceDesk requests 4 hours1  3.5 hours 
Response-time to 15% of EU telematics IT ServiceDesk requests 2 days1 1.5 days 
EudraNet availability of services (excluding local NCA downtime) 99% 98.5% 
Response-time to 80% of EudraNet and EudraLink IT ServiceDesk 
requests 
3 hours1 2.5 hours 
Response-time to 15% of EudraNet and EudraLink IT ServiceDesk 
requests 
1.5 days1 1.5 days 
 
                                                     
1 These targets reflect the time required to fix the problem. 
6. SUPPORT ACTIVITIES 
6.1 Administration 
Administration tasks include managing revenue, expenditure and accounts according to existing rules and 
regulations, recruiting, managing and administering staff and seconded personnel, and providing and 
running the necessary infrastructure services for an effective functioning of the Agency. To achieve this, 
close cooperation is required with the European Parliament and the European Council (Budgetary 
Authority), as well as with the Commission and the Court of Auditors on matters relating to 
administration, the budget, personnel, and rules and regulations on finances, audit and accounting. 
Personnel and budget 
The principal objectives and tasks in the personnel and budget area are the development and timely and 
accurate management of EMEA’s human and financial resources, including budget estimation and 
management, overall financial coordination, personnel administration, recruitment procedures and 
professional training, as well as the provision of information to staff and other concerned persons on these 
matters. 
 The Agency’s total budget in 2007 was €163,113,000. 
 The number of staff employed at the EMEA was 441, plus 124 seconded national experts and contract 
agents. 
 Twenty-nine internal and external recruitment procedures were carried out. 
 The EMEA continued to invest in the professional development of staff. The number of training days 
taken by EMEA staff was up by almost 30% on the previous year, reaching a total of 4,166 days. 
 Preparations for a tender procedure for insurance provider were undertaken. A contract notice for open 
tender procedure was published on 20 November 2007. 
 An online missions system was tested in 2007. As the tested system revealed a number of difficulties, 
implementation had to be postponed. 
 A 360-degree performance-evaluation system for managers was discussed; adoption of the new 
system is expected for 2008. 
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Geographical Distribution at EMEA - 16 December 2007
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 2005 (final) 2006 (final) 2007 (final) 
Workload    
Total staff 3722 + 4433 4352 + 623 4412 + 1243 
EMEA budget €107,322,031 €136,147,083 €163,113,000 
Selection procedures 39 32 29 
Mission claims 1,186 953 940 
Salary payments 4,613 5,232 6,003 
Staff mobility 318 446 486 
 
Accounts 
The principal activities in the accounts area include: maintaining the accounts, making payments and 
collecting revenue in accordance with the procedures laid down in the Financial Regulation; efficiently 
managing the cash resources of the Agency and maintaining relationships with the Agency’s banks; 
providing accurate and timely financial information to management. 
 
 Discharge for the 2006 accounts was given by the European Parliament. 
                                                     
2 Establishment plan minus vacancy rate plus contract agents. 
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3 Number of interims, trainees, auxiliary agents and national experts. 
 A new budget and accounting system, replacing the current EMEA financial system, SI2, was selected 
in 2007. To this end, a feasibility study for a new integrated accounting system was carried out, which 
resulted in a recommendation for a new system. 
 The introduction of a new batch-invoicing system leads to important efficiency gains in that a higher 
number of recoveries could be achieved by a smaller number of invoices. 
 A contract for banking services was signed in December 2007. 
 
Accounts - payments (2005-2007)
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Infrastructure services at the EMEA 
The Agency’s main aim in the area of infrastructure services is to ensure a safe and efficient working 
environment for staff, delegates and visitors. The area covers a wide range of services, including office-
accommodation planning and acquisition, environmental management, contracts and procurement, 
security, telecommunications, reception, switchboard, archiving, mail, reprographics, technical assistance 
to meeting rooms, management of confidential waste, health & safety, fire and emergency plans, business-
continuity planning, inventory, office equipment and supplies, maintenance, refurbishment and fitting-out, 
management of the catering facilities, and the financial management of 30 budget lines. 
 
 New office and meeting facilities were made available to EMEA staff and delegates. 
− Refurbishment of the second floor of 7 Westferry Circus was finalised in the first half of 2007, 
providing a larger number of meeting rooms. 
− Refurbishment of the sixth floor of 1 Westferry Circus was finalised in the second half of 2007, 
providing office facilities for EMEA staff. 
 The restaurant servery was refurbished. 
 Good progress was made with business-continuity planning and arrangements. 
− A business-continuity exercise took place in September 2007, allowing EMEA staff to rehearse 
necessary procedures. 
− Following a tender procedure, a contract was awarded for an automated alert system to be used in 
a business-continuity scenario. 
 The Agency progressed the introduction of e-procurement tools, systems and procedures. A process 
analysis to permit e-procurement under €25,000 is underway. 
 A number of health & safety awareness campaigns for staff were carried out in 2007. 
 Integration of a building-services helpdesk and a computer-aided facilities-management system is 
pending installation from IT. 
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Verification service 
The Agency’s verifying officer is responsible for the mandatory ex-ante verification of each operation 
having a financial impact. The verifying officer cannot modify the operation that has been initiated. 
He/she verifies (the ‘four eyes’ principle) whether the operation is legal, regular and compliant with the 
principle of sound financial management. He/she also ensures that all tasks have been carried out correctly 
in conformity with the requirements of the financial, fees and/or staff regulations and their implementing 
rules, the VO Charter and other working instructions in force. 
 
 The verification function was partly decentralised across the Agency. Following this, it has become 
more complex to coordinate and improve the verification in order to keep the efficiency and the 
effectiveness of the ex-ante controls. 
 Following the implementation of the new staff regulation and financial regulation, all processes, work 
instructions and checklists had to be reviewed and updated simultaneously with an increasing 
workload. 
 The complexity of regulations required more attention whereas the increasing workload required more 
time. Following remarks of the Internal Audit Service, the requirement for distinct operational ex-ante 
checks is being investigated. 
Workload/Performance Indicators 
 
 2005 (final) 2006 (final) 2007 (final) 
Transactions checked* 24,500 27,150 20,050 
Decentralised verification**    
Meeting reimbursements N/A 24% 23% 
Fee revenue & expenditure N/A N/A 8% 
Administrative expenditure N/A 2% 2% 
* Corresponding to a number financial transactions having been checked by the centralised verifying 
officer. 
** Corresponding to the percentage of low-risk transactions having been checked locally. 
 
6.2 Information technology 
In the past three years, information technology (IT) has progressed from being a facility and a service to 
being a business enabler. This principle continued to be extended in 2007 through direct partnering with 
business units in order to develop and implement a range of critical applications. 
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 IT services were provided to staff, delegates and all users of pan-European systems. 
 The Corporate Service Desk provided a very good service to users and delegates alike, responding to 
requests in most cases within 2 hours. 
 The overall support function provided excellent levels of back-up, operation of servers, SAN, LAN, 
application of patches and bug fixes to the OS, operation, support and maintenance of all existing 
hardware and software of the Agency, virus protection, etc. 
 New software to improve Service Desk support was identified and will be implemented in 2008. New 
hardware and software was procured to improve the archiving and back-up of data, while maintaining 
a high level of security and confidentiality for all data held on EMEA systems. 
 A business-continuity IT solution to support a range of disaster-recovery scenarios initiated in 2006 
was further progressed and tested in 2007, with parts of the solution becoming operational.  This is an 
integral part of the EMEA’s business-continuity plans and includes major improvements to back-up 
and storage systems. As part of this, additional secure-access facilities were provided in 2007 to allow 
for location-independent working of staff, a key component of the business-continuity solution. 
 The virtual-meetings system Vitero was deployed in 2007, allowing attendees to participate in 
meetings using their PCs. This system, which is also developed towards the national competent 
authorities, provides for a new way of conducting meetings, and ultimately aims to reduce the number 
of reimbursed meetings. Pilot web broadcasts of scientific meetings were held in 2007. Video links for 
experts from national competent authorities were added. 
 A range of EMEA core applications were further developed in 2007. 
− The first milestone in the multiannual project to deliver a new version of SIAMED, the 
application and product-tracking database, was delivered. This involved upgrading the underlying 
database, leading to better sharing of information with other systems. 
− The scientific-advice database was extended for use in relation to veterinary medicines, with 
deployment scheduled for 2008. 
− The Meeting Management System (MMS) was progressed in order to facilitate the smooth 
running of meetings of the scientific committees. 
− An enhanced recruitment database allowing online applications was implemented. 
 IT infrastructure was provided for the new office and meeting room facilities at the EMEA. 
 The project to introduce an electronic records-management system was initiated and work on the 
initial stages of the project completed in line with the overall plan. 
 
Performance indicators 
Performance indicator Target Outcome 
Corporate availability of services 
(excluding planned maintenance 
downtime) 
99.35% 99.8% 
Response-time to 80% of 
corporate IT Service Desk 
requests 
2 hours4  2 hours 
Response-time to 15% of 
corporate IT Service Desk 
1 day4 1 day 
                                                     
4 These targets reflect the time required to fix the problem. 
requests 
 
 
6.3 Meetings and conferences at the EMEA 
The EMEA ensures efficient support for meetings organised by the Agency, provides facilities and 
services, and constantly improves the resources available. The Agency assists delegates with logistics and 
practical arrangements. This includes organisation of meetings, organisation of travel and hotel 
arrangements for delegates and hosts, reception of visitors, reimbursement of delegates’ expenses and 
payment of suppliers’ invoices, as well as preparation and follow-up of meeting-room facilities. The 
Meeting Management and Conference (MM&C) sector coordinates enlargement activities for new 
Member States and candidate countries. 
 
 The number of meetings held at the EMEA in 2007 (569) was comparable to previous years. 
 The number of delegates coming to the Agency increased by 12% to 7,797. 
 A procedure to organise emergency meetings was established as part of the Agency’s preparation for 
pandemic influenza. 
 Measures were put in place to improve the efficiency of reimbursement procedures, including the 
introduction of a staff ‘rota system’ to avoid payment delays and provision of better information on 
payments made to the national competent authorities. 
 The Agency carried out extensive negotiations with hotels regarding an EMEA corporate rate for the 
provision of accommodation to experts attending meetings at the EMEA. 
 The Meeting Management System (MMS) module to allow participants to book their hotel and travel 
when attending meetings at the EMEA was delivered to be tested by staff in the MM&C Sector. When 
fully operational in 2008, it will save time for both staff and delegates by making these details 
available online. 
 Room-based videoconferencing using a dedicated facility with special equipment was further 
developed. A number of scientific meetings were broadcast via the Internet, as part of a pilot 
programme. 
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Number of delegates visiting the Agency (2005-2007)
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In addition to the core activities in the area of meetings management, the following objectives were 
targeted. 
Objectives 
 The best-possible support was provided to delegates attending meetings and to EMEA staff members. 
A survey amongst delegates was carried out in 2007 showing a high level of satisfaction. 
 The meetings-organisation workflow and procedures (Meeting Management System) was improved. 
 Videoconferencing and meeting-broadcasting facilities were developed to assist national competent 
authorities and EMEA experts to facilitate virtual communication. 
 Methods were developed to improve efficiency of reimbursement procedures, where appropriate, and 
the reimbursement rules were revised to streamline the reimbursement process. Adoption of the 
revised reimbursement rules was deferred to 2008. 
 Negotiations with hotels were developed and extended. Delegates were consulted regarding their 
accommodation requirements. 
 The ability to organise meetings within 24 hours, including outside of working hours and during 
weekends (in case of emergency situations such as pandemic influenza), was tested successfully. 
 
Performance indicators 
Performance indicator Target Outcome 
Proportion of virtual meetings 
compared to all meetings 
20% of all meetings 20% 
Delegates’ satisfaction regarding 
travel and accommodation 
bookings 
95% 100% 
 
6.4 EMEA document management and publishing 
The Agency ensures full compliance with all regulatory and quality requirements in the areas of document 
and records management. This includes: ensuring best practice in document and records management; 
verifying the quality of all published documents (excluding content); providing Agency staff with the most 
effective access to internal and external information needed to perform their professional duties; verifying 
the accuracy of translations (excluding product information); and organising and supporting the Agency’s 
exhibitions. 
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 The EMEA received a total of 92 requests for access to documents, an increase of more than 30% over 
2006. 
 Thirty-seven out of the 92 requests were refused. 
− 50% of refusals for access to documents at the initial stage concerned the protection of 
commercial interests of a natural or legal person (Article 3(2)(a) of the EMEA Implementing 
Rules). 
− 33% of refusals for access to documents at the initial stage concerned the protection of the 
Agency’s decision-making process (Article 3(3) of the EMEA Implementing Rules). 
− 17% of refusals for access to documents at the initial stage concerned the protection of personal 
data (Article 3(1)(b)), the protection of the purpose of inspections (Article 3(2)(c)) or the 
protection of international relations (Article 3(1)(a)). 
 95% of requests for access to documents were processed within the established timelines. 
 EMEA internal procedures for access to documents were strengthened. After finalisation of the 
internal EMEA policy on the practical operation of access to EMEA documents, standard operating 
procedures came into effect in April and October 2007. In addition, training sessions were organised 
for staff. 
 3.477 requests for information were received, 95% of which were processed within the established 
timelines. 
 The EMEA copyright licensing policy was reviewed to take into account a revision of European 
copyright laws. As a result of this review, the EMEA copyright policy changed on 1 January 2008 and 
no longer requests copyright fees. The new policy allows for the reproduction and/or distribution of all 
EMEA public documents for both non-commercial and commercial purposes, as long as the EMEA is 
acknowledged. 
 The electronic document management system (EDMS) was enhanced to assist with effective 
publishing of core business information to the web interface, and document-management, records-
management (including retention policies) and mail-registration capabilities were further developed. 
 Development and implementation of an electronic records management system was initiated. 
 The Agency’s translation policies were re-examined to take into account the increase in multilingual 
communication activities following EU enlargement and the growing volume of translations. 
 Development and implementation of a terminology- and translation-memory database in order to 
maintain and improve the quality of translations of non-product information documents had to be 
postponed. 
 
Performance indicators 
Performance indicator Target Outcome 
Percentage of requests for 
information processed within 48 
hours 
95% 95% 
Percentage of requests for 
documents processed within 
established timelines 
95% 95% 
Percentage of requests for 
copyrights processed within 48 
hours 
100% 100% 
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Percentage of translations 
processed within established 
timelines 
100% 100% 
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Annex 1 Members of the Management Board 
Chair: Pat O’MAHONY5 
EMEA contact: Martin HARVEY ALLCHURCH 
 
Members 
 
European Parliament Guiseppe NISTICÓ6, Björn LEMMER7 
  (Substitute: Jozef HOLOMÁŇ8) 
European Commission Heinz ZOUREK, Andrzej RYŚ 
  (Alternates: Georgette LALIS, Bernard MERKEL) 
Belgium Xavier DE CUYPER9 (Alternate: André LHOIR10) 
Bulgaria Emil IVANOV HRISTOV11 (Alternate: Meri BORISLAVOVA PEYTCHEVA12) 
Czech Republic Eva NIKLÍČKOVÁ13 (Alternate: Jiří BUREŠ14) 
Denmark Jytte LYNGVIG (Alternate: Paul SCHÜDER) 
Germany Walter SCHWERDTFEGER (Alternate: Hans-Peter HOFMANN15) 
Estonia Kristin RAUDSEPP (Alternate: Alar IRS) 
Ireland Pat O’MAHONY (Alternate: Joan GILVARRY) 
Greece Dimitrios VAGIONAS (Alternate: Catherine MORAITI16) 
Spain Cristina AVENDAÑO-SOLÀ17 (Alternate: Teresa PAGES) 
France Jean MARIMBERT18 (Alternate: Pascale BRIAND19) 
Italy Nello MARTINI (Alternate: Silvia FABIANI) 
Cyprus Panayiota KOKKINOU (Alternate: George ANTONIOU20) 
Latvia Inguna ADOVICA21 (Alternate: Dace ĶIKUTE22) 
Lithuania Aurelija KULČICKIENĖ-GUTIENĖ23 (Alternate: Juozas JOKIMAS) 
Luxembourg Mariette BACKES-LIES (Alternate: Claude A HEMMER) 
Hungary Tamás L PAÁL (Alternate: Beatrix HORVÁTH) 
Malta Patricia VELLA BONANNO (Alternate: Kenneth MIFSUD) 
Netherlands Aginus A W KALIS (Alternate: Rob DE HAAN) 
Austria Marcus MÜLLNER (Alternate: Christian KALCHER) 
Poland Piotr BLASZCZYK (Alternate: Jacek SPLAWINSKI) 
                                                     
5 Replaced Hannes WAHLROOS as of June 2007 meeting. 
6 Replaced Gianmartino BENZI as of June 2007 meeting. 
7 Replaced José-Luis VALVERDE LÓPEZ as of June 2007 meeting. 
8 As of June 2007 meeting. 
9 Replaced Johan van CALSTER as of June 2007 meeting. 
10 Replaced André PAUWELS as of October 2007 meeting. 
11 As of 1.January 2007. 
12 As of 1.January 2007. 
13 Replaced Milan ŠMÍD as of June 2007 meeting. 
14 Replaced Alfred HERA as of June 2007 meeting. 
15 Replaced Ilse-Dore SCHÜTT as of June 2007 meeting. 
16 Replaced Vassilis KONTOZAMANIS as of June 2007 meeting. 
17 Replaced Val DIEZ as of October 2007 meeting. 
18 Replaced Philippe DUNETON as of October 2007 meeting. 
19 Replaced Jean MARIMBERT as of October 2007 meeting. 
20 Replaced Louis PANAYI as of June 2007 meeting. 
21 As of June 2007 meeting. 
22 Replaced Inguna ADOVICA as of June 2007 meeting. 
23 Replaced Mindaugas PLIESKIS as of October 2007 meeting. 
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Portugal Vasco A J MARIA (Alternate: Hélder MOTA FILIPE) 
Romania Magdalena BADULESCU24 (Alternate: Rodica BADESCU25) 
Slovenia Martina CVELBAR26 (Alternate: Vesna KOBLAR) 
Slovakia Ján MAZÁG27 (Alternate: Dagmar STARÁ28) 
Finland Hannes Wahlroos (Alternate: Pekka JÄRVINEN) 
Sweden Gunar ALVÁN (Alternate: Anders BROSTRÖM) 
United Kingdom Kent WOODS (Alternate: Steve DEAN) 
Representatives of  Mary BAKER, Jean GEORGES 
patients’ organisations 
Representative of  Lisette TIDDENS-ENGWIRDA (Vice-chair29) 
doctors’ organisations 
Representative of  Fritz Rupert UNGEMACH 
veterinarians’ organisations 
 
 
Observers 
 
Iceland Rannveig GUNNARSDÓTTIR30 (Alternate: Ingolf J PETERSEN31) 
Liechtenstein Brigitte BATLINER (Alternate: Sabine ERNE32) 
Norway Gro Ramsten WESENBERG (Alternate: Hans HALSE) 
                                                     
24 As of 1 January 2007. 
25 As of 1 January 2007. 
26 Replaced Stanislav PRIMOŽIČ as of June 2007 meeting. 
27 Replaced Dagmar STARÁ as of June 2007 meeting. 
28 As of June 2007 meeting. 
29 Replaced Jytte LINGVIG as of June 2007 meeting. 
30 Replaced Ingolf J PETERSEN as of June 2007 meeting. 
31 Replaced Rannveig GUNNARSDÓTTIR as of June 2007 meeting. 
32 Replaced Peter MALIN as of December 2007 meeting. 
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Annex 2 Members of the Committee for Medicinal Products for Human Use 
Chair: Eric ABADIE* 
EMEA contact: Anthony HUMPHREYS 
 
Member  
• Viorel Robert ANCUCEANU (Romania)  
Alternate: Victoria SUBTIRICA 
• John Joseph BORG (Malta) 
Alternate: Patricia VELLA BONANNO 
• János BORVENDÉG (Hungary) 
Alternate: Agens GYURASICS 
• Gonzalo CALVO ROJAS (Spain) 
Alternate: Concepcion PRIETO YERRO 
• Pierre DEMOLIS1 (France)  
Alternate: Philipe LECHAT2 
• Nikolaos DRAKOULIS (Greece) 
Alternate George AISLAITNER 
• Harald ENZMANN (Germany) 
Alternate: Karl BROICH 
• Jacqueline GENOUX-HAMES 
(Luxembourg) 
Alternate: nomination awaited3 
• Robert James HEMMINGS4 (United 
Kingdom) (co-opted) 
• Ian HUDSON (United Kingdom) 
Alternate: Rafe SUVARNA5 
• Alar IRS (Estonia) 
Alternate: Irja LUTSAR6 
• Arthur ISSEYEGH (Cyprus) 
Alternate: Panayiota KOKKINOU 
• Pirjo LAITINEN-PARKKONEN7 (Finland) 
Alternate: Outi LAPATTO-REINILUOTO8 
                                                     
                                                     
* Replaced Daniel BRASSEUR as of June 2007 meeting. 
1 Replaced Eric ABADIE as of October 2007 meeting. 
2 Replaced Jean-Hugues TROUVIN as of October 2007 
meeting. 
3 Nomination awaited following appointment of Jean-
Louis ROBERT as co-opted member in September 
2004. 
4 Elected as Co-opted member from March 2008. 
5 Replaced Matthew THATCHER (who in turn replaced 
Julia DUNNE in September 2007)  as of February 2008 
meeting. 
6 Replaced Raul KIIVET as of January 2007 meeting. 
7 Member as of March 2007 meeting. 
8 Replaced Pirjo LAITINEN-PARKONNEN as of 
October 2007 meeting. 
• Metoda LIPNIK-STANGELJ (Slovenia) 
Alternate: Maja LUŠIN9 
• David LYONS (Ireland) 
Alternate: Patrick SALMON 
• Romaldas MAČIULAITIS (Lithuania) 
Alternate: Donatas STAKIŠAITIS 
• Ján MAZÁG (Slovakia) 
Alternate: Karol KRALINKSY10 
• Pieter NEELS (Belgium) 
Alternate: Bruno FLAMION 
• Giuseppe NISTICÒ (Italy) 
Alternate: Pasqualino ROSSI 
• Sif ORMARSDÓTTIR (Iceland) 
Alternate: Magnús JÓHANNSSON 
• Ingemar PERSSON (Sweden) (co-opted) 
• Michał PIROŻYŃSKI (Poland) 
Alternate: Piotr SIEDLECKI 
• Heribert PITTNER (Austria) 
Alternate: Andrea LASLOP11 
• Juris POKROTNIEKS (Latvia) 
Alternate: Natalja KARPOVA12 
• Jean-Louis ROBERT (Luxembourg) (co-
opted) 
• Sol RUIZ13 (Spain) (co-opted) 
• Tomas SALMONSON (Sweden) (vice-
chair)14 
Alternate: Bengt LJUNGBERG 
• Christian SCHNEIDER15 (Germany) (co-
opted) 
• Beatriz SILVA LIMA (Portugal) 
Alternate: Cristina SAMPAIO 
9 Replaced Barbara RAZINGER-MIHOVEC as of 
May 2007 meeting. 
10 Alternate member as of November 2007 meeting. 
11 Replaced Josef SUKO as of May 2007 meeting. 
12 Replaced Indulis PURVINŠ as of May 2007 
meeting. 
13 Elected as Co-opted member from September 2007. 
14 Vice-chair as of June 2007 meeting. 
15 Co-opted member from September 2007. 
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• Eva SKOVLUND (Norway) 
Alternate: Liv MATHIESEN 
• Dimiter TERZIIVANOV NIKOLOV 
(Bulgaria) 
Alternate: Ivanka ATANASOVA  
• Steffen THIRSTRUP (Denmark) 
Alternate: Jens ERSBØLL  
• Barbara VAN ZWIETEN-BOOT 
(Netherlands) 
Alternate: Pieter DE GRAEFF16 
• Martin VOTAVA17 (Czech Republic) 
Alternate: Ondřej SLANAŘ18 
16 Replaced Frits LEKKERKERKER as of June 2007 
meeting. 
17 Replaced Milan ŠMÍD as of May 2007 meeting. 
18 Alternate member as of May 2007 meeting. 
  
 
 
Working parties, ad hoc groups and scientific advisory groups 
 
Scientific Advice Working Party 
Chair: Bruno FLAMION 
EMEA contact: Spiros VAMVAKAS 
Biologics Working Party 
Chair: Jean-Hugues TROUVIN 
EMEA contact: John PURVES 
Blood Products Working Party 
Chair: Rainer SEIZ 
EMEA contact: John PURVES 
Cell-based Products Working Party 
Chair: Paula SALMIKANGAS1 
EMEA contact: John PURVES 
Efficacy Working Party 
Chair: Barbara VAN ZWIETEN-BOOT 
EMEA contact: Xavier LURIA 
Gene Therapy Working Party 
Chair: Klaus CICHUTEK 
EMEA contact: Marisa PAPALUCA AMATI 
Joint CHMP/CVMP Quality Working Party 
Chair: Jean-Louis ROBERT 
EMEA contact: Emer COOKE 
Pharmacogenetics Working Party 
Chair: Eric ABADIE 
EMEA contact: Marisa PAPALUCA AMATI 
Pharmacovigilance Working Party 
Chair: June RAINE 
EMEA contact: Panos TSINTIS 
Safety Working Party 
Chair: Beatriz SILVA LIMA 
EMEA contact: Xavier LURIA 
Vaccine Working Party 
Chair: Daniel BRASSEUR2 
EMEA contact: John PURVES 
Paediatric Working Party 
(until June 2007; replaced by Paediatric 
Committee) 
Chair: Daniel BRASSEUR 
EMEA contact: Agnès SAINT-RAYMOND 
Working Party on Similar Biological 
(Biosimilar) Medicinal Products 
Chair: Pekka KURKI 
EMEA contact: Marisa PAPALUCA AMATI 
Scientific Advisory Group on Anti-infectives 
Chair: Barbara BANNISTER 
EMEA contact: Xavier LURIA 
Scientific Advisory Group on Cardiovascular 
Issues 
Chair: Henry DARGIE 
EMEA contact: Xavier LURIA 
Scientific Advisory Group on Central 
Nervous System 
Chair: Michael DONAGHY 
EMEA contact: Xavier LURIA 
Scientific Advisory Group on 
Diabetes/Endocrinology 
Chair: Edwin GALE 
EMEA contact: Xavier LURIA 
Scientific Advisory Group on Diagnostics 
Chair: Jean-Noël TALBOT  
EMEA contact: Xavier LURIA 
Scientific Advisory Group on HIV/Viral 
Diseases 
Chair: Ian WELLER 
EMEA contact: Xavier LURIA 
Scientific Advisory Group on Oncology 
Chair: Michel MARTY 
EMEA contact: Xavier LURIA 
Invented Name Review Group 
Chair: Zaïde FRIAS 
EMEA contact: Zaïde FRIAS 
EMEA Human Scientific Committees' 
Working Party with Patients' and 
Consumers' Organisations 
Chair: Frits LEKKERKERKER/Isabelle 
MOULON 
EMEA contact: Isabelle MOULON 
                                                     
1 Replaced Pekka KURKI as of December 2007 meeting. 
2 Replaced Roland DOBBELAER as of May 2007 meeting. 
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EMEA/CHMP Working Group with 
Healthcare Professionals’ Organisations 
Chair: Noël WATHION/Giuseppe NISTICO 
EMEA contact: Isabelle MOULON 
Working Group on Quality Review of 
Documents 
Chair: Isabelle MOULON 
EMEA contact: Isabelle MOULON 
  
Annex 3 Members of the Committee for Medicinal Products for Veterinary Use 
Chair: Gérard MOULIN  
EMEA contact: David MACKAY 
 
Members
• Birgit AASMÄE (Estonia) 
Alternate: Helen MAHLA 
• Gabriel BEECHINOR (Ireland) 
Alternate: David MURPHY 
• Rory BREATHNACH (Ireland)  
(co-opted) 
• Jiří BUREŠ1 (Czech Republic) 
Alternate: Alfred HERA2  
• Peter EKSTRÖM3 (Sweden) (co-opted) 
• Christian FRIIS (Denmark) (co-opted) 
• Irmeli HAPPONEN4 (Finland) 
Alternate: Tita-Maria MUHONEN 
• Judita HEDEROVÁ (Slovakia) 
Alternate: Eva CHOBOTOVA 
• Anja HOLM (Denmark) (vice-chair) 
Alternate: Ellen-Margrethe 
VESTERGAARD 
• Tonje HØY (Norway) 
Alternate: Hanne BERGENDAHL 
• Laimis JODKONIS (Lithuania) 
Alternate: Juozas JOKIMAS 
• Charalambos KAKOYIANNIS5 
(Cyprus) 
Alternate: Ioanna TALIOTI 
• Ruth KEARSLEY6 (United Kingdom) 
Alternate: Martin ILOTT7 
• Boris KOLAR8 (Slovenia) (co-opted) 
• Reinhard KROKER (Germany) 
Alternate: Manfred MOOS 
• Ioannis MALEMIS (Greece) 
Alternate: Georgios BATZIAS9 
• Kenneth MIFSUD (Malta) 
Alternate: Joseph VELLA 
                                                     
HLUMBOHM  (Germany) 
) 
ÁR 
a Camelia TABAN 
en) 
ST 
15 
 
 
• Franciszek ŻMUDZIŃSKI  (Poland)1 Replaced Alfred Hera in June 2007. 
2 Replaced Jiří Bures in June 2007. 
3 Until November 2007. 
4 Replaced Liisa Kaartinen in January 2007. 
5 Replaced Giorgos Neophytou in October 2007. 
6 Replaced Martin Ilott in March 2007. 
7 Replaced Lesley Anne Johnson in March 2007. 
8 Since November 2007. 
9 Replaced Orestis Papadopoulos in August 2007. 
• Cristina MUÑOS MADERO (Spain)  
Alternate: Consuelo Rubio 
MONTEJANO 
• Eugen OBERMAYR (Austria) 
Alternate: Jean-Pierre BINDER 
• Sigurður ÖRN HANSSON (Iceland) 
Alternate: Halldór RUNÓLFSSON 
• Maria Helena PONTE (Portugal) 
Alternate: Berta Maria Fernandes10  
• Jean-Claude ROUBY (France) 
Alternate: Michael HOLZHAUSER-
ALBERTI 
• G Johan SCHEFFERLIE11 
(Netherlands) 
• Wilhelm SC 12
(co-opted) 
13
• Valda SEJANE  (Latvia
• Tibor SOÓS (Hungary) 
Alternate: Gábor KULCS
• Stane SRČIČ (Slovenia) 
14Alternate: Katarina STRAUS   
• Lollita Sand
(Romania) 
Alternate: Simona STURZU 
• Karolina TÖRNEKE (Swed
Alternate: Henrik HOL
• Maria TOLLIS (Italy) 
Alternate: Virgilio DONINI 
• Bruno URBAIN (Belgium) 
Alternate: Frédéric DESCAMPS
• Marc WIRTOR (Luxembourg)
Alternate: Maurice HOLPER 
• Paskal Todorov ZHELYAZKOV 
(Bulgaria). Alternate: Ilian GETCHEV
16
                                                     
10 Replaced Leonor Maria Meisel in September 2007. 
ogland in March 2007. 
 
11 Replaced Johannes P Ho
12 Since November 2007. 
13 Replaced Arvils Jakovskis in May 2007. 
14 Replaced Blanka Emersic in June 2007.
15 Replaced Lionel Laurier in June 2007. 
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16 Replaced Katarzyna Krzyżańska in June 2007. 
  
Working parties, ad hoc groups and scientific advisory groups 
Efficacy Working Party 
LBERTI 
Safety Working Party 
Chair: Johan G SCHEFFERLIE 
EMEA contact: Kornelia GREIN 
gicals Working Party Scientific Advice Working Party 
EMEA contact: Jill ASHL
Sc roup on Antimicrobials 
EMEA contact: Kornelia GREIN 
ty 
working party) 
 
Chair: Michael HOLZHAUSER-A
EMEA contact: Jill ASHLEY-SMITH 
Immunolo
Chair: Jean-Claude ROUBY 
EMEA contact: Jill ASHLEY-SMITH 
Chair: Rory BREATHNACH 
EY-SMITH 
ientific Advisory GPharmacovigilance Working Party 
Chair: Cornelia IBRAHIM 
EMEA contact: Kornelia GREIN 
Chair: Karolina TÖRNEKE 
Joint CHMP/CVMP Quality Working Par
Chair: Jean-Louis ROBERT 
EMEA contact: Emer COOKE 
Environmental Risk Assessment (temporary 
Chair: Joop A DE KNECHT  
EMEA contact: Kornelia GREIN 
  
Members of the Committee for Orphan Medicinal Products 
 
Annex 4 
Chair: Kerstin WESTERMARK 
EMEA contact: Agnès SAINT RAYMOND
 
Members 
• Björn BEERMANN1 (Sweden) 
• Brigitte BLÖCHL-DAUM (Austria) 
• Andrew BORG2 (Malta) 
• Heidrun BOSCH-TRABERG 
(Denmark) 
• Vessela BOUDINOVA3 (Bulgaria) 
• Birthe BYSKOV HOLM (patients’ 
organisation representative) (vice-chair) 
• Yann LE CAM (patients’ organisation 
representative) 
• Ana CORRÊA NUNES (Portugal) 
• Bożenna DEMBOWSKA-BAGIŃSKA 
(Poland) 
• Julia DUNNE4 (EMEA representative)  
• Judit EGGENHOFER (Hungary) 
• Rembert ELBERS (Germany) 
• Pauline EVERS (patients’ organisation 
representative) 
• Lars GRAMSTAD (Norway) 
• Evija GULBE (Latvia) 
• Emmanuel HÉRON (France) 
                                                     
1 Joined the Committee as of February 2007 meeting. 
2 Resigned in August 2007. 
3 Replaced Detelina IVANOVA as of October 2007 
meeting. 
4 Resigned in August 2007. 
• Ioannis KKOLOS (Cyprus) 
• Kateřina KUBÁČKOVÁ (Czech 
Republic) 
• Magdaléna KUŽELOVÁ (Slovakia) 
• André LHOIR (Belgium) 
• David LYONS (EMEA representative) 
• Greg MARKEY (United Kingdom) 
• Aušra MATULEVIČIENĖ (Lithuania) 
• Henri METZ (Luxembourg) 
• Martin MOŽINA (Slovenia) 
• Veijo SAANO (Finland) 
• Flavia SALEH (Romania) 5 
• Patrick SALMON (Ireland) 
• Miranda SIOUTI (Greece) 
• Domenica TARUSCIO (Italy) 
• Sigurður B. THORSTEINSSON 
(Iceland) 
• Vallo TILLMANN (Estonia) 
• Josep TORRENT-FARNELL (Spain) 
• Bettie VOORDOUW (the Netherlands) 
 
                                                     
5 Replaced Daniela STANCIU as of December 2007 
meeting. 
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Working parties and ad hoc groups
 
 
 
hair: Yann LE CAM/Agnès SAINT RAYMOND
tact: Frida RIVIERE 
Significant Benefit ad hoc Group 
Chair: Kerstin WESTERMARK 
EMEA contact: Jordi LLINARES-GARCIA 
Working Group with Interested Parties
C
EMEA con
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 on Herbal Medicinal Products 
REYS 
Annex 5 Members of the Committee
Chair: Konstantin KELLER 
EMEA contact: Anthony HUMPH
 
Members 
 Linda ANDERSON (Unite
Alternate: Sue HARRIS 
d Kingdom) 
embourg) 
X-HAMES 
Hungary) 
1 
ON 
 
N5 
7 
land) 
nds) 
in) 
 Ioanna CHINOU (Greece) (vice-chairman) 
UTOVÁ (Czech Republic) 
9
TTIR 
             
 Mariette BACKES-LIES (Lux
Alternate: Jacqueline GENOU
 Steffen BAGER (Denmark) 
Alternate: Kristine HVOLBY 
 Zsuzsanna BIRÓ-SÁNDOR (
Alternate: Nóra Piroska FÜLÖP
 Per CLAESON (Sweden) 
Alternate: Ubonwan CLAES
 Caroline ATTARD2 (Malta) 
Alternate: Everaldo ATTARD3 
 Cora NESTOR4 (Ireland)
Alternate: Sinead HARRINGTO
 Michal RÓŻAŃSKI6 (Poland) 
Alternate: Iwona Dróżdż-Jablońska
 Anneli TÖRRÖNEN (Fin
Alternate: Sari KOSKI 
 Emiel VAN GALEN (Netherla
Alternate: Burt H KROES 
 Gloria GARCÍA LORENTE (Spa
Alternate: Adela Núñez Velázquez8 
Alternate: Eleni SKALTSA 
 Marie HERO
Alternate: Helena LÁTALOVÁ  
 Thorbjörg KJARTANDSDÓTTIR (Iceland) 
Alternate: Sesselja ÓMARSDO
 Peter POTÚČEK10 (Slovakia) 
Alternate: Milan NAGY11  
                                        
ember as of September 2007 meeting. 
HIERI as of January 2007 meeting. 
ATTARD as of September 2007 meeting. 
4 Replaced Dairíne DEMPSEY as of January 2007 meeting. 
g. 
. 
ng. 
 meeting. 
1 Alternate m
2 Replaced Christian CUSC
3 Replaced Caroline 
5 Replaced Cora NESTOR as of January 2007 meetin
6 Replaced Wojciech DYMOWSKI as of October 2007 meeting. 
7 Replaced Elżbieta WOJTASIK as of October 2007 meeting
8 Replaced Adela VELÁZQUEZ as of October 2007 meeti
9 Alternate member as of July 2007 meeting. 
10 Replaced Dáša SALUGOVÁ as of January 2007
11 Replaced Pavol MUČAJI as of March 2007 meeting. 
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ras KAŽEMEKAITIS (Lithuania) 
Alternate: Kristina RAMANAUSKIENÈ12 
rtugal) 
INTO FERREIRA 
IHOVEC 
 
 Heribert PITTNER (Austria)  
Alternate: Reinhard LÄNGER13  
stonia) 
 Antoine SAWAYA (France) 
PELLOZ 
y) 
 Panayiotis Triantafyllis (Cyprus) 
AV OU 
 Stefan NIKOLOV (Bulgaria) 
Alternate: Elena MUSTAKEROVA  
 Maria NICULESCU (Romania) 
Alternate: Robert ANCUCEANU18 
 
 Artū
 Steinar MADSEN (Norway) 
Alternate: Gro FOSSUM 
 Ana Paula MARTINS (Po
Alternate: Maria Helena P
 Samo KREFT (Slovenia) 
Alternate: Barbara RAZINGER-M
 Dailonis PAKALNS (Latvia)
Alternate: Dace KALKE 
 Werner KNÖSS (Germany) 
Alternate: Christine WERNER 
 Marje ZERNANT (E
Alternate: Ain RAAL 
Alternate: Jacqueline VIGUET POU
 Marisa DELBÓ14 (Ital
Alternate: Monica CAPASSO15 
Alternate: Maria ST R
 Heidi NEEF16 (Belgium) 
Alternate: Arnold J Vlietinck17 
Co-opted members 
 
 Ulrike WISSINGER-GRÄFENHAHN (Germany) 
 Olavi PELKONEN (Finland) 
 Gert LAEKEMAN (Belgium) 
 Kurt WIDHALM (Austria) 
 
 
 
                                                     
ctober 2007 meeting. 
er 2007 meeting. 
r 2007 meeting. 
ctober 2007 meeting. 
 meeting. 
12 Alternate member as of September 2007 meeting. 
13 Replaced Wolfgang KUBELKA as of O
14 Replaced Vittorio SILANO as of Octob
15 Replaced Marisa DELBÓ as of Octobe
16 Replaced Arnold J VLIETINCK as of O
17 Alternate member as of October 2007
18 Replaced Laurentia RUSCAN as of October 2007 meeting. 
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Observers 
DQM) 
20 (Croatia) 
 
urkey) 
 
 Michael WIERER (E
 Melanie BALD19 (EDQM) 
 Josipa CVEK
 Ivan KOSALEC21 (Croatia)
 Meral GÜNDOĞAN22 (T
 Mehtap VAREL23 (Turkey) 
 Yasemin SAZAK24 (Turkey) 
 
Working parties, ad hoc groups and Scientific A
raphs and 
up  
 
 
                                                     
dvisory Groups 
Community List  
 
Working party on Community Monog
Chair: Heribert PITTNER 
EMEA contact: Anthony HUMPHREYS 
 
 
Organisational Matters Drafting Gro
Chair: Emiel VAN GALEN 
EMEA contact: Anthony HUMPHREYS
 
 
Quality Drafting Group  
Chair: Burt KROES25 Dairíne DEMPSEY 
EMEA contact: Anthony HUMPHREYS
19 Replaced Ellen PEL as of January 2007 meeting. 
20 Observer as of January 2007 meeting. 
21 Observer as of January 2007 meeting. 
aced Dairíne DEMPSEY as of January 2007 meeting. 
22 Observer as of January 2007 meeting. 
23 Observer as of January 2007 meeting. 
24 Observer as of March 2007 meeting. 
25 Repl
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E
E
Annex 6 Members of the Paediatric Committee  
Chair: Daniel BRASSEUR 
EMEA contact: Agnès SAINT RAYMOND 
 
Members 
 Alar IRS (CHMP, Estonia) 
IŠAITIS 
HMP, Romania) 
TIRICA 
vakia) 
SKI 
MP, United Kingdom) 
 Christoph MALE (Austria) 
te: Thomas FRISCHER 
 )1 
HORTE 
NSTANTINOV 
IDOU (Cyprus) 
ech Republic) 
ANYI 
 Marianne ORHOLM (Denmark) 
 
 KI (Finland) 
ana JOENSUU 
 Chair 
ermany) 
 (Greece)2 
I3
                                                   
Alternate: Irja LUTSAR 
 Romaldas MAČIULAITIS (CHMP, 
Lithuania) 
Alternate: Donatas STAK
 Robert ANCUCEANU (C
Alternate: Victoria SUB
 Jan MAZAG (CHMP, Slo
Alternate: Karol KRALIN
 Ian HUDSON (CH
Alternate: Matthew THATCHER 
Alterna
 Hugo DEVLIEGER (Belgium
Alternate: Christophe LA
 Margarita GUIZOVA (Bulgaria) 
Alternate: Dobrin KO
 Eleni TOFAR
Alternate: pending 
 Hubert MOTTL (Cz
Alternate: Peter SZIT
Alternate: Karen TORNØE
 Maria VIRK
Alternate: Ja
 Gérard PONS (France) Vice
Alternate: Sophie FORNAIRON 
 Dirk MENTZER (G
Alternate: Birka LEHMANN 
 Christos KATTAMIS
Alternate: Angeliki ROBOT
  
niel Brasseur, September 2007. 
papetropoulus, October 2007. 
rina Karamani-Kehagia, November 
007. 
Lajos KOSAS (Hungary) 
Alternate: pending 
 Kevin CONNOLLY (Ireland) 
Alternate: Yvonne LOONEY 
 Paolo ROSSI (Italy) 
Alternate: Francesca ROCCHI 
 Dina APELE-FREIMANE (Latvia) 
Alternate: Ilze BĀRENE 
 Carine de BEAUFORT (Luxembourg) 
Alternate: pending 
 John Joseph BORG (Malta) 
Alternate: Herbert LENICKER 
 Johannes TAMINIAU (The Netherlands) 
van den BERG 

WIN 

DE 
 Janez JAZBEC (Slovenia) 
TELINO 
 in) 
CORTIZO 
 STRÖM (Sweden) 
arie JOHANNESSON 

 
  (Norway) 
 
1 Replaced Da
2 Replaced Andreas Pa
3 Replaced Kate
2
 
Alternate: Hendrik 
 Marek MIGDAL (Poland) 
Alternate: Mieczyslaw LIT
 Helena FONSECA (Portugal) 
Alternate: Cristina TRINDA
 
Alternate: Tadej BAT
 Fernando de ANDRÉS TRELLES (Spa
Alternate: Maria Jesús FERNÁNDES 
Marta GRAN
Alternate: M
 Gylfi OSKARSSON (Iceland) 
Alternate: pending
 Siri WANG
Alternate: Ingvild AALØKEN 
  
National competent authority partners 
Fu mation on the national competent authorities is also available on the national authorities’ 
Int hma.eu/human_heads.html and http://www.hma.eu/veterinary_heads.html 
BELGIUM  
oor Geneesmiddelen en 
 - Agence Fédérale des 
taplein 40 bus 40 
 Bloc 2 - 8D030 
40 / 40 
russels - Bruxelles 
 
yper@fagg-afmps.be 
 
Annex 7 
rther infor
ernet sites: http://www.
Xavier DE CUYPER 
Federaal Agentschap v
Gezondheidsproducten
Médicaments et des Produits de Santé 
Eurostation Blok 2 
Victor Hor
Eurostation
place Victor Horta, 
B-1060  B
 
Tel. (32-2) 524 84 00
Fax (32-2) 524 80 03 
E-Mail: xavier.decu
BULGARIA  
ция по лекарствата 
bda.bg 
нска служба 
National Veterinary Service 
бул. “Пенчо Славейков” № 15А 
15a, Pencho Slaveykov Blvd. 
BG – 1606 Sofia 
 
Tel. (359-2) 91 59 821 
Fax (359-2) 91 59 846 
E-Mail: j.baichev@nvms.government.bg 
Emil IVANOV HRISTOV 
General Executive 
Изпълнителна аген
26 Yanko Sakazov Blvd 
BG – 1504 Sofia 
 
Tel. (359-2) 943 40 46 
4 87 Fax (359-2) 943 4
-Mail: hristov@E
Jeko BAICHEV 
Национална ветеринарномедици
CZ  
Director 
tav pro kontrolu léčiv 
 
2 18 58 34 
2 73 99 95 
n.benes@sukl.cz 
kl.cz 
Alfred HERA 
Director 
stav pro státní kontrolu veterinárních 
iopreparátů a léčiv 
udcova 56a 
Medlánky 
CZ – 621 00 Brno 
 
Tel. (420-541) 21 00 22 
Fax (420-541) 21 26 07 
E-mail: hera@uskvbl.cz 
Internet: http://www.uskvbl.cz 
ECH REPUBLIC 
Martin BENEŠ 
Státní ús
Šrobárova 48 
 10CZ – 100 41 Praha
 
) 7Tel. (420-2
Fax (420-2) 7
-Mail: martiE
Internet: http://www.su
Ú
b
H
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K  
 København S 
el. (45-44) 88 95 95 
.dk 
DENMAR
Jytte LYNGVIG 
Direktør 
Lægemiddelstyrelsen 
Axel Heides Gade 1 
DK – 2300
 
T
Fax (45-44) 88 95 99 
E-mail: jyl@dkma.dk 
Internet: http://www.dkma
 
GERMANY  
nes LÖWER 
t für Sera und Impfstoffe 
h Straße 51-59 
n 
el. (49-6103) 77 10 00 
 
einhard KROKER 
eiter des Fachbereichs 
Bundesamt für Verbraucherschutz und 
Lebensmittelsicherheit 
Diedersdorfer Weg 1 
D – 12277 Berlin 
 
Tel. (49-1888) 412 23 64 
Fax (49-1888) 412 29 65 
E-mail: reinhard.kroker@bvl.bund.de 
Internet: http://www.bvl.bund.de 
Johan
Präsident 
Bundesam
Paul-Ehrlich-Institut 
Paul-Ehrlic
D – 63225 Lange
 
T
Fax (49-6103) 77 12 40
E-mail: loejo@pei.de 
Internet: http://www.pei.de 
R
L
Reinhard KURTH 
ssarischer Leiter 
zneimittel und 
rM) 
 
rm.de 
 
ESTONIA  
Kristin RAUDSEPP 
Director Gerneral 
Ravimiamet 
Nooruse 1 
50411 Tartu 
 
Tel. (372-7) 37 41 40 
Fax (372-7) 37 41 42 
E-mail: kristin.raudsepp@ravimiamet.ee 
Internet: http://www.ravimiamet.ee 
 
 
 
 
 
Kommi
Bundesinstitut für Ar
BfAMedizinprodukte (
Kurt-Georg-Kiesinger-Allee 3 
D – 53175 Bonn 
 
Tel. (49-228) 207 32 03 
ax (49-228) 207 55 14 F
E-mail: kurth@bfarm.de
Internet: http://www.bfa
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AS 
geion Av. 
ns 
el. (30-210) 650 72 16 
 
r 
GREECE  
Dimitrios VAGION
President 
National Organization for Medicines 
284 Meso
Holargos 
GR – 155 62 Athe
 
T
Fax (30-210) 654 95 86
E-mail: president@eof.g
Internet: http://www.eof.gr 
 
SPAIN  
ristina AVENDAÑO SOLÁ  
tor 
cia Española de Medicamentos y Productos 
 Madrid 
0 44 
ax (34-91) 822 50 10 
s 
ed.es 
 C
Direc
Agen
Sanitarios 
Calle Alcalá 56 
E – 28071
 
Tel. (34-91) 822 5
F
E-mail: sdaem@agemed.e
Internet: http://www.agem
FRANCE  
Jean MARIMBERT 
Directeur Général 
Agence Française de Sécurité Sanitaire des 
Produits de Santé 
143-147, boulevard Anatole France 
F – 93285 Saint-Denis Cedex 
 
Tel. (33-1) 55 87 30 14 
Fax (33-1) 55 87 30 12 
E-mail: jean.marimert@afssaps.sante.fr 
Internet: http://afssaps.sante.fr 
 de Sécurité Sanitaire des 
ts Vétérinaires 
s Cedex 
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Patrick DEHAUMONT 
Directeur ANMV 
ançaiseAgence Fr
Aliments 
enLaboratoire des Médicam
 BP 90 203 Javené 
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Tel. (33-2) 99 94 78 71 
Fax (33-2) 99 94 78 99 
E-mail: p.dehaumont@anm
Internet: http://www.afssa.
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cutive officer 
 - Bord Leigheasra na 
arlsfort Terrace 
E-mail: pat.omahony@imb.ie 
Internet: http://www.imb.ie 
IRELAND  
Pat O’MAHONY 
Chief exe
Irish Medicines Board
hÉirann 
Earlsfort Centre 
E
IRL – Dublin 2 
 
Tel. (353-1) 676 49 71 
Fax (353-1) 661 47 64 
 
 
  
ITALY  
INI 
l Agenzia Italiana del 
armaco 
a 60 
Fax (39-06) 59 78 40 54 
i@sanita.it 
afarmaco.it 
LLI 
inistero della Salute 
 
Tel. (39-06) 59 94 69 45 
ax (39-06) 59 94 62 17 
ail: alimentivet@sanita.it 
ternet: http://www.ministerosalute.it 
Nello MART
Direttore Generale de
F
Viale della Sierra Nevad
I – 00144 Roma 
 
Tel. (39-06) 59 78 42 05 
E-mail: n.martin
Internet: http://www.agenzi
Romano MARABE
Direttore Generale  
M
Servizi Veterinari Roma
Piazzale Marconi 25 
I – 00144 Roma 
 
F
E-m
In
 Enrico GARACI 
President 
Istituto Superiore di Sanità 
Viale Regina Elena 299 
IT – 00161 Roma 
 
Tel. (39-06) 44 86 94 55 
Fax (39-06) 44 86 94 40 
E-mail: presidenza@iss.it 
Internet: http://www.iss.it 
CYPRUS  
KOKKINOU 
lth 
rvices 
 
hs.moh.gov.cy 
cy 
iorgos NEOPHYTOU 
griculture, Natural Resources and 
1 
 
vs.moa.gov.cy 
oa.gov.cy 
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Ministry of Hea
Pharmaceutical se
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efkosia CY – 1475 L
 
el. (357-22) 40 71 03 T
Fax (357-22) 40 71 49
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icosia CY – 1417 N
 
el. (357-22) 80 52 00/T
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lv 
.gov.lv 
LATVIA  
Inguna ADOVIČA  
Director 
Valsts zāļu aģentūra 
Jersikas iela 15 
LV – 1003 Riga IV 
 
Tel. (371-70) 784 24 
Fax (371-70) 784 28 
E-mail: info@vza.gov.lv 
Internet: http://www.vza.gov.
Vinets VELDRE 
Pārtikas un veterinārais dienests 
Republikas laukums 2 
LV – 1010 Riga 
 
Tel. (371-70) 952 30 
Fax (371-73) 227 27 
E-mail: pvd@pvd.gov.lv 
Internet: http://www.pvd
 
Ė GUTIENĖ 
t.lt 
KIMAS 
irector 
Valstybinė maisto ir veterinarijos tarnyba 
J. Naujalio g. 21B 
LT – 3026 Kaunas 26s 
 
Tel. (370-37) 31 15 58 
Fax (370-37) 36 12 41 
E-mail: vet.prep.lab@vet.lt 
Internet: http://www.vet.lt 
LITHUANIA 
 
Aurelija KULČICKIEN
Director 
Valstybinė vaistų kontrolės tarnyba 
Traku g. 14 
LT – 01132 Vilnius 
 
Tel. (370-5) 263 92 64 
Fax. (370-5) 263 92 65 
E-mail: vvkt@vvkt.lt 
Internet: http://www.vvk
Juozas JO
D
LU  
ien-Inspecteur - Chef de Division 
é 
1er étage 
arc de la Ville – Allée Marconi 
Internet: http://www.ms.etat.lu 
XEMBOURG 
Mariette BACKES-LIES 
Pharmac
Ministère de la Sant
Direction de la Santé 
rmacie et des Médicaments Division de la Pha
 Villa Louvigny –
P
L – 2120 Luxembourg 
 
Tel. (352) 478 55 90 
Fax (352) 26 20 01 47 
E-mail: luxdpm@ms.etat.lu 
 
HUNGARY  
Tamás PAÁL 
Director General 
Országos Gyógyszer Intézet eterinary Medicinal Products 
 
Zrínyi U. 3 
HU – 1051 Budapest 
 
Tel. (36-1) 317 40 44 
Fax (36-1) 317 14 88 
E-mail: tpaal@ogyi.hu 
Internet: http://www.ogyi.hu 
Tibor SOÓS 
Director 
Institute for V
Szállás u. 8 
HU – 1107 Budapest 
 
Tel. (36-1) 433 03 45 
Fax (36-1) 262 28 39 
E-mail: soos@oai.hu 
Internet: http://www.ivmp.gov.hu
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ov.mt 
E-mail: joseph-john.vella@gov.mt 
Internet: http://www.gov.mt 
MALTA 
Patricia VELLA BONANNO 
Medicines Authority 
198 Rue D'Argens 
MT – GRZ 003 Gzira 
 
el. (356-23) 43 90 00 T
Fax (356-23) 43 91 61 
E-mail: patricia.vella@g
Internet: http://www.gov.mt 
Joseph VELLA 
Ministry for Rural Affairs and the Environment 
gulation Division Food and Veterinary Re
he Abattoir T
Albert Town 
MT – CMR 02 Marsa 
 
Tel. (356-21) 24 26 94 
Fax (356-21) 23 81 05 
NETHERLANDS  
Aginus A W KALIS 
Executive Director 
er Beoordeling van College T Geneesmiddelen 
g 
Fax (31-70) 356 75 15 
-mail: aaw.kalis@cbg-meb.nl 
Internet: http://www.cbg-meb.nl 
Agentschap 
alvermarkt 53 K
Postbus 16229 
NL – 2500 CB Den Haa
 
Tel. (31-70) 356 74 00 
E
 
AUSTRIA  
Hubert HRABCIK 
Bundesministerium für Gesundheit und Frauen 
Radetzkystraße 2 
A – 1030 Wien 
 
Tel. (43-1) 711 00 47 17 
Fax (43-1) 711 00 48 30 
bert.hrabcik@bmgf.gv.at 
mgf.gv.at 
Marcus MÜLLNER 
Österreichische Agentur für Gesundheit und 
Ernährungssicherheit (AGES) 
S
A
 
Tel. (43-50) 55 53 60 00 
Fax (43 50) 55536009 
uellner@ages.at 
w.ages.at/ 
E-mail: hu
Internet: http://www.b
chnirchgasse 9 
 – 1030 Vienna 
E-Mail: marcus.m
Internet: http://ww
PO  
SKI 
duktów Leczniczych 
yrobow Medycznych i Produktów 
Tel. (48-22) 492 11 00 
Fax (48-22) 492 11 09 
E-Mail: justyna.madejska@urpl.gov.pl 
Internet: http://www.urpl.gov.pl 
AK 
roduktów Leczniczych, 
Wyrobow Medycznych i Produktów 
Tel. (48-22) 492 11 00 
Fax (48-22) 492 11 09 
E-Mail : monika.marczak@urpl.gov.pl 
Internet: http://www.urpl.gov.pl 
 
LAND 
Leszek BORKOW
Urząd Rejestracji Pro
W
Biobójczych 
Ząbkowska 41 
PL – 03-736 Warszawa 
 
Monika MARCZ
Urząd Rejestracji P
Biobójczych 
ul. Ząbkowska 41 
PL – 03-736 Warszawa 
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S MARIA 
e Nacional do Medicamento e Produtos 
aúde de Lisboa 
T – 1749-004 Lisboa 
d.pt 
Internet: http://www.infarmed.pt 
PINHEIRO 
Geral de Veterinária 
s Artes, 2 
5 00 
ax (351-21) 346 35 18 
n-agricultura.pt 
-agricultura.pt 
PORTUGAL  
Vasco de JESU
Autoridad
de Saúde, I.P. (INFARMED) 
Parque de S
Av. do Brasil, 53 
P
 
Tel. (351-21) 798 71 09 
Fax (351-21) 798 71 20 
E-mail: vasco.maria@infarme
Carlos AGRELA 
Direcção 
Largo da Academia Nacional de Bela
PT – 1249-105 Lisboa 
 
Tel. (351-21) 323 9
F
E-mail: dirgeral@dgv.mi
Internet: http://www.min
ROMANIA  
scu 
s Agency 
ănătescu 48 
t 
m.ro 
I 
itary Veterinary and Food Safety 
O – 023951 Bucharest 
Mrs Magdalena Badule
Nationa Medicine
Str. Aviator S
Sector 1 
RO – 011478 Buchares
 
Tel. (402-13) 16 10 79 
Fax (402-13) 16 34 97 
E-Mail : magdalena.badulescu@an
Gabriel PREDO
National San
Authority 
Str. Negostori nr.1 bis 
Sector 2 
R
 
Tel. (402-13) 15 78 75 
Fax (402-13) 12 49 67 
E-Mail: predoi@ansv.ro 
 Razvan TIRU 
ational Sanitary Veterinary and Food Safety 
uthority 
Str. Negostori nr.1 bis 
Sector 2 
RO – 023951 Bucharest 
 
Tel. (402-13) 15 78 75 
Fax (402-13) 12 49 67 
E-Mail: tiru@ansv.ro 
SL  
 
publike Slovenije za zdravila 
na 
jazmp.si 
p.si 
Vesna KOBLAR 
D r 
J ublike Slovenije za zdravila in 
m
P
S
 
Tel. (386-1) 
F
E mp.si 
I
N
A
OVENIA 
Martina CVELBAR
Director 
Javna agencija Re
in medicinske pripomočke 
Ptujska ulica 21 
SI - 1000 Ljublja
 
Tel. (386-8) 20 00 508 
ax (386-8) 20 00 510 F
E-Mail: martina.cvelbar@
Internet: http://www.jazm
eputy Directo
avna agencija Rep
edicinske pripomočke 
tujska ulica 21 
I - 1000 Ljubljana 
20 00 502 
ax (386-1) 20 00 510 
-mail: vesna.koblar@jaz
nternet: http://www.jazmp.si 
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re kontrolu liečiv 
el. (421-2) 50 70 11 19 
27 
l.sk 
adislav SOVÍK 
Director 
Ústav štátnej kontroly veterinárnych 
biopreparátov a liečiv 
Biovetská 4 
SK – 949 01 Nitra 
 
Tel. (421-37) 651 55 03 
Fax (421-37) 651 79 15 
E-mail: uskvbl@flynet.sk 
Internet: http://www.uskvbl.sk 
SLOVAKIA
Ján MAZÁG 
Director 
Štátny ústav p
Kvetná 11 
SK – 825 08 Bratislava 26 
 
T
Fax (421-2) 55 56 41 
E-mail: martinec@suk
Internet: http://www.sukl.sk 
L
FINLAND  
Hannes WAHLROOS 
 Helsinki 
45 
os@nam.fi 
ekka KURKI 
Lääkelaitos 
P.O.Box 55 
Mannerheiminitie 103b 
FIN – 00301 Helsinki 
 
Tel. (358-9) 47 33 42 25 
Fax (358-9) 47 33 43 50 
E-Mail : pekka.kurki@nam.fi 
Internet: http://www.nam.fi 
Director General 
Lääkelaitos  
intie 103b Mannerheim
FIN – 00300
 
el. (358-9) 47 33 42 00 T
Fax (358-9) 47 33 43 
E-mail: hannes.wahlro
Internet: http://www.nam.fi 
P
SWEDEN  
LVÁN 
 
 42 
 46 00 
mpa.se 
Gunnar A
Generaldirektör 
Läkemedelsverket
Dag Hammarskjölds väg
S – 751 83 Uppsala 
 
el. (46-18) 17T
Fax (46-18) 54 85 66 
E-mail: gunnar.alvan@
Internet: http://www.mpa.se 
 
UN  
Kent WOODS 
Chief Executive 
Medicines and Healthcare products Regulatory 
Agency 
Market Towers 
1 Nine Elms Lane 
UK – London SW8 5NQ 
 
Tel. (44-20) 70 84 25 46 
Fax (44-20) 70 84 25 48 
E-mail: kent.woods@mhra.gsi.gov.uk 
Internet: http://www.mhra.gov.uk 
Steve DEAN 
Chief Executive 
Veterinary Medicines Directorate 
Woodham Lane 
New Haw, Addlestone 
UK – Surrey KT15 3LS 
 
Tel. (44-1932) 33 83 01 
Fax (44-1932) 33 66 18 
E-mail: s.dean@vmd.defra.gsi.gov.uk 
Internet: http://www.vmd.gov.uk 
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Rannveig GUNNARSDÓTTIR 
Lyfjastofnun 
Eidistorg 13-15 
2 Seltjarnarnes 
00 
ir@lyfjastofnun.is 
.is 
 
ICELAND  
Director 
PO Box 180 
IS – 17
 
Tel. (354) 520 21 
Fax (354) 561 21 70 
E-mail: rannveig.gunnarsdott
Internet: http://www.lyfjastofnun
LIECHTENSTEIN  
Brigitte BATLINER 
ntrollstelle für Arzneimittel, beim Amt für 
Lebensmittelkontrolle und Veterinärwesen 
Postfach 37 
Schaan 
l. (423) 236 73 25 
F
E atliner@alkvw.llv.li 
Internet: http://www.llv.li 
Ko
Postplatz 2 
FL – 9494 
 
Te
ax (423) 236 73 10 
-mail: brigitte.b
 
NOR
Gro Ramsten WESENBERG 
Director Gen
S
N
 
T
F
E middelverket.no 
I et.no 
http://www.noma.no 
WAY  
eral 
tatens legemiddelverk 
Sven Oftedals vei 8 
 – 0950 Oslo 
el. (47-22) 89 77 01 
ax (47-22) 89 77 99 
ge-mail: gro.wesenberg@le
nternet:  http://www.legemiddelverk
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006–2008 
he summarised comparative budget statements for 2006 to 2008 are as follows: 
2006 20071
Annex 8 EMEA budget summaries 2
T
20082
  € ‘000 %     
Revenue       
Fees 92,580 66.76 8,570 66.5 126,318 10 6 72.89 
General EU tion 22,000 15.87 9,813 12.1 16,816 9.70  contribu 1 5
EU contrib ME policy 3,895 2.3 3,702 2.14 ution for S 9
EU contrib aediatrics polic a 0.00 2,022 1.2 2,710 1.56 ution for P y n/ 4
EU contrib T Telematics strategy 8,000 5.77 ,914 8.5 8,772ution for I 13 3  5.06 
Special EU ion for orphan medicinal products 7,400 5.34 3.6 6,000 contribut 6,000 8  3.46 
Contributio A 0 0.47 904 0.5 765n from EE 65 5  0.44 
Community mes 0 0.55 706 0.4 600 program 76 3  0.35 
Other 7,286 5.25 4.4 7,6247,289 7  4.40 
   
TOTAL REVENUE 138,676 100.00 ,113 100.0 173,307 .00 163 0  100
 
Expenditure       
Staff       
11 Staff yment 41,376 29.84 7,259 28.9 54,411  in active emplo 4 7 31.40 
13 Missi ses 6 0.42 660 0.4 639 0.37 on expen 58 0
14 Socio-medical infrastructure 0 0.32 459 0.2 60344 8  0.35 
15 Exch vil servants and  1,119 0.81 0.7 2,437ange of ci experts 1,205 4  1.41 
16 Social 5 0.11 55 0.0 55 welfare 15 3  0.03 
17 Enter and representatio xpenses 1 0.02 37 0.0 38tainment n e 3 2  0.02 
18 Staff s 1,214 0.88 0.8 1,657insurance 1,457 9  0.96 
 Total 44,921 32.39 ,132 31.3 59,840 .53  Title 1 51 5  34
Building/equipment       
20 Inves mmovable property, renting ots 17,260 12.45 ,740 10.2 15,618
tment in i f 
building and ass cos 16 6  9.01 
21  processing 14,623 10.54 ,460 15.6 20,50 .83 Ex tapenditure on da  25 1 2 11
22 M costs 1,057 0.76 ,148 1.9 1,61ovable property and ass 3 3 7 0.93 
23 Other administrative expenditure 756 0.55 792 0.49 861 0.50 
24 Postage and communications 684 0.49 983 0.60 1048 0.60 
25 Expenditure on formal and other meetings 74 0.05 75 0.05 79 0.05 
 Total Title 2 34,454 24.84 47,198 28.94 39,725 22.92 
Operational expenditure       
300 Meetings 6,355 4.58 7,144 4.38 8,156 4.71 
301 Evaluations 49,827 35.93 53,632 32.88 60,406 34.85 
302 Translation 2,215 1.60 3,183 1.95 4,001 2.31 
303 Studies and consultants 170 0.12 100 0.06 80 0.05 
304 Publications 124 0.09 74 0.05 499 0.29 
305 Community programmes 610 0.44 650 0.40 600 0.35 
 Total Title 3 59,301 42.76 64,783 39.72 73,742 42.55 
     
TOTAL EXPENDITURE  138,676 100.00 163,113 100.00 173,307 100.00 
                                                     
31 December 2007. 
plit of 
1 Appropriation/Budget 2007 as of 
2 Appropriation/Budget 2008 as adopted by the Management Board on 13 December 2007 with adjusted s
contributions. 
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 Aut Authorised for 
4
 
Annex 9 EMEA establishment plan 
 
Occupied as per 
331.12.06
horised for 
2007 2008
Function group & Grad
Permane
s 
Temporary 
s 
e 
Permanent Temporary 
posts posts post
nt Temporary Permanent 
posts posts post
AD 16 1 - 1 - 1 - 
AD 15 - 3 - 3 - 3 
AD 14 - 3 - 4 - 4 
AD 13 - 4 - 5 - 4 
AD 12 - 34 - 34 - 33 
AD 11 - 33 - 33 - 33 
AD 10 - 33 - 34 - 33 
AD 9 - 11 - 13 - 20 
AD 8 - 32 - 36 - 41 
AD 7 - 38 - 43 - 43 
AD 6 - - 8 12 - 22 
AD 5 - - 10 - 9 - 
Total grade AD 0 199 0 227 0 248 
AST 11 - - - - - - 
AST 10 - 6 - 6 - 6 
AST 9 2 - 2 - 2 - 
AST 8 - 10 - 11 - 10 
AST 7 - 12 - 14 - 14 
AST 6 33 - 30 - 30 - 
AST 5 32 - 34 - 29 - 
AST 4 - 50 - 54 - 56 
AST 3 - 24 - 26 - 20 
AST 2 - 9 - 10 - 19 
AST 1 - 28 - 32 - 26 
Total grade AST 0 196 0 0 227 214 
Grand Total 0 395 0 441 0 475 
 
 
                                                     
3 Revised as of 23 February 2007. 
4 Excluding the six additional posts for Paediatrics legislation as per decision by the Management Board 
(EMEA/MB/244582/2007). 
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Annex 10 IT projects and operational activities 
Service or project  Description of measure Details of progress 
Business Continuity IT  and
r data in BCP
ses 1 and 2 com
y phasesInfrastructure 
Success of deployment
recove
 ability to Pha
 scenarios Deplo
pleted in 2007. 
 3 and 4 in 2008 
Citrix Rollout Success of deplo
provide LIW to selected users Deploy phase 1 
yment and ability to Pilot successfully completed in 2007. 
in April 2008 
Exchange Upgrade Success of upgrade and ab
provide new features to us
ility to 
rs
Planning completed in 
e  Deploy upgrade 
2007. 
in A pril 2008 
Virtual meetings Deploy 2 VITERO meeting 
and fully test and pilot 
rooms Successfully completed in 2007 
Paediatrics Database Success of deployme Form to be completed in 2008 nt of PIP PDF PIP Modification 
form. 
Paediatrics Database Success of deplo
Flex application (Register
Forms) 
yment of phase 1 
ing of PDF 
Application will be further developed in 2008 
SIAMED Success of database migration fr o refined and put into production om MRL part was als
FoxPro to Oracle 
EURS Central Reposito  has bry een installed Database will be
for NCAs will b
 further populated in 2008 and access 
e tested 
EV DWH Deploy Datawarehouse solution for Successfully completed in 2007 
EudraVigilance 
EudraGMP Deploy first EudraGMP release Successfully completed in 2007 
ECD, ECDManager Delegated user management h
introduced, NCAs manage th
users and allow  access 
 in 2008 
as been 
eir own 
to EudraGMP 
Further significa
users is expected
nt growth on the number of external 
ITIL tool introduction 
NFRA) 
Introduce best pr
ITIL and supporting too
Most su
(I
actices compliant to 
lset been successfully
itable vendor has been selected and pilot has 
 completed 
Percentage of systems 
“down-time”  
0.01% downtime Achieved in 2007 
Delivery of IT Projects 
 and u
95% delivered against p 7 
against plan b dget 
lan/budget Achieved in 200
Effective transition 
roduction/operation  
to 95% moved into
p
 production Achieved in 2007 
Percentage of EudraNet 
“down-time”  
99% availability Achieved in 2007 
  
EMEA annual report 2007 
EMEA/MB/17464/2008 2.4, CURRENT 
Page 104/138 
Annex 11 CHMP opinions in 2007 on medicinal products for h
CHMP positive opinions in 2007 on non-orphan medicinal products for human use 
uman use 
Product 
 Brand name 
 INN 
Marketing authorisation 
holder 
Therapeutic area 
 ATC code 
 Summary of indication 
EMEA.CHMP 
 Validation 
 Opinion 
 Active time 
 Clock stop 
European Commission 
 Opinion received 
 Date of decision 
 Notification 
 Official Journal 
 Xelevia 
 sitagliptin phospha
monohydrate 
 
diabete
 44 days 
27.04.2007, p. 15 
te 
 Merck Sharp & Dohme  A10BH01 
 Improvement of glycae
control in combination with 
metformin and PPAR 
gamma agonist in patients 
mic  24.01.2007
 85 days 
with type 2 s mellitus 
 06.09.2006 
 
 21.02.2007 
 21.03.2007 
 23.03.2007 
 OJ C 92 of 
 Januvia 
sitagliptin phos phate 
monohydrate 
 
 Merck Sharp & Doh
metformin and PPAR 
nist in p
 99 days 
 15 
me  A10BH01 
 Improvement of glycaemic 
control in combination with 
 24.01.2007
 202 days 
gamma ago atients 
with type 2 diabetes mellitus 
 29.03.2006 
 
 21.02.2007 
 21.03.2007 
 23.03.2007 
 OJ C 92 of 
27.04.2007, p.
 

Focetria 
 Influenza virus 
surface antigens 
 Chiron Behring Gmb 2 
 Prophylaxis of influenza in 
a pandemic situation 
07 
 162 days 
 5 
 
H  J07BB0  31.01.2006 
 22.02.20
 224 days 
 27.03.2007 
 02.05.2007 
 04.05.2007 
 OJ C 144 of 
29.06.2007, p.
 Docetaxel Winthrop 
 docetaxel 
 
 Aventis Pharma S.A. 
g cancer, 
07 
 60 days 
 3 
 L01CD02 
 Treatment of breast cancer,
non-small cell lun
 

prostate cancer, gastric 
adeno-carcinoma and head 
and neck cancer 
 27.12.20
 22.02.20
06  22.03.2007 
 20.04.2007 
 24.04.2007 
 0 days  OJ C 115 of 
25.05.2007, p.
 

Advagraf 
 tacrolimus 
 Astellas Pharma Gm
pressio
ith other 
essive drugs 
06 
 22.02.2007 
 3 
 
bH  L04AA05 
 Primary 
immunosup n in adult  201 days 
liver or kidney allog
recipients; treatment of 
allograft rejection resistant 
to treatment w
raft  157 days 
immunosuppr
 01.03.20  23.03.2007 
 23.04.2007 
 25.04.2007 
 OJ C 115 of 
25.05.2007, p.
 Sebivo 
 telbivudine 
 
 Novartis Europharm
Limited 
ie
evidence of viral replication 
liver 
 148 days 
 p. 3 
  J05AF11 
 Treatment of chronic 
hepatitis B in pat nts with  210 days 
and active 
inflammation 
 01.03.2006 
 22.02.2007 
 23.03.2007 
 24.04.2007 
 26.04.2007 
 OJ C 115 of 
25.05.2007,
 Toviaz 
 fesoterodine 
fumarate 
 Schwarz Pharma 
 Symptomatic treatm
overactive bladder  210 days 
 3 
 
 G04BD11 
ent of  22.02.2007 
syndrome 
 29.03.2006 
 120 days 
 22.03.2007 
 20.04.2007 
 24.04.2007 
 OJ C 115 of 
25.05.2007, p.
 Orencia 
 abatacept 
 Bristol-Myers Squibb 
Pharma EEIG 
rthritis  204 days 
 245 days  OJ C 144 of 
29.06.2007, p. 5 
 
 L04AA24 
 Treatment of patients wit
severe rheumatoid a
h  22.03.2007 
 28.12.2005  19.04.2007 
 21.05.2007 
 23.05.2007 
 Altargo 
 retapamulin 
 Glaxo Group Ltd. 
f uncomplicated 
 struc
 19.07.2006 
 22.03.2007 
 24.04.2007 
 24.05.2007 
 5 
 
 D06AX13 
 Treatment o
skin and skin ture  191 days 
infections  55 days 
 29.05.2007 
 OJ C 144 of 
29.06.2007, p.
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Product 
 Brand name 
 INN 
Marketing authorisation 
holder 
Therapeutic area 
 ATC code 
 Summary of indication 
EMEA.CHMP 
 Validation 
 Opinion 
 Active time 
 Clock stop 
European Commission 
 Opinion received 
 Date of decision 
 Notification 
 Official Journal 
 Invega 
 paliperidone ational N
inclu
maintenance treatm
 
 Janssen-Cilag 
Intern V.  Treatment of adult 
schizophrenia 
 N05AX13 
ding  202 days 
ent  135 days 
 24.05.2006 
 26.04.2007 
 25.05.2007 
 25.06.2007 
 27.06.2007 
 OJ C 174 of 
27.07.2007, p. 3 
 Circadin 
 melatonin aceuticals E
Ltd nia 
characterised by poor 
quality of sleep in patients 
 Neurim 
Pharm EC  Short-term treatment of
primary insom
 N05CH01 
 
who are aged 55 or over 
 26.10.2005 
 26.04.2007 
 209 days 
 338 days 
 06.06.2007 
 29.06.2007 
 05.07.2007 
 OJ C 174 of 
27.07.2007, p. 3 
 Pergoveris 
follitropin alfa 
lutropin alfa 
 
o Europe L
folli
development in wo
LH and FSH deficiency  185 days 
 p. 3 
 
 Seron td  G03GA05 
 Stimulation of cular  26.04.2007 
men with  208 days 
 29.03.2006  29.05.2007 
 25.06.2007 
 01.08.2007 
 OJ C 203 of 
31.08.2007,
 Optaflu 
 A (H1N1), A 
(H3N2) and B 
 
 Novartis Vaccine
Diagnostics GmbH 
 79 days 
27.07.2007, p. 3 
 and  J07BB02 
 Prophylaxis of influenza in 
adults 
 19.07.2006 
 26.04.2007 
 202 days 
 16.05.2007 
 01.06.2007 
 05.06.2007 
 OJ C 174 of 
 Orlistat GSK  Glaxo Group Ltd 
 orlistat 
 
 A08AB01 
 Weight loss in obese or 
overweight adults in 
conjunction with a mildly 
hypocaloric diet  
 25.03.2007 
 24.05.2007 
 60 days 
 0 days 
 20.06.2007 
 23.07.2007 
 25.07.2007 
 OJ C 203 of 
31.08.2007, p. 3 
 Aerinaze 
in
te 120 mg 
 Shering - Plough 52  
anied by na
congestion 
 16.08.2006  03.07.2007 
. 3 
 desloratad e 2.5mg Europe 
pseudoephedrine 
sulpha
 
 R06AX27 R01BA
 Sypmptomatic treatment of  24.05.2007 
seasonal allergic rhiniti
accomp
s  196 days 
sal  85 days 
 30.07.2007 
 01.08.2007 
 OJ C 203 of 
31.08.2007, p
 Optimark 
setam
 Tyco Healthcare 
d G
 V08CA06 
agnetic 
 24.05.2006 
. 3 
 gadover ide Deutschlan
 
mbH  Use with m
resonance imaging (MR
the central nervous system
and the liver 
I) of  196 days 
 
 24.05.2007 
 169 days 
 20.06.2007 
 23.07.2007 
 25.07.2007 
 OJ C 203 of 
31.08.2007, p
 Mircera  Roche Registration Ltd  B03XA03 
f anaem
 24.05.2006 
1.08.2007, p. 3 
 pegserepoetin 
 
alfa  Treatment o ia  24.05.2007 
associated with chronic 
kidney disease  
 176 days 
 189 days 
 21.06.2007 
 20.07.2007 
 25.07.2007 
 OJ C 203 of 
3
 Riprazo  Novartis Europharm  C09XA02 
f essen
 25.03.2007  18.07.2007 
. 2 
 aliskiren Ltd.  Treatment o tial  21.06.2007 
hypertension  77 days 
 11 days 
 22.08.2007 
 24.08.2007 
 OJ C 228 of 
28.09.2007, p
 Flebogammadif 
n 
 Instituto Grifols S.A.  Not yet assigned 
ary hypogamma-
ia and recur
 27.09.2006 
 3 
 human 
immunoglobi
(IVIg) 
 
 Replacement therapy in:  21.06.2007 
immunodeficiency 
syndromes, myeloma or 
chronic lymphatic 
leukaemia with severe 
second
globulinem
infections  
rent 
 177 days 
 90 days 
 24.07.2007 
 25.07.2007 
 27.08.2007 
 OJ C 228 of 
28.09.2007, p.
 Rasilez 
 aliskiren 
 Novartis Europharm
Ltd 
2  
 Treatment of essential  2.08.2007 
 2 
 
  C09XA0
hypertension 
 27.09.2006 
 21.06.2007
 194 days 
 73 days 
 18.07.2007 
 2
 24.08.2007 
 OJ C 228 of 
28.09.2007, p.
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Product 
 Brand name 
 INN 
Marketing authorisation 
holder 
Therapeutic area 
 ATC code 
 Summary of indication 
EMEA.CHMP 
 Validation 
 Opinion 
 Active time 
 Clock stop 
European Commission 
 Opinion received 
 Date of decision 
 Notification 
 Official Journal 
 Tekturna 
 aliskiren 
 
 Novartis Europharm 
Ltd. 
 C09XA02 
 Treatment of essential 
hypertension 
J C 228 of 
 p. 3 
 25.03.2007 
 21.06.2007 
 77 days 
 11 days 
 18.07.2007 
 22.08.2007 
 24.08.2007 
 O
28.09.2007,
 Enviage 
 aliskiren 
 
 Novartis Europharm
Ltd. 
 11 days 
4.08.2007 
 OJ C 228 of 
 p. 2 
  C09XA02 
 Treatment of essential 
hypertension 
 25.03.2007 
 21.06.2007 
 77 days 
 18.07.2007 
 22.08.2007 
 2
28.09.2007,
 Sprimeo 
 aliskiren 
 
 Novartis Europharm
Ltd. 
 11 days 
4.08.2007 
 OJ C 228 of 
 p. 2 
  C09XA02 
 Treatment of essential 
hypertension 
 25.03.2007 
 21.06.2007 
 77 days 
 18.07.2007 
 22.08.2007 
 2
28.09.2007,
 Celsentri 
 maraviroc 
 
 Pfizer Limited 
in combination with 
oviral 
 35 days 
0.09.2007 
 OJ C 251 of 
 p. 10 
 J05AX09 
 For use in HIV-1 treatment-
experienced HIV-1 infect
patients 
ed  169 days 
other antiretr
medicinal products 
 27.12.2006 
 19.07.2007 
 15.08.2007 
 18.09.2007 
 2
26.10.2007,
 Galvus 
 vildagliptin 
 
 Novartis Pharma AG 
 sulphony ur
 203 days 
 134 days 
.09.2007 
 28.09.2007 
 OJ C 251 of 
 p. 10 
 A10BH02 
 Treatment of type 2 dia
mellitus as add-on therapy 
in combination with 
betes  19.07.20
metformin,
pioglitazon
l ea or 
e 
 16.08.2006 
07  26
 16.08.2007 
26.10.2007,
 Cervarix 
 human papilloma 
 GlaxoSmithKline 
Biologicals  Prevention of cervical  
3.08.2007 
0.09.2007 
 10 
virus 
 
 Not yet assigned 
cancer 
 29.03.2006 
 19.07.2007
 202 days 
 275 days 
 1
 2
 24.09.2007 
 OJ C 251 of 
26.10.2007, p.
 Ecalta 
anidulafungin 
 Pfizer Ltd 6 
 Treatment of invasive 
candidiasis in adult non-
neutropenic patients 
 
 19.07.2007 
 210 days 
 85 days 
0.09.2007 
 20.09.2007 
 24.09.2007 
 OJ C 251 of 
26.10.2007, p. 10 
 
 
 J02AX0  27.09.2006  1
 Pioglitazone  Takeda Europe R&D  A10BD05  23.07.2007 
metf
 piog
ormin 
litazone 
ype 2 diabetes 
ts 


 21.09.2007 
metformin 
 
Centre Ltd  Treatment of t
mellitus patien
 20.09.2007 
 59 days 
 0 days 
 11.12.2007 
 13.12.2007 
  
 Cyanokit 
 hydroxocobalamin 
 Merck Sante s.a.s.  V03AB33 
 Treatment of known or
yanide poisoni
 42 
 
 

suspected c ng  177 days 
 27.12.2006 
 20.09.2007 
 90 days 
 26.09.2007 
 23.11.2007 
 27.11.2007 
 OJ C 316 of 
28.12.2007, p.
 Eucreas 
 vildagliptin. 
in  
 Novartis Europharm 
Ltd 
 Not yet assigned  
 Treatment of type 2 diabetes 
ients with 
 20.09.2007 
metform
 
mellitus pat
insufficient glycaemic 
control with oral metformin 
alone 
 24.01.2007 
 177 days 
 62 days 
 18.10.2007 
 14.11.2007 
 16.11.2007 
 28.12.2007 
OJ C 316, p. 42  
 Avamys 
ne 
 Glaxo Group  R01AD12 
f allergic
 16.08.2006 
 fluticaso furoate 
 
 Treatment o  
rhinitis 
 18.10.2007 
 202 days 
 226 days 
 24.10.2007 
 11.01.2008 
 16.01.2008 
  
 Atripla 
 efavirenz 
emtricitabine 
tenofovir 
 
 Bristol-Myers Squibb, 
Gilead Sciences and 
MSD Ldt 
 Combination treatment of 
HIV infected adults 
 18.10.2007 
 202 days 
 156 days 
 18.12.2007 
  
 Not yet assigned  25.10.2006  15.11.2007 
 13.12.2007 
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Product 
 Brand name 
 INN 
Marketing authorisation 
holder 
Therapeutic area 
 ATC code 
 Summary of indication 
EMEA.CHMP 
 Validation 
 Opinion 
 Active time 
 Clock stop 
European Commission 
 Opinion received 
 Date of decision 
 Notification 
 Official Journal 
 Abraxane 
Inc.  paclitaxel 
 
 American BioScience  L01CD01 
 Treatment of breast cancer  18.10.2007 
 27.09.2006 
 202 days 
 184 days 
 24.10.2007 
 11.01.2008 
 15.01.2008 
  
 Nevanac 
 
 Alcon Laboratories L
and treatm
 24.01.2007 
 nepafenac
 
td  S01BC10 
 Prevention ent of  18.10.2007 
post-operative pain and 
inflammation associated 
with cataract surgery 
 205 days 
 62 days 
 14.11.2007 
 11.12.2007 
 13.12.2007 
  
 Ivemend 
t 
 Merck Sharp & Doh
of 
 24.05.2006 
 aprepitan
 
me  Not yet assigned 
 Prevention 
chemotherapy-induced 
nausea and vomiting 
(CINV) 
 15.11.2007 
 197 days 
 343 days 
 21.11.2007 
 11.01.2008 
 16.01.2008 
  
 Isentress  Merck Sharp & Dohme  Not yet assigned 
f HIV-1 
trov
agents  
 23.05.2007 
 raltegravir 
 
 Treatment o
infection in combination 
with other anti-re ial  35 days 
 15.11.2007 
 141 days 
 30.11.2007 
 20.12.2007 
 02.01.2008 
  
 Tesavel 
in p
 Merck Sharp & Dohme  A10BH01 
nt of glycae
gamma agonist in patients 
with type 2 diabetes mellitus 
 16.09.2007 
 sitaglipt hosphate 
monohydrate 
 
 Improveme mic  15.11.2007 
control in combination with 
metformin and PPAR 
 60 days 
 0 days 
 21.11.2007 
 10.01.2008 
 14.01.2008 
   
 Tyverb 
 lapatinib 
 
 GlaxoSmithKline  L01XE07 
 Treatment of advanced
metastatic breast cancer 
 or  13.12.2007 
 25.10.2006 
 202 days 
 212 days 
 13.01.2008 
  
  
  
 Vectibix 
 panitumumab 
 
 Amgen Europe B.V.  L01XC08 
 Treatment of metastatic 
carcinoma of the colon or 
rectum 
 24.05.2006 
 24.05.2007 
 204 days 
 161 days 
 05.12.2007 
 03.12.2007 
 05.12.2007 
  
 
CHMP positive opinions in 2007 on orphan medicinal products for human use 
Product 
 Brand name 
 INN 
Marketing authorisation 
holder 
Therapeutic area 
 ATC code 
 Summary of indication 
EMEA.CHMP 
 Validation 
 Opinion 
 Active time 
 Clock stop 
European Commission 
 Opinion received 
 Date of decision 
 Notification 
 Official Journal 
 Revlimid 
 lenalidomide 
 
 Celgene Europe Ltd  L04AX04 
 Treatment of multiple 
myeloma  
 29.03.2006 
 22.03.2007 
 199 days 
 159 days 
 16.05.2007 
 14.06.2007 
 19.06.2007 
 OJ C 174 of 
27.07.2007, p. 3 
 Soliris 
 eculizumab 
 
 Alexion Europe  L04AA25 
 Treatment of patients with 
paroxysmal nocturnal 
hemoglobinuria  
 25.10.2006 
 26.04.2007 
 147 days 
 36 days 
 31.05.2007 
 20.06.2007 
 22.06.2007 
 OJ C 174 of 
27.07.2007, p. 3 
 Siklos 
 hydroxycarbamide 
 
 OTL Pharma  L01XX05 
 Prevention of vaso-occlusive 
crises in patients suffering 
from sickle cell syndrome 
 26.10.2005 
 26.04.2007 
 208 days 
 339 days 
 25.05.2007 
 29.06.2007 
 05.07.2007 
 OJ C 174 of 
27.07.2007, p. 3 
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Product 
 Brand name 
 INN 
Marketing authorisation 
holder 
Therapeutic area 
 ATC code 
 Summary of indication 
EMEA.CHMP 
 Validation 
 Opinion 
 Active time 
 Clock stop 
European Commission 
 Opinion received 
 Date of decision 
 Notification 
 Official Journal 
 Increlex 
 mecasermin 
 
 Tercica Inc (US
 Long-term treatment 
growth failure in children with 
ary IGF-1 
 2 
)  H01AC03 
of  24.05.2007 
severe prim
deficiency 
 28.12.2005 
 208 days 
 304 days 
 05.07.2007 
 03.08.2007 
 06.08.2007 
 OJ C 228 of 
28.09.2007, p.
 Atriance 
 nelarabine 
 GlaxoSmithKline 
 203 days
 162 days  OJ C 228 of 
28.09.2007, p. 3 
 L01BB07 
 Treatment of T-cell acute 
lymphoblastic leukaemia and 
T-cell lymphoblastic 
lymphoma 
 21.06.2006 
 21.06.2007 
 

 04.07.2007 
 22.08.2007 
 24.08.2007 
 Gliolan 
 5-aminolevulinic 
 Medac 
hydrochloride 
 
 L01XD04 
 Visualisation of malignant 
tissue during surgery for 
malignant glioma 
 24.05.2006 
 21.06.2007 
 199 days 
 194 days 
 25.07.2007 
 07.09.2007 
 12.09.2007 
 OJ C 251 of 
26.10.2007, p. 10 
 Yondelis 
 trabectedin 
 
 PharmaMar S.A.  16.08.2006 
 19.07.2007 
 210 days 
 17.08.2007 
 17.09.2007 
 20.09.2007 
 10 
 L01CX01 
 Treatment of patients with soft 
tissue sarcoma  
 127 days  OJ C 251 of 
26.10.2007, p.
 Torisel 
 temsirolismus 
 
 Wyeth Europa Ltd. 
a  203 days
 127 days  OJ 316 of 
28.12.2007 
 L01XE09 
 Treatment of patients wit
advanced renal cell carcinom
h  20.09.2007
 25.10.2006 
 
 

 18.10.2007 
 19.11.2007 
 21.11.2007 
 Tasigna  Novartis Pharma AG 
f chronic 
 25.10.2006  22.10.2007 
 nilotinib  
 
 L01XE08 
 Treatment o
myelogenous leukaemia   200 days 
 20.09.2007 
 130 days 
 19.11.2007 
 21.11.2007 
  
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man use CHMP positive opinions in 2007 on similar biological medicinal products for hu
Product 
 Brand name 
 INN 
Marketing authorisation 
holder 
Therapeutic area 
 ATC code 
 Summary of indication 
EMEA.CHMP 
 Validation 
 Opinion 
 Active time 
 Clock stop 
European Commission 
 Opinion received 
 Date of decision 
 Notification 
 Official Journal 
 Binocrit 
 epoetin alfa 
 
 Sandoz GmbH  B03XA01 
 Treatment of anaemia 
associated with chronic ki
disease and in oncology 
patients and to reduce blood 
dney  205 days 
transfusion r
oncology pa
equireme s nt in 
tients and prior to 
elective orthopaedic surgery 
 29.03.2006 
 21.06.2007 
 244 days 
 19.07.2007 
 28.08.2007 
 31.08.2007 
 OJ C 228 of 
28.09.2007, p. 2 
 Abseamed 
 epoetin alfa 
 MEDICE 
ARZNEIMITTEL 
ith chronic kidney 
 21.06.2007 
 3 
 PÜTTER GMBH & 
CO. KG 
 B03XA01 
 Treatment of anaemia 
associated w
disease and in oncology 
patients and to reduce blood 
transfusion requirements i
oncology patients and prior to 
elective orthopaedic surgery 
n 
 29.03.2006 
 205 days 
 244 days 
 19.07.2007 
 28.08.2007 
 31.08.2007 
 OJ C 228 of 
28.09.2007, p.
 Epoetin alfa Hex
 epoetin alfa 
al  Hexal Biotech 
ForschungsGm
 
bH  Treatment of anaemia 
associated with chronic kidney 
disease and in oncology 
patients and to reduce blood 
 B03XA01 
transfusion requirem
s 
8.08.2007 
3.09.2007 
J C 228 of 
28.09.2007, p. 3 
ents in 
oncology patients and
elective orthopaedic surgery 
 prior to 
 29.03.2006 
 21.06.2007 
 205 days 
 244 day
 19.07.2007 
 2
 0
 O

 
 Retacrit 
epoetin zeta  
 Hospira Enterprises 
B.V. 
associated with chronic kidney 
disease and in oncology 
patients to treat anaemia and 
reduce blood transfusion 
requirements, and to increase 
the yield of autologous blood 
in a pre-donation programme 
07 
 18.10.2007 
 85 days 
 66 days 
5.11.2007 
 18.12.2007 
 20.12.2007 
  
 
 B03XA01 
 Treatment of anaemia 
 20.05.20  1
 Silapo 
 epoetin zeta  
 
 Stada R&D GmbH  B03XA01 
 Treatment of anaemia 
associated with chronic kidney 
disease and in oncology 
patients to treat anaemia and 
reduce blood transfusion 
requirements, and to increase 
the yield of autologous blood 
in a pre-donation programme 
 19.07.2006 
 18.10.2007 
 202 days 
 254 days 
 15.11.2007 
 18.12.2007 
 20.12.2007 
  
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an use CHMP positive opinions in 2007 on generic medicinal products for hum
Product 
 Brand name 
 INN 
Marketing authorisation 
holder 
Therapeutic area 
 ATC code 
 Summary of indication 
EMEA.CHMP 
 Validation 
 Opinion 
 Active time 
 Clock stop 
European Commission 
 Opinion received 
 Date of decision 
 Notification 
 Official Journal 
 Zalasta 
 olanzapine 
 
severe manic episode and 
recurrence in  bipolar disorder 2007, p. 11 
 Krka  d.d. Novo Mesto  N05AH03 
 Treatment of schizophrenia
treatment of moderate 
;  19.07.2007 
to  177 days 
 25.10.2006 
 90 days 
 17.08.2007 
 27.09.2007 
 01.10.2007 
 OJ C 251 of 
26.10.
 Olanzapine
 olanzapine 
 
treatment of moderate to 
severe manic episode and 
 disor
 18.10.2007 
 14.10.2007 
 16.11.2007 
 28.12.2007 
 p. 42 
 
Neopharma 
 Cipla Ltd.  N05AH03 
 Treatment of schizophrenia; 
recurrence in bipolar der 
 25.10.2006 
 20.09.2007 
 205 days 
 127 days 

OC C 316,
 Olanzapine Teva 
 olanzapine 
 
armanceut
Ltd. schizop
treatment of moderate to 
 
 14.11.2007 
 12.12.2007 
 1412.2007 
 Not yet published 
 Teva Ph icals  N05AH03 
 Treatment of hrenia;  18.10.2007
severe manic episode and 
recurrence in bipolar disorder. 
 118 days 
 27.12.2006 
 177 days 

 Myfenax 
 mycophenolate 
 TEVA Pharmaceuti
Europe B.V. 
n in patients 
 
 
 21.12.2007 
  
mofetil 
 
cals  L04AA06 
 Prophylaxis of acute 
transplant rejectio
receiving allogeneic re
cardiac or hepatic trans
nal, 
 138 days 
 8 days 
plants 
 20.07.2007
 13.12.2007
  
  
 Mycophenolate 
mofetil Teva 
 TEVA Pharmaceuticals 
Europe B.V. 
 L04AA06 
 Prophylaxis of acute 
ejection in patients 
 13.12.20
 
 mycophenolate 
mofetil 
 
transplant r
receiving allogeneic renal, 
cardiac or hepatic transplants 
 20.07.2007 
07 
 21.12.2007
  
 138 days 
 8 days 
  
  
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CHMP negative opinions in 2007 on medicinal products for human use 
Product 
 Brand name 
 INN 
Marketing authorisation 
holder 
Therapeutic area 
 ATC code 
 Summary of indication 
EMEA.CHMP 
 Validation 
 Opinion 
 Active time 
 Clock stop 
European Commission 
 Opinion received 
 Date of decision 
 Notification 
 Official Journal 
 Genasense 
 oblimersen sodium 
 Genta Development  L01XX36 
 Treatment of advanced or
ma
 15.10.2007 
 18.10.2007 
 316 of 28.12.2007, 
p. 57 
 
metastatic melano  
 31.03.2006 
 26.04.2006 
 210 Days 
 239 Days 
 14.09.2007 


 Cimzia 
 certolizumab pegol 
 UCB S.A 
's disease 
.2006 
 15.11.2007 
  L04AB05 
 Treatment of Crohn
 24.05
 202 Days 
 338 Days 
 Kiacta 
 eprodisate 
 Neurochem Luco II
SARL 
d 
 Treatment of patients with 
.2006 
.2007 
   Not yet assigne
amyloidosis 
 27.09
 13.12
 202 Days 
 240 Days 
 Rhucin 
 rhC1INH 
 Pharming Group N. ned 
 Treatment of acute attacks of
with 
.2006 
.2007 
 V  Not yet assig
 
edema in patients 
hereditary angioedema 
 16.08
 13.12
 176 Days 
 308 Days 
 Mycograb 
 myctumab 
 NeuTec Pharma plc 
iv
 
.2005 
.2007 
 12.04.2007 
 22.05.2007 
 29.05.2007 
 OJ 144 of 
29.06.2007, p. 6 
 Not yet assigned 
 Treatment of invas e  20.03
candidiasis
 14.03
 207 Days 
 391 Days 


 Natalizumab 
ab
 Elan Pharma 
f modera
.2004  13.12.2007 
 11.01.2008 
 15.01.2008 
 
 natalizum  International Ltd.  Treatment o
 L04AA23 
tely to  19.07.2007 
severely active Crohn's 
disease for the reduction of 
signs and symptoms 
 18.10
 204 Days 
Days  800 


 Mylotarg  Wyeth Europa Ltd 
f CD33-p
 28.12.2005  
 gemtuzumab 
ozogamicin 
 L01XC05 
 Treatment o ositive  20.09.2007 
acute myeloid leukaemia 
patients in first relapse who 
are not candidates for other 
cytotoxic chemotherapy 
 200 Days 
Days  431 
  
EMEA annual report 2007 
EMEA/MB/17464/2008 2.4, CURRENT 
Page 112/138 
 
opinion 
Centralised applications for medicinal products for human use – withdrawals in 2007 prior to
Product 
 Brand name 
 INN 
Marketing authorisation 
holder 
Therapeutic area 
 ATC code 
 Summary of indication 
EMEA.CHMP 
 Validation 
 Date of 
withdrawal 
 Active time 
 Clock stop 
European Commission 
 Opinion received 
 Date of decision 
 Notification 
 Official Journal 
 Garenoxacin   SP Europe  Not yet assigned 
ent of bronchitis, 
neumonia, skin and 
ure and post-
surgical infections 
mesylate 
 garenoxacin 
mesylate 
  Treatm
sinusitis, p
skin struct
 24/05/2006 
 25/07/2007 
 174 
 253 
 
 Gastromotal 
c 13C-octanoi a
t assigned 
 cid 
  INFAI  Not ye
 In vivo diagnosis of gastric 
emptying rate 
 24/05/2006 
 05/11/2007 
 193 
 337 
 
 Arxxant 
 ruboxistaurin 
  Elli Lilly and Compan
Limited 
y  Not yet assigned 
 Treatment of diabetic 
retinopathy 
 21/06/2006 
 13/03/2007 
 117 
  148
 
 Iplex 
 mecasermin 
 Insmed Europe Ltd  Not yet assigned 
rowth failur
IGF-1 deficiency 
 Treatment of g
children with severe pri
e in  22/03/2007 
mary  117 
 21/06/2006 
 157 
 
 Retisert 
 fluociolone 
acetonide 
 Bausch & Lom A15 b Inc.  S01B
 Treatment of chronic non-
infectious uveitis affecting 
posterior segment of the eye 
the  117 
 25/10/2006 
 18/07/2007 
 149 
 
 Sinerem 
 superpara-
magnetici
oxidenan
ron 
o-particles 
03 
diagnosis of lymph node 
metastases in pelvic cancers 
 
  Guerbet S.A.  V08C B
 Contrast agent for magnetic 
resonance imaging for the 
 22/11/2006 
 12/12/2007 
  175
 210
 
 Voraxaze 
glucarpidase  
 Protherics PLC  V03AF09 
 Adjunctive treatment of 
patients experiencing or
of methotrexate toxicity due to 
mination or
 at risk  174
 468 
delayed eli  
inadvertent overdose 
 17/08/2005 
/2007  21/05
 
 
 Vitragan 
 ovine hyaluronidase 
 ISTA Pharma Limited 
 
 B06A A03 
 Treatment of vitreous 
rrhage to improve visual 
lyi
pathology 
/2005 
2007 
 
hemo
acuity and to facilitate 
diagnosis of under ng retinal 
 28/12
 25/04/
 174 
 308 
 Cerepro 
 adenovirus-
  Ark therapeutics Ltd 
 
 Not yet assigned 
 In conjunction with 
th 
opera oma 
 26/10/2005 
 13/07/2007 
 210 
 336 
 
mediated HSV 
thymidine kinase 
ganciclovir sodium for 
treatment of patients wi
gene ble high-grade gli
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Annex 12 CVM 0 odu  
Centralised applications – Positive opinions  
P Opinions in 20 7 on Medicinal Pr cts for Veterinary Use
Product 
 Brand name 
 INN 
Marketing authorisation 
holder 
Therapeutic area 
 ATC code 
 Summary of indication  
EMEA.CHMP 
 Validation 
 Opinion 
 Active time 
 Clock stop 
European Commission 
 Opinion received 
 Date of decision 
 Notification 
 Official Journal 
 Slentrol 
 Dirlotapide  
 Pfizer  Dogs 
 Obesity   
 21/02/2006 
 14/02/2007 
 209 
 148 
 19/02/2007 
 13/04/2007 
   
 OJ C 174/9 
 Suprelorin 
 Deslorelin 
 
 Cyton Biosciences Ltd  Dogs 
 Temporary infertility in male 
dogs 
 20/09/2005 
 15/05/2007 
 211 
 301 
 12/062007 
 10/07/2007 
   
 OJ C 203/8 
 Nobilis Influenza 
H7N1 
 Vaccine 
 
 Intervet International 
bv 
 Chickens  
 Vaccine against avian 
influenza 
 18/10/2006 
 14/03/2007 
 120 
 28 
 15/03/2007 
 14/05/2007  
   
 OJ C 144/10 
 Prilactone 
 Spironolactone 
 
 Ceva Sante Animale  Dogs 
 Heart failure  
 07/06/2005 
 17/04/2007 
 210 
 469 
 22/05/2007 
 20/06/2007 
   
 OJ C 174/9 
 Circovac 
 Inactivated vaccine 
 
 Merial  Pigs 
 Passive immunity against 
porcine circovirus type 2. 
 21/12/2005 
 17/04/2007 
 210 
 274 
 15/05/2007 
 21/06/2007 
   
 OJ C 174/9 
 Nobilis Influenza 
H5N6 
 Vaccine 
 
 Intervet International 
BV 
 Birds 
 Prevention of avian influenza 
 13/02/2007 
 11/07/2007 
 90 
 28 
 
 Meloxivet 
 Meloxicam  
 
 Janssen Pharmaceutica 
N.V. 
 Dogs 
 Musculo-skeletal disorders 
 19/12/2006 
 12/09/2007 
 210 
 57 
 18/09/2007 
 14/11/2007 
 
 Rheumocam 
 Meloxicam  
 Chanelle 
Pharmaceuticals 
 Dogs  
 Musculo-skeletal disorders 
 18/08/2006  
 07/11/2007 
 208 
 231 
 
 Ingelvac CircoFLEX 
 Porcine Circovirus 
 Boehringer Ingelheim 
Vetmedica GmbH 
 Pigs 
 Imunisation against porcine 
circovirus type 2 
 13/02/2007 
 12/12/2007 
 210 
 92 
 
 
Establishment of maximum residue limits for new substances 
Substance INN 
 
 
Therapeutic area 
 Target species 
EMEA/CVMP 
 Validation 
 Opinion 
 Active time 
 Clock stop 
European Commission 
 Opinion received 
 Date of regulation 
 Official Journal 
 Avilamycin  Pigs, poultry and rabbits  13/01/2005 
 10/10/2007 
 120 
 670 
 24/10/2007 
 Monensin  Dairy Cattle  17/02/2005 
 15/05/2007 
 119 
 698 
 12/06/2007 
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Substance INN 
 
 
Therapeutic area 
 Target species 
EMEA/CVMP 
 Validation 
 Opinion 
 Active time 
 Clock stop 
European Commission 
 Opinion received 
 Date of regulation 
 Official Journal 
 Gamithromycin  Bovine  10/08/2006 
07 
 117 
 215 
 24/10/2007 
 10/10/20
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Annex 13 COMP opinions in 2007 on designation
Positive COMP designation opinions 
 of orphan medicinal products 
Product INN Sponsor Summary of indication EMEA/COMP 
 Submission 
 Start date 
 Opinion 
 Active time 
European Commission 
 Opinion received 
 Date of decision 
(1R,2R)-octanoic acid[2-(2',3'-
dihydro-benzo[1,4] dioxin-6'-
-
(Genz-112638) 
e Europe BV - 
The Netherlands 
Treatment of Gaucher Disease 
7 
 30/10/2007 
 04/12/2007 
yl)-2-hydroxy-1-pyrrolidin-1
ylmethyl-ethyl]-amide-L-
tartaric acid salt  
Genzym  29/06/20
 13/07/200
07 
 10/10/2007 
 89 days 
(manganese, dichloro [(4aR, 
13aR, 17aR, 21aR)-1, 2, 3, 4, 
4a, 5, 6, 12, 13, 13a, 14, 15, 16, 
17, 17a, 18, 19, 20, 21, 21a-
adecine-κN5, 
N13, κN18, κN21, κN22]-)  
(M40403) 
Ltd - UK and neck cancer patients 
undergoing radiation therapy
eicosahydro-11, 7-nitrilo-7H-
dibenzo[ b,h] [1,4,7,10] 
tetraazacyclohept
κ
Celtic Bio-Pharma 
Services 
Prevention of oral mucositis in head  24/08/2007 
 
 10/09/2007 
 05/12/2007 
 17/12/2007 
 Pending 
(R)-2-Methyl-6-nitro-2-{4-[4-
-
trifluoromethoxyphenoxy)piper
idin-1-yl]phenoxymethyl}-2,3-
oxazole  
Europe Ltd - UK (4
dihydroimidazo[2,1-b]
Otsuka Pharmaceutical Treatment of tuberculosis  27/09/2007 
 15/10/2007 
 05/12/2007 
 17/12/2007 
 Pending 
(S)-2-nitro-6-(4-
ifluoromethoxy) benzyloxy)-
6,7-dihydro-5H-imidazo[2,1-b] 
lrich Granzer - 
Germany 
f tuberculosis 
07/ 
 29/11/2007 tr
[1,3] oxazine  
(PA-824) 
Dr U Treatment o  13/07/2007/ 
 13/08/2007 
 10/10/20
 58 days 
 30/10/2007 
1-{3-[3-(4-
chlorophenyl)propoxy]propyl}
hloride  
Bioprojet - France Treatment of narcolepsy 
07 
 15/06/2007 
 10/07/2007 
piperidine, hydroc
rocognil) (P
 16/10/2006 
 05/03/20
 31/05/2007 
 87 days 
17-(allylamino)-17-
demethoxygeldanamycin, 
e, hydrochloride  
MedImmune Oncology,  
Inc. - The Netherlands 
Treatment of malignant 
gastrointestinal stromal tumours 07 
 30/10/2007 
 29/11/2007 
hydroquinon
PI-504) (I
 23/07/2007 
 13/08/20
 10/10/2007 
 58 days 
3-methoxy-pregnenolone  
 
MAPREG SAS - France Treatment of spinal cord injury 
07 
 30/10/2007 
 04/12/2007 
 27/07/2007 
 13/08/20
 10/10/2007 
 58 days 
4-[3,5-
bis(trimethylsilyl)benzamido] 
Quintiles Ireland Ltd - 
Ireland 
Treatment of hepatocellular 
carcinoma 07 
 26/09/2007 
 22/10/2007 
benzoic acid  
 31/05/2007 
 13/07/20
 12/09/2007 
 61 days 
4-Amino-1-[5-O-[(2R,4S)-2-
oxido-4-(4-pyridinyl)-1,3,2-
-
 
Interface International 
Consultancy Ltd - 
Treatment of  hepatocellular 
carcinoma 07 
 02/08/2007 
 14/09/2007 
dioxaphosphorinan-2-yl]-β-D
arabinofuranosyl]-2(1H)-
pyrimidinone  
(MB07133)
United Kingdom 
 31/05/2007 
 15/06/20
 25/07/2007 
 40 days 
4-ethoxy-2-
yridin-4-
(piperazin-1-yl)-7-
yl)-5H-
yrimido[5,4-b]indol  
 
(p
p
Curacyte Discovery
GmbH - Germany 
Treatment of chronic lymphocytic 
leukaemia 
 27/06/2007 
 13/07/2007 
 12/09/2007 
 61 days 
 26/09/2007 
 14/11/2007 
5(S)-(2'-hydro
ptothecin  
xy ethoxy)-
20(S)-Cam
ClinTec International 
Ltd - UK 
Treatment of osteosarcoma  13/02/2007 
 05/03/2007 
 12/04/2007 
 38 days 
 04/05/2007 
 08/06/2007 
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Product INN Sponsor Summary of indication EMEA/COMP 
 Submission 
 Start date 
 Opinion 
 Active time 
European Commission 
 Opinion received 
 Date of decision 
5'-O-(trans-9"-octadecenoyl)
ß-D-arabinofuranosyl c
-1-
ytosine  
lacyt) 
leukaemia 
(E
Clavis Pharma ASA - 
Norway 
Treatment of acute myeloid  31/05/2007 
 15/06/2007 
 25/07/2007 
 40 days 
 02/08/2007 
 14/09/2007 
Adenovirus associated viral 
ector serotype 4 containing the 
human RPE65 gene  
itaire de Nantes - 
France 
v
Centre Hospitalier 
Univers
Treatment of retinitis pigmentosa  30/05/2007 
 13/07/2007 
 12/09/2007 
 61 days 
 26/09/2007 
 14/11/2007 
Adenovirus associated viral 
ector serotype 4 containing the 
human RPE65 gene 
itaire de Nantes - 
France 
v
Centre Hospitalier 
Univers
Treatment of Leber's congenital 
amaurosis 
 30/05/2007 
 13/07/2007 
 12/09/2007 
 61 days 
 26/09/2007 
 22/10/2007 
Alginate oligosaccharide (G-
block) fragment  
AlgiPharma AS - 
Norway 
Treatment of cystic fibrosis  05/01/2007 
 27/04/2007 
 25/07/2007 
 89 days 
 02/08/2007 
 14/09/2007 
Alpha1-proteinase inhibitor 
e)  
 
Germany (inhalation us
CSL Behring GmbH - Treatment of cystic fibrosis  30/05/2007 
 15/06/2007 
 25/07/2007 
 40 days 
 02/08/2007 
 14/09/2007 
Alvocidib  
 
Sanofi Aventis - France Treatment of patients with chronic 
lymphocytic leukaemia 
 27/06/2007 
 13/07/2007 
 12/09/2007 
 61 days 
 26/09/2007 
 23/10/2007 
Amonafide L-malate  
(Xanafide) 
 
INC Research UK Ltd - 
UK 
Treatment of acute myeloid 
leukaemia 
 29/06/2007 
 13/07/2007 
 12/09/2007 
 61 days 
 26/09/2007 
 22/10/2007 
Antisense oligonucleotide 
TCGCCA
Gene Signal SAS - Prevention of corneal graft rejection  20/11/2006  21/03/2007 
(TATCCGGAGGGC
TGCTGCT)  
(GS 101) 
France  11/12/2006 
 08/03/2007 
 87 days 
 17/04/2007 
Arsenic trioxide  Cephalon Europe - Treatment of acute myeloid 07  09/07/2007 
 France leukaemia 
 10/04/20
 27/04/2007 
 27/06/2007 
 61 days 
 02/08/2007 
Artesunate  ACE Pharmaceuticals 
 
Treatment of malaria 06  24/01/2007 
 BV - The Netherlands
 26/10/20
 10/11/2006 
 10/01/2007 
 61 days 
 20/02/2007 
Artesunate  Sigma-tau Pharma UK - alaria 07  26/09/2007 
 UK 
Treatment of m  27/07/20
 13/07/2007 
 10/10/2007 
 58 days 
 06/12/2007 
Autologous CD34+ cells 
atase A cDNA  
thon - Treatment of metachromat 06  22/03/2007 
transfected with lentiviral 
ector containing the human v
arylsulf
Fondazione Tele
Italy 
ic  27/12/20
leukodystrophy  15/01/2007 
 08/03/2007 
 52 days 
 13/04/2007 
Autologous dendritic cells 
mour 
Dorian Regulatory Treatment of glioma 06  24/01/2007 
pulsed with autologous tu
ell lysate  c
Affairs BV - The 
Netherlands 
 27/09/20
 10/11/2006 
 10/01/2007 
 61 days 
 15/02/2007 
Aviptadil  mondoBIOTECH 
 
Treatment of sarcoidosis 07  02/08/2007 
 Laboratories Anstalt -
Liechtenstein 
 14/02/20
 27/04/2007 
 30/07/2007 
 93 days 
 14/09/2007 
Azacitidine  
(Vidaza) 
 
Pharmion Ltd - United 
Kingdom 
Treatment of acute myeloid 
leukaemia 
07 
 13/08/2007 
 10/10/2007 
 58 days 
 30/10/2007 
 29/11/2007 
 27/07/20
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Product INN Sponsor Summary of indication EMEA/COMP 
 Submission 
 Start date 
 Opinion 
 Active time 
European Commission 
 Opinion received 
 Date of decision 
Chimeric-anti-interleukin 6 
onoclonal antibody  
 
m
Centocor, B.V. - The 
Netherlands 
Treatment of Castleman's disease  26/07/2007 
 13/08/2007 
 10/10/2007 
 58 days 
 30/10/2007 
 30/11/2007 
Ciclosporin  
 
Novagali Pharma SA - 
France 
Prevention of corneal graft rejection  27/06/2007 
 13/07/2007 
 12/09/2007 
 61 days 
 26/09/2007 
 22/10/2007 
Ciclosporin  
 
Novagali Pharma SA
France 
 - 
atitis 
Treatment of herpes simplex v
stromal ker
irus  27/06/2007 
 13/07/2007 
 12/09/2007 
 61 days 
 26/09/2007 
 29/10/2007 
Ciprofloxacin (inhalation use)  
 
Bayer HealthCare  AG 
(Wuppertal) - Germany 
Treatment of cystic fibrosis  24/11/2006 
 30/03/2007 
 27/06/2007 
 89 days 
 09/07/2007 
 03/08/2007 
Cisplatin (liposomal)  
(Lipoplatin) 
Regulon AE - Greece Treatment of pancreatic cancer  29/12/2006 
 15/01/2007 
 12/04/2007 
 87 days 
 04/05/2007 
 08/06/2007 
Cyclo {{(E,Z)-(2S,3R,4R)-3-
hydroxy-4-methyl-2-
(methylamino)nona-6,8-
dienoyl}-L-2-aminobutyryl-N-
-
L-
leucyl-N-methyl-L-valyl}  
iences GmbH 
uveitis 
methyl-glycyl-N-methyl-L
leucyl-L-valyl-N-methyl-L-
leucyl-L-alanyl-D-alanyl-N-
methyl-L-leucyl-N-methyl-
(LX211) 
Lux Biosc
- Germany 
Treatment of chronic non-infectious  24/08/2006 
 27/04/2007 
 25/07/2007 
 89 days 
 02/08/2007 
 14/09/2007 
Dihydroartemisinin, 
piperaquine  
(Eurartesim) 
Farmaceutiche Riunite 
S.p.A - Italy 
f malaria 
07 
 03/08/2007 
Sigma Tau Industrie Treatment o  

14/03/2007 
 30/03/2007 
 27/06/20
 87 days 
 09/07/2007 
Doxorubicin hydrochloride 
rug eluting beads)  
(CM-BC1) 
ermany 
07 
 29/11/2007 (d
L01DB01 
CellMed AG - G Treatment of glioma  31/05/2007 
 13/08/2007 
 10/10/20
 58 days 
 30/10/2007 
Elafin  
 
 - 
Germanay  chronic 
thromboembolic pulmonary 07 
 20/03/2007 
Proteo Biotech AG Treatment of pulmonary arteri
hypertension and
al  13/10/2006 
 
hypertension 
 11/12/2006 
 07/02/20
 89 days 
 22/02/2007 
Eltrombopag olamine  
(Revolade) 
 
GlaxoSmithKline 
Research & 
Development Limited 
Treatment of idiopathic 
thrombocytopenic purpura 
07 
 03/08/2007 
(Harlow) - UK 
 13/04/2007 
 27/04/2007 
 27/06/20
 61 days 
 09/07/2007 
Enzastaurin hydrochloride  land B.V. 
- The Netherlands 
Treatment of diffuse large B 
lymphoma 
07 
 20/03/2007  
Eli Lilly Neder cell  24/11/2006 
 11/12/2006 
 07/02/20
 58 days 
 22/02/2007 
Eptacog alfa (activated)  
 
f post-neonatal 
intracerebral haemorrhage 
07 
 20/03/2007 
Novo Nordisk A/S - 
Denmark 
Treatment o  26/10/2006 
 11/12/2006 
 07/02/20
 89 days 
 22/02/2007 
Everolimus  
(RAD001) 
 07 
 05/06/2007 
Novartis Europharm 
Limited - UK 
Treatment of renal cell carcinoma  14/02/2007 
 05/03/2007 
 12/04/20
 38 days 
 04/05/2007 
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Product INN Sponsor Summary of indication EMEA/COMP 
 Submission 
 Start date 
 Opinion 
 Active time 
European Commission 
 Opinion received 
 Date of decision 
Everolimus  
 
Novartis Europharm 
Limited - UK 
Treatment of gastro-entero-
pancreatic neuroendocrine tumours  15/06/2007 
 29/05/2007 
 12/09/2007 
 89 days 
 26/09/2007 
 14/11/2007 
Ex-vivo cultured adult human 
esenchymal stem cells  
(Prochymal) 
- rsus-
disease m
Quintiles UK Limited 
UK 
Treatment of Graft-ve Host  24/08/2006 
 10/11/2006 
 10/01/2007 
 61 days 
 24/01/2007 
 20/02/2007 
Fampridine  
 
Dr Ulrich Granzer - 
Germany 
Treatment of Guillain-Barré 
syndrome 
 87 days 
7 
  
 28/12/2006 
 05/03/2007 
 31/05/2007 
 15/06/2007 
 10/07/200
H-Arg-Leu-Phe-Phe-Tyr-Arg-
Lys-Ser-Val-OH, acetate salt& 
he-Phe-Tyr-Arg-
Lys-Ser-Val-OH, acetate salt  
ositiv
small cell lung cancer in HL
positive patients H-Tyr-Leu-P
Vaxon Biotech - France Treatment of TERT p e non-  26/07/2007 
A-A2  13/18/2007 
 08/11/2007 
 87 days 
 23/11/2007 
 18/12/2007 
Heterologous human adult liver 
erived stem cells  syndrome d
Prof Etienne Sokal - 
Belgium 
Treatment of Crigler-Najjar  29/05/2007 
 13/08/2007 
 10/10/2007 
 58 days 
 30/10/2007 
 29/11/2007 
HLA class I/II binding tumour 
eptides (ADF-
UC-K67-MET-
MMP-MUC-RGS)  
hnologies GmbH - 
Germany 
associated p
APO-CCN-G
Immatics 
Biotec
Treatment of  renal cell carcinoma  26/07/2006 
 10/11/2006 
 10/01/2007 
 61 days 
 24/01/2007 
 15/02/2007 
Human autol
forming cells derived fro
ogous bone-
m 
one marrow stem cells  
- 
 b
Bone Therapeutics SA 
Belgium 
Treatment of non-traumatic 
osteonecrosis 
 31/05/2007 
 15/06/2007 
 12/09/2007 
 89 days 
 26/09/2007 
 29/10/2007 
Human coag
 
ulation factor X  ry 
gdom 
Bio Products Laborato
- United Kin
Treatment of hereditary fa
deficiency 
ctor X  30/05/2007 
 15/06/2007 
 25/07/2007 
 40 days 
 02/08/2007 
 17/09/2007 
Human heterologous liver cells o. 
any (for infusion)  
 
Cytonet GmbH & C
KG - Germ
Treatment of ornithine-
transcarbamylase deficiency 
 29/05/2007 
 15/06/2007 
 25/07/2007 
 40 days 
 02/08/2007 
 14/09/2007 
Human papilloma virus type 16
E6/E7synthetic long peptide
 
s  
V 
papilloma virus 
 87 days 
7 
ISA Pharmaceuticals B
- The Netherlands 
Treatment of epithelial neop
the vulva positive for human 
lasia of  24/07/2007 
 13/08/2007 
 08/11/2007 
 23/11/2007 
 20/12/200
Human plasminogen  
 
Kedrion S.p.A. - Italy Treatment of ligneous conjunctivitis  11/04/2007 
 27/04/2007 
 27/06/2007 
 61 days 
 09/07/2007 
 03/08/2007 
H
release t
ydrocortisone (modified 
ablets)  
(Chronocort) 
ited - UK 
Phoqus Pharmaceuticals 
Lim
Treatment of adrenal insufficiency  24/11/2006 
 11/12/2006 
07  07/02/20
 58 days 
 22/02/2007 
 20/03/2007 
Idebenon
 
e  Santhera 
Pharmaceuticals 
(Deutschland) GmbH - 
Germany 
Treatment of Duchenne muscular 
dystrophy 
 08/09/2006 
 11/12/2006 
07  07/02/20
 89 days 
 22/02/2007 
 20/03/2007 
Idebenone Santhera 
Pharmaceuticals 
(Deutschland) GmbH - 
Germany 
editary optic 
neuropathy 
 Treatment 
of Leber's her
 14/09/2006 
 13/10/2006 
07  10/01/20
 89 days 
 24/01/2007 
 15/02/2007 
Interferon beta  
(Traumakine) 
L03AB02 
Faron Pharmaceuticals 
Limited - Finland 
Treatment of acute lung injury  26/07/2007 
 13/08/2007 
 10/10/2007 
 58 days 
 30/10/2007 
 29/11/2007 
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Product INN Sponsor Summary of indication EMEA/COMP 
 Submission 
 Start date 
 Opinion 
 Active time 
European Commission 
 Opinion received 
 Date of decision 
Interferon gamma  
 
Foundation for Fatal 
Rare Diseases - 
Liechtenstein 
Treatment of idiopathic pulmonar
fibrosis 
y  22/06/2007 
 13/07/2007 
 12/09/2007 
 61 days 
 26/09/2007 
 29/10/2007 
Iodine (
 
131I) Chlorotoxin  The Weinberg Group 
LLC - UK 
Treatment of glioma  29/05/2007 
 13/07/2007 
 26/09/2007 
 22/10/2007 

 12/09/2007 
 61 days 
Iodine (131I) io
(Azedra Ultratr
benguane  
ace Iobenguane 
Molecular Insight 
Limited - UK 
Treatment of neuroblastom
 15/10/2008 
 17/12/2007 
 pending 
131I) 
V10XA02 
a  28/09/2007 
 05/12/2007 
Irinotecan hydro
eluting beads)  
chloride (drug 
(CM-BC2) 
CellMed AG - Germany Treatment of glioma 
7 
 30/10/2007 
 29/11/2007 
 31/05/20
 13/08/200
07 
 10/10/2007 
 58 days 
Isofagomine tartrate  
 
Amicus Therapeutics 
UK Ltd - United 
Treatment of Gaucher disease 
7 
 26/09/2007 
 23/10/2007 
Kingdom 
 27/06/20
 13/07/200
07 
 12/09/2007 
 61 days 
Lenalidomide  
(Revlimid) 
Celgene Europe Limited 
- UK 
Treatment of chronic lymphocytic 
leukaemia 7 
 25/10/2007 
 19/11/2007 
L04 AX04 
 29/06/20
 13/07/200
07 
 12/09/2007 
 61 days 
L-threo-3,4-
dihydroxyphenylserine  
The Weinberg Group 
LLC - UK 
Treatment of orthostatic 
hypotension in patients with 7 
 09/07/2007 
 02/08/2007 
 multiple system atrophy 
 11/04/20
 27/04/200
07 
 27/06/2007 
 61 days 
L-threo-3,4-
dihydroxyphenylserine  
The Weinberg Group 
LLC - UK 
Treatment of orthostatic 
hypotension in patients with pur 7 
 09/07/2007 
 02/08/2007 
 
e 
 11/04/20
 27/04/200
autonomic failure 
07 
 27/06/2007 
 61 days 
Lusupultide  
(Venticute) 
Nycomed GmbH - 
Germany 
Treatment of aspiration pneu
requiring intubation and mechanical 7 
 15/06/2007 
 10/07/2007 
 
monitis  15/02/20
 05/03/200
ventilation 
07 
 31/05/2007 
 87 days 
Lutetium (177Lu)-N-[(4,7,10-
Tricarboxymethyl-1,4,7,10-
dodec-1-
l)acetyl]-D-phenylalanyl-L-
cysteinyl-L-tyrosyl-D-
tryptophanyl-L-lysyl-L-
steinyl-L-
c(2-7)disulfide  
BioSynthema Global 
Operations B.V - The 
Treatment of gastro-entero-
pancreatic neuroendocrine tu 7 
 17/12/2007 
 pending 
tetraazacyclo
y
threoninyl-L-cy
threonine-cycli
Netherlands 
mours 
 27/09/20
 15/10/200
07 
 05/12/2007 
Maribavir  
 
imited - 
UK 
Prevention of cytomegalovir
(CMV) disease in patients with 
y
08 
 23/11/2007 
 18/12/2007 
ViroPharma L us  29/06/2007/ 
impaired cell-mediated immunit
deemed at risk 
 
 13/08/20
 08/11/2007 
 87 days 
Mercaptopurine (oral liquid)  
(Loulla) 
Only For Children 
Pharmaceuticals - France leukaemia 07 
 26/09/2007 
 22/10/2007 
Treatment of acute lymphoblastic  28/06/2007 
 13/07/20
 12/09/2007 
 61 days 
Methotrexate (oral liquid)  
(Philla) 
Only For Children 
Pharmaceuticals - France 
Treatment of acute lymphoblastic 
leukaemia 07 
 26/09/2007 
 24/10/2007 
 28/06/2007 
 13/07/20
 12/09/2007 
 61 days 

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Product INN Sponsor Summary of indication EMEA/COMP 
 Submission 
 Start date 
 Opinion 
 Active time 
European Commission 
 Opinion received 
 Date of decision 
Methyl 4,6-diamino-2-[1-(2-
fluorobenzyl)-1H-pyrazolo[3,4-
b]pyridine-3-yl]-5-
pyrimidinyl(methyl)carbamate  
re AG 
y 
chronic thromboembolic pulm
hypertension 9 days 
(BAY 63-2521) 
C & R 
Bayer HealthCa
(Leverkusen) - German
Treatment of pulmonary arterial
hypertension including treatment o
 
f  10/09/2007 
onary  08/11/2007 
 24/08/2007 
 5
 
 23/11/2007 
 20/12/2007 
N- (2-Amino-phenyl)-4-[(4-
pyridin-3-yl-pyrimidin-2-
 
Pharmion Ltd - United 
Kingdom 
Treatment of acute myeloid 
leukemia 07 
 17/12/2007 
 pending 
ylamino)-methyl] benzamide 
(MGCD0103) 
 28/09/2007/ 
 15/10/20
 05/12/2007 
N-(2-amino-phenyl)-4-[(4-
pyridin-3-yl-pyrimidin-2-
ylamino)-methyl] benzamide  
Pharmion Ltd - United 
Kingdom 
Treatment of Hodgkin's lym
07 
 25/07/2007 
 02/08/2007 
 14/09/2007 
(MGDC0103) 
phoma  31/05/2007 
 15/06/20
 40 days 
N-[4-(3-amino-1H-indazol-4 
l)phenyl]-N'-(2-fluoro-5-
methylphenyl) urea  
Limited - UK carcinoma 
07 
 20/12/2007 y
Abbott Laboratories Treatment of hepatocellular  24/08/2007 
 10/09/2007 
 08/11/20
 59 days 
 23/11/2007 
N-adamantanyl-N'-Geranyl-
ethylenediamine  
 
sulting - 
Belgium 
07 
 14/09/2007 
RLM Con Treatment of tuberculosis  21/05/2007 
 15/06/2007 
 25/07/20
 40 days 
 02/08/2007 
Naptumomab estafenatox  
 
Active Biotech Research 
AB - Sweden 
of renal cell carcino
07 
 14/09/2007 
Treatment ma  31/05/2007 
 15/06/2007 
 25/07/20
 40 days 
 02/08/2007 
Nilotinib hydrochloride 
monohydrate  
(Tasigna) 
Novartis Europharm 
Limited - UK 
07 
 87 days 
 13/04/2007 
Treatment of gastrointestinal 
stromal tumours 
 24/11/2006 
 11/12/2007 
 08/03/20
 22/03/2007 
Olaparib  
 
AstraZeneca AB - 
Sweden 
 28/06/2007 
 13/08/2007 
 10/10/2007 
 58 days 
 30/10/2007 
 06/12/2007 
Treatment of ovarian cancer 
Panobinostat lactate  
 
Novartis Europharm 
Limited - UK Lymphoma 
Treatment of cutaneous T-Cell  09/03/2007 
 27/04/2007 
07  27/06/20
 61 days 
 09/07/2007 
 02/08/2007 
Picoplatin  
 
Kendle International L
- UK 
td Treatment of small cell lung cancer  25/06/2007 
 13/08/2007 
07  10/10/20
 58 days 
 30/10/2007 
 06/12/2007 
P
 
olihexanide  
aceutica Italiana 
S.p.A. - Italy 
S.I.F.I. Società Industria 
Farm
Treatment of acanthamoeba 
keratitis 
 25/05/2007 
 13/07/2007 
07  12/09/20
 61 days 
 26/09/2007 
 14/11/2007 
Pralatrexate  
 
Oxford Regulatory 
Solutions Ltd - UK l 
 19/12/2006 
 15/01/2007 
 08/03/2007 
 52 days 
 22/03/2007 
 13/04/2007 
Treatment of peripheral T-cell 
lymphoma (nodal, other extranoda
and leukaemic/disseminated) 
Pyridoxalated hemoglobin 
polyoxyethylene  
(Hemoximer) 
 
 
Curacyte AG - Germany Treatment of cardiogenic shock  15/03/2007 
 27/04/2007 
 27/06/2007 
 61 days 
 09/07/2007 
 02/08/2007 
R-1-[2,3-dihydro-2-oxo-1-
pivaloylmethyl-5-(2-pyridyl)-1 
H-1,4-benzodiazepin-3-yl]-3-
-methylaminophenyl)urea  
(Eclant) 
K 
(3
Trio Medicines Ltd - U Treatment of gastric carcinoid  20/02/2007 
 05/03/2007 
 12/04/2007 
 38 days 
 04/05/2007 
 14/06/2007 
  
EMEA annual report 2007 
EMEA/MB/17464/2008 2.4, CURRENT 
Page 121/138 
Product INN Sponsor Summary of indication EMEA/COMP 
 Submission 
 Start date 
 Opinion 
 Active time 
European Commission 
 Opinion received 
 Date of decision 
Recombinant adeno-associated 
iral vector containing human 
acid alfa-glucosidase-gene  
Consultancy Ltd - UK disease type II (Pompe's disease) v
The Matthews Treatment of glycogen storage  01/02/2007 
 05/03/2007 
 31/05/2007 
  
 15/06/2007 
 09/07/2007 
Recombinant adeno-associat
viral vector containing hum
ed 
an 
lpha-1 antitrypsin gene  
Consultancy Ltd - UK antitrypsin deficiency 
a
The Matthews Treatment of congenital alpha-1  06/09/2006 
 11/12/2006 
 07/02/2007 
 58 days 
 22/02/2007 
 20/03/2007 
Recombinant fusion protein 
onsisting of human 
coagulation factor IX attached 
to the Fc domain of human 
c
IgG1  
Biovitrum AB - Sweden Treatment of haemophilia B 
(congenital factor IX deficiency)  05/03/2007 
 16/02/2007 
 12/04/2007 
 38 days 
 04/05/2007 
 08/06/2007 
Recombinant human C1-
inhibitor  
 
.V. - 
The Netherlands 
07 
 89 days 
 20/02/2007 
Pharming Group N Prevention of delayed graft function 
after solid organ transplantation  10/11/2006 
 17/08/2006 
 10/01/20
 24/01/2007 
Recombinant human hepatitis 
C monoclonal antibody against 
GENimmune, N.V. - 
Belgium 
Prevention of recurrent hepatitis C 
virus induced liver disease in liver 
transplant recipients 
 27/06/2007 
 13/07/2007 
 10/10/2007 
 89 days 
 30/10/2007 
 06/12/2007 
C4 region of E1  
Recombinant human histone 
H1.3 and recombinant human 
N-bis-met-histone H1.3  
(Oncohist) 
mbH - 
Germany 
id 
leukemia 
 SymbioTec G Treatment of acute myelo  24/08/2007
 10/09/2007 
7  08/11/200
 59 days 
 23/11/2007 
 20/12/2007 
Recombinant human 
 
Novartis Europharm Treatment of cryopirin-associated 
Muckle-Wells Syndrome (MW
and Neonatal Onset Multisystem 
Inflammatory Disease (NOMID), 
also known as Chronic Infantile 
Neurological Cutaneous Articular 
Syndrome (CINCA)) 
 22/02/2007 
monoclonal antibody to human 
IL-1beta of the IgG1/K class  
(ACZ885)
Limited - UK periodic syndromes (Familial Co
Urticaria Syndrome (FCUS), 
ld  11/12/2006 
S),  58 days 
 25/08/2006 
 07/02/2007 
 20/03/2007 
Recombinant human rod 
derived cone viability factor  
 
Fovea Pharmaceuticals 
SA - France 
Treatment of retinitis pigmentosa  23/07/2007 
 13/08/2007 
 10/10/2007 
 58 days 
 30/10/2007 
 29/11/2007 
Recombinant human soluble 
Fc-gamma receptor I I b  
SuppreMol GmbH - 
Germany 
Treatment of idiopathic 
thrombocytopenic purpura 
 12/04/2007 
 27/04/2007 
 27/06/2007 
 61 days 
 09/07/2007 
 02/08/2007 
Rilonacept  
 
Regeneron UK Limited - 
UK 
Treatment of cryopirin-associated 
periodic syndromes (Familial Cold 
Urticaria Syndrome (FCUS), 
Muckle-Wells Syndrome (MWS), 
and Neonatal Onset Multisystem 
Inflammatory Disease (NOMID), 
also known as Chronic Infantile 
Neurological Cutaneous Articular 
Syndrome (CINCA)) 
 12/03/2007 
 30/03/2007 
 31/05/2007 
 62 days 
 15/06/2007 
 10/07/2007 
R-salbutamol  
(ASF-1096 Cream 0.5%) 
 
Astion Pharma A/S - 
Denmark 
Treatment of cutaneous forms of 
lupus erythematosus 
 13/04/2007 
 27/04/2007 
 25/07/2007 
 89 days 
 02/08/2007 
 14/09/2007 
Sulfonated 
monophosphorylated mannose 
oligosaccharide  
 
Constella Group Ltd - 
UK 
Treatment of  hepatocellullar 
carcinoma 
 31/05/2007 
 15/06/2007 
 25/07/2007 
 40 days 
 02/08/2007 
 14/09/2007 
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Product INN Sponsor Summary of indication EMEA/COMP 
 Submission 
 Start date 
 Opinion 
 Active time 
European Commission 
 Opinion received 
 Date of decision 
Talactof Agennix L a  04/05/2007 
 05/06/2007 
errinum alfa  
 
imited - UK Treatment of renal cell carcinom  16/02/2007 
 05/03/2007 
 12/04/2007 
 38 days 
Tegaf
 
sanofi Aventis - Fr
 08/11/2007 
 23/11/2007 
 20/12/2007 
ur, gimeracil, oteracil 
potassium  
ance Treatment of gastric cancer  16/07/2007 
 13/08/2007 
 87 days 
Terguride  
 
Ergon
Regulator
- Liec
pertension and chronic 
hypertension 
 13/08/2007 
 58 days 
 30/10/2007 
 29/11/2007 
ex Licensing and 
y Services AG 
Treatment of pulmonary arterial 
hy
htenstein thromboembolic pulmonary 
 30/07/2007 
 10/10/2007 
Zanolimumab  
 
Seron
United
) 
 58 days 
22/02/2007 
20/03/2007 
o Europe Limited - 
 Kingdom 
Treatment of peripheral T-cell 
lymphoma (nodal, other extranodal 
and leukaemic/disseminated
 24/11/2006 
 11/12/2006 
 
 
 07/02/2007 
 
Negative COMP designation opinions 
Product INN Sponsor Summary of indication EMEA/COMP 
 Submission 
 Start date 
 Opinion 
 Active time 
European Commission 
 Opinion received 
 Date of decision 
Chelidonii radix special liquid 
extract  
(Ukrain) 
 
L
7 
7 
 
Now Pharm AG - 
uxembourg 
Treatment of pancreatic cancer  06/02/2007 
 05/03/2007 
 31/05/2007 
 29/10/200
 04/12/200
Opinion after 
appeal: 
10/10/2007  
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Annex 14 HMPC munity herbal monographs 
Reference number Document title Status  
EMEA/HMPC/137423/2007 Community herbal monograph on Anisi fructus Adopted July 2007 
EMEA/HMPC/263273/2006 Community herbal monograph on Anisi 
aetheroleum 
07 Adopted July 20
EMEA/HMPC/137428/2006 Community herbal monograph on Foeniculi amari 
fructus 
Adopted July 2007 
EMEA/HMPC/263292/2006 Community herbal monograph on Foeniculi amari fructus aetheroleum 
Adopted July 2007 
EMEA/HMPC/263293/2006 Community herbal monograph on Foeniculi dulcis 
fructus 
Adopted July 2007 
EMEA/HMPC/5341/2007 Community herbal monograph on Melissae folium Adopted October 2007 
EMEA/HMPC/349466/2006 Community herbal monograph on Menthae 
piperitae aetheroleum 
Adopted October 2007 
EMEA/HMPC/230962/2006 Community herbal monograph on Passiflorae herba Adopted September 2007 
EMEA/HMPC/64684/2007 Community herbal monograph on Primulae flos Adopted September 2007 
EMEA/HMPC/143370/2006 Community herbal monograph on Primulae radix Adopted September 2007 
EMEA/HMPC/513579/2006 Community herbal monograph on Rhamni 
purshianae cortex 
Adopted September 2007 
EMEA/HMPC/189624/2007 Community herbal monograph on Rhei radix Adopted October 2007 
EMEA/HMPC/234113/2006 Community herbal monograph on Thymi herba Adopted October 2007 
EMEA/HMPC/202966/2007 Community herbal monograph on Avenae herba Released for public consultation 
October 2007 
EMEA/HMPC/368600/2007 Community herbal monograph on Avenae fructus Released for public consultation 
October 2007 
EMEA/HMPC/260019/2006 Community herbal monograph on Betulae folium Released for public consultation 
May 2007 
EMEA/HMPC/179281/2007 Community herbal monograph on Calendulae flos Released for public consultation  
July 2007 
EMEA/HMPC/104945/2006 Community herbal monograph on Echinaceae 
purpureae herba 
Released for public consultation 
March 2007 
EMEA/HMPC/394894/2007 Community herbal monograph on Equiseti herba Released for public consultation 
October 2007 
EMEA/HMPC/244569/2006 Community herbal monograph on Eleutherococci 
radix 
Released for public consultation 
July 2007 
EMEA/HMPC/513617/2006 Community herbal monograph on Lupuli flos Released for public consultation 
July 2007 
EMEA/HMPC/354177/2007 Community herbal monograph on Meliloti herba Released for public consultation 
October 2007 
EMEA/HMPC/193909/2007 Community herbal monograph on Menthae 
piperitae folium 
Released for public consultation 
July 2007 
EMEA/HMPC/261938/2007 Community herbal monograph on Rusci aculeati 
rhizoma 
Released for public consultation 
September 2007 
EMEA/HMPC/295338/2007 Community herbal monograph on Salicis cortex Released for public consultation 
September 2007 
EMEA/HMPC/283166/2007 Community herbal monograph on Sambuci flos Released for public consultation 
September 2007 
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EMEA/HMPC/285758/2007 Community herbal monograph on Solidaginis 
virgaureae herba 
Released for public consultation 
October 2007 
EMEA/HMPC/170261/2006 Community herbal monograph on Urticae herba Released for public consultation 
September 2007 
EMEA/HMPC/395213/2007 al monograph on Verbasci flos  for public consultation Community herb Released
October 2007  
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Annex 15 Entries to the ‘List of herbal substances, preparations and 
combinations thereo
 
Reference number Document title Status  
EMEA/HMPC/428817/2006 Community list entry on Foeniculi amari fructus  2007 Adopted September
EMEA/HMPC/428963/2006 Community lis s fructus 07t entry on Foeniculi dulci Adopted September 20  
EMEA/HMPC/297757/2007 Community lis  Anisi fructus Released for public consultation t entry on
July 2007 
EMEA/HMPC/179283/2007 Community list try on Calendulae flos  
July 2007 
en Released for public consultation
EMEA/HMPC/189629/20 is purpure ns07 Community l
herba 
t entry on Echinaceae ae Released for public co ultation 
May 2007 
EMEA/HMPC/83756/2007 Community list entry on Eleutherococci radix Released for public consultation 
 July 2007 
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and waivers in 2007 
Annex 16 PDCO opinions and EMEA decisions on paed
 
Product INN/ 
Invented Name 
Applicant Condition PIP/ 
Full waiver 
PDCO 
 Start date 
 Opinion 
EMEA Decision 
Everolimus  Novartis Europha carcin
uro
aive
 
7 
07 
07 m Ltd Renal cell 
pancreatic ne
tumour  
oma and 
endocrine 
Full w r  30/08/200
 26/10/20
11/12/20
 
Candesartan/Hydrochlorot AstraZeneca AB pertension Full waive  30/08/2007 
 2007 
11/12/2007 
 hiazide 
(Atacand Plus and 
 
associated names) 
Essential hy
 
r 
26/10/
Candesartan/ 
drochlorothiazide 
Ta
& DHy
associated na
keda Global Research 
evelopment Centre 
tial hypertension Full waiver  2007 
 26/10/2007 
11/12 7 
 
(Blopress Comp and Ltd  
mes) 
Essen
 
30/08/ /200
Lasofoxifene tartrate  
 
Pfizer Limit
 
ed  tment of osteoporosis in
menopausal women at 
increased risk of fracture 
Full waiver  27/09/2007 
 23/11/2007 
07/01/ 08 Trea
post
 20
Tacrolimus monohydrate Astellas Phar
(Prograf
ma GmbH splant of whole organ   
 
PIP  2007 
 20/12/2007 
 
 and associated 
names,  
Advagraf) 
 
Tran 02/08/
Recombinant L- M
Asparaginase 
 
Klinisch
Spezialp
edac Gesellschaft für 
e 
raeparate mbH 
mphoblastic 
leukaemia, lymphoblastic 
phoma 
PIP  2007 
 20/12/2007 
 Acute ly
lym
02/08/
Telmisartan / ramipril  
 
Boehring
Internati
 
er Ingelheim 
onal GmbH 
Risk of myocardial 
infarction, stroke, death from
cardiovascular causes, or 
hospitalization for congestive 
heart failure in patients at 
high risk of developing majo
c diovascular events. 
Full waiver  25/10/2007 
 20/12/2007 
` 
 
r 
ar
Indacaterol m  Ltd Chronic obstructive 
pulmonary disease 
Full waiver  25/10/2007 
 20/12/2007 
 aleate 
 
Novartis Europharm
Glycopyrronium bromide Novartis Europharm Ltd Chronic obstructive 
pulmonary disease 
Full waiver  25/10/2007 
 20/12/2007 
 
Indacaterol maleate / 
Glycopyrronium bromide 
Novartis Europharm Lt Chronic obstructive 
pulmonary disease 
Full waiver  25/10/2007 
 20/12/2007 
 
Rosiglitazone maleate 
 
GlaxoSmithKline R&D 
Limited 
Alzheimer's disease 
 
Full waiver  25/10/2007 
 20/12/2007 
 
Panobinostat lactate salt Novartis Europharm Ltd Cutaneous T-cell lymphoma 
(including mycosis fungoides 
and Sezary's disease) 
Full waiver  25/10/2007 
 20/12/2007 
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delines and working documents in 2007 
Committee for Medicinal Products for Human Use (CHMP)  
CHMP guidelines overview 
Annex 17 Gui
Working Party/Group Total number of 
adopted guidelines/ 
documents for which 
working party/group is 
responsible 
Number of concept 
papers/ guidelines/ 
documents initiated 
during 2007 
Number of concept 
papers/ guidelines/ 
documents in 
progress during 
2007 
Number of 
guidelines/ 
documents adopted 
during 2007 
CHMP Biologics Working Party 11 57 7 27 
CHMP Blood Products Working Party 4 26 0 7 
CHMP Efficacy Working Party 227 15 33 15 
CHMP Gene Therapy Working Party 8 4 6 5 
CHMP Paediatrics Working Party 7 19 2 10 
CHMP Pharmacogenetics Working Party 10 5 5 4 
CHMP Pharmacovigilance Working Party     
CHMP Safety Working Party 44 4 12 5 
CHMP Similar Biological (Biosimilar) 
arty 0 3 2 Medicinal Products Working P 19 
CHMP Vaccine Working Party 8 13 11 7 
CHMP Working Party on Cell-based 
Products 3 0 1 2 
EMEA Human Scientific Committees 
Working Party with Patients and 
Consumers’ Organisations 
    
CHMP Working Group with Health-C
Professionals’ Organisations 
are     
CHMP Invented Name Review Group     
Joint CHMP/CVMP Quality Working Party     
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CHMP guidelines 
Working Party/Group Subject of concept papers/guidelines/documents of significant scientific/therapeutic 
interest 
CHMP Biologics Working Party l technology (PAT) for quality of biological medicinal products 
ered pro
Process analytica  control 
(report of workshop) 
Cell and gene therapy and tissue engine ducts (guidelines) 
CHMP Blood Products Working Party Factor VIII inhibitors (report of international workshop) 
CHMP Efficacy Working Party ) Tuberculosis, HIV and hepatitis C (guidelines
CHMP Gene Therapy Working Party  treated with gene therapy medicinal products 
ne therapy
rst clinica roducts 
 products containing genetically modified cells (guideline) 
Clinical monitoring and follow-up of patients
(guideline) 
Environmental Risk Assessment of ge
Non-clinical studies required before fi
(guideline) 
Medicinal
 medicinal products (guideline) 
l use of gene therapy medicinal p
CHMP Paediatrics Working Party Neonates (guideline) 
Off-patent medicines (priority research list) 
Paediatric needs for several therapeutic areas (lists of paediatric needs) 
CHMP Pharmacogenetics Working Party ogenomic DNA and RNA-containing specimens, and 
ensuring scientific reliability of results obtained (reflection paper) 
Use of genomics in cardiovascular clinical trials intended for medicinal product development 
s in pharmacokinetic evaluation of medicinal products (reflection 
paper) 
Sampling and handling of pharmac
(reflection paper) 
Use of pharmacogenetic
CHMP Safety Working Party First-in-man clinical trials (guideline) 
CHMP Similar Biological (Biosimilar) 
Medicinal Products Working Party 
logy-d teins (guideline) 
 recombinant interferon alpha (guideline) 
taining low molecular weight heparins (guideline) 
Immunogenicity assessment of biotechno
Biosimilar medicinal products containing
Biosimilar medicinal products con
erived therapeutic pro
CHMP Vaccine Working Party Pandemic and pre-pandemic influenza vaccines (guideline, core SPC) 
Clinical evaluation of vaccines (guideline) 
Live recombinant vector vaccines (concept paper) 
DNA vaccines (concept paper) 
CHMP Working Party on Cell-based herapy products (concept pape
linProducts 
Xenogeneic cell t r) 
Human cell-based medicinal products (guide e) 
CHMP Biologics Working Party AT) for quality control of biological medicinal products 
ered pro
Process analytical technology (P
(report of workshop) 
Cell and gene therapy and tissue engine ducts (guidelines) 
CHMP Blood Products Working Party l workshop) Factor VIII inhibitors (report of internationa
CHMP Efficacy Working Party Tuberculosis, HIV and hepatitis C (guidelines) 
CHMP Gene Therapy Working Party s treated with gene therapy medicinal products 
 therapy medicinal products (guideline) 
 first clinical use of gene ther medicinal products 
odified cells (guideline) 
Clinical monitoring and follow-up of patient
(guideline) 
Environmental Risk Assessment of gene
Non-clinical studies required before
(guideline) 
Medicinal products containing genetically m
apy 
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roducts fro Veterinary Use (CVMP)  Committee for Medicinal P
CVMP Efficacy  
Reference number Document title Status 
EMEA/CVMP/EWP/170208/2005 Guideline on the summary of product 
characteristics for anthelmintics 
Adopted July 2007 
EMEA/CVMP/EWP/362275/2007-
N 
pis 
d for consultation September 2007.   
arch 2008) 
CONSULTATIO
Concept paper for the revision of the 
guideline on “Veterinary medicinal products 
controlling Varroa destructor and Acara
woodi parasitosis in bees” 
Adopte
(End of consultation: M
EMEA/CVMP/EWP/85954/20
CONSULTATION 
07-
r use in farmed aquatic 
 2007 (end 
ary 2008)  
Concept paper for the revision of the 
“Guideline on Efficacy of veterinary 
medicinal products fo
species” 
Adopted for consultation October
of consultation: Janu
EMEA/CVMP/EWP/005/2000-Rev.2 ing and Evaluation of 
 Substances for 
n of Tick and 
Adopted November 2007 
ne 2008) 
Guideline for the Test
the Efficacy of Antiparasitic
the Treatment and Preventio
Flea Infestation in Dogs and Cats 
(Implementation 1 Ju
 
CVMP Environmental Risk Assessment (ERA)  
Reference number Document title Status 
EMEA/CVMP/ERA/418282/2005 Guideline on Environmental Impact 
Assessment for VMPs in support of the 
GL6 and GL38 
Adopted April 2007 
VICH guidelines 
 
CVMP Immunologicals  
Reference number Document title Status 
EMEA/CVMP/IWP/23332/2006 Guideline on user safety for immunological 
veterinary medicinal products” 
Adopted April 2007 
EMEA/CVMP/IWP/222624/2006 Adopted April 2007 Guideline on data requirements for an 
authorisation under exceptional 
circumstances for vaccines in birds against 
avian influenza”  
EMEA/CVMP/IWP/205351/2006 Guideline on the procedure to be followed 
when a batch of a vaccine finished product 
is suspected to be contam
A
inated with bovine 
do
viral diarrhoea (BVD) virus”  
pted April 2007 
EMEA/CVMP/IWP/105008/2007 
isation under 
ongue”  
Adopted AprReflection paper on minimum data 
requirements for an author
exceptional circumstances for vaccines for 
emergency use against Bluet
il 2007 
EMEA/CVMP/IWP/501304/2006 
to demonstrate the influence of maternally 
derived antibody on the vaccination of very 
young animals”  
oConcept paper on the need for requiring data Ad pted April 2007 
EMEA/CVMP/IWP/90459/2007 Concept paper on requirements for multi-
strain dossiers”  
Adopted April 2007 
EMEA/CVMP/IWP/123243/2007  2007 Guideline on data requirements for 
immunological veterinary medicinal 
products intended for minor use or minor 
species/limited markets 
Adopted July
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ce  CVMP Pharmacovigilan
Reference number Document title Status 
EMEA/CVMP/PhVWP/73213/2007 
 medicinal 
products during the past year 
EMEA Public Bulletin 2006 on Veterinary 
Pharmacovigilance on activities regarding 
pharmacovigilance for veterinary
Adopted February 2007 
EMEA/INS/PhV/47075/2007 Guideline on monitoring of co
pharmacovigilance regulatory 
and pharmacovigilance inspect
mpliance with 
obligations 
ions  
Adopted February 2007. Published on the 
European Commission website on 4 April 
2007 
SOP/V/4023 P agement of Periodic 
S
c
 March 2007 rocedure for man
afety Update Reports (PSURs) for 
entrally authorised products 
Adopted
EMEA/CVMP/413/99-Rev.4 VEDDRA list of clinical terms for adverse 
reactions in animals 
Adopted June 2007 
EMEA/CVMP/891/04-Rev.2 V se 
r
Adopted June 2007 EDDRA list of clinical terms for adver
eactions in humans 
EMEA/CVMP/553/03-Rev.2 L Adopted June 2007 ist of species and breeds 
Published by the European Commission’s 
EudraLex 
Phamacovigilance for Veterinary Medicinal 
Products – Procedures for Marketing 
Authorisation Holders 
Adopted June 2007 
EMEA/CVMP/PhVW
CONSULTATION 
P/4550/2006- Guideline on M ent and Assessment 
o Update Reports (PSURs) 
o
 consultation October 2007  
consultation: April 2008)  
anagem
f Periodic Safety 
f Veterinary Medicinal Products 
Adopted for
(end of 
Joint CHMP/CVMP Quality  
Reference number Document title Status 
EMEA/CVMP/VICH/899/99-Rev.1 S  of new veterinary drug 
substances and 
Adopted February 2007 tability testing
medicinal products 
EMEA/CVMP/VICH/837/99-Rev.1 Im  purities in new veterinary drug substances Adopted February 2007 
EMEA/CVMP/VICH/838/99-Rev.1 Im medicinal products Adopted February 2007 purities in new veterinary 
EMEA/CVMP/QWP/103377/2007 C
g e 
substances and r oducts  
7 oncept Paper on the revision of the CVMP 
uideline on stability testing of existing activ
elated finished pr
Adopted April 200
EMEA/HMPC/CHMP/CVMP/287539/2005 G
S
 uideline on the Declaration of Herbal 
ubstances in the SPC 
Adopted July 2007
EMEA/CHMP/CVMP/QWP/221930/2007-
CONSULTATION 
G erbal 
Medicinal Products / Traditional Herbal 
M
Adopted for consultation July 2007 
(end of consultation October 2007) 
uideline on the Quality of Combination H
edicinal Products 
EMEA/CVMP/QWP/846/99-Rev.1 R  Stability
testing of existing active substances and related 
fi
er 2007 
  
evised Guideline on Stability Testing:  Adpted for consultation Octob
(end of consultation: April 2008)
nished products 
EMEA/CVMP/QWP/544461/2007- Guideline on the quality aspects of single-dose 
v
Adopted for consultation December 
CONSULTATION eterinary spot-on products 2007 (end of consultation: June 2008) 
EMEA/CVMP/422/99-Rev.3 G itiouideline on the declaration of storage cond ns Adopted December 2007 
 
CVMP Safety  
Reference number Document title Status 
E
C
MEA/CVMP/95682/2007-
ONSULTATION 
Reflection paper on assessment of 
bioavailability of bound residues in food 
commodities of animal origin in the context 
of Council Regulation (EEC) No 2377/90 
Adopted for consultation May 2007 (end of 
consultation November 2007) 
EMEA/CVMP/VICH/1052/2004 “VICH GL41 Target animal safety: 
examination of live veterinary vaccines in 
target animals for absence of reversion to 
virulence” 
Adopted September 2007  
(Implementation: July 2008) 
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tion September 2007  
M
EMEA/CVMP/VICH/359665/2005-
CONSULTATION 
“VICH GL44 Guideline Target Animal 
Safety for veterinary live and inactivated 
Adopted for consulta
vaccines” (end of consultation: arch 2008) 
EMEA/CVMP/IWP/339116/2007-
CONSULTATION 
o
va l 
 2
tio
on: M
Reflection paper on c
adjuvants and preser
Regulation (EEC) No
nsideration of 
tives under Counci
377/90  
Adopted for consulta
(end of consultati
n December 2007 
arch 2008)  
 
CVMP Scientific Advisory Group on Antimicrobials 
Reference number Document title Status 
EMEA/CVMP/SAGAM/383441/2005 Revised guidel PC for Adopted Novemp
 (Implementation 1 May 2008) 
ine on the S
antimicrobial products 
er 2007 
EMEA/CVMP/SAGAM/184651/2005 Public statement on the use of 
(fluoro)quinolones in food-producing 
animals in the European Union: 
development of resista
human and animal health 
nce and impact on 
d February 2007 Adopte
 
CVMP General 
Reference number Document title Status 
EMEA/CVMP/422/04-Rev.1 Revised CVMP rules of procedure  Adopted in February 2007 
EMEA/4789/2007 Procedure for the nomination and 
appointment of co-opted members of the 
A
Committee 
dopted March 2007 
SOP/INSP/2019 
ns 
ACoordination of pre-approval GxP 
Inspectio
dopted April 2007 
EMEA/328/98-Rev.3-CONSULTATION ary 
medicinal products processed through the 
A
(e ) 
 The acceptability of names for veterin
centralised procedure 
dopted for consultation June 2007 
nd of consultation: September 2007
EMEA/CVMP/425558/2006  
tions for 
Veterinary Medicinal Products 
Adopted July 2007 Reflection paper on Withdrawals of
Marketing Authorisation Applica
EMEA/CVMP/459912/2006 Reflection paper on the publication of the 
CVMP’s Negative Opinion and Refusal to 
Adopted July 2007 
Recommend the granting of a Marketing 
Authorisation for Veterinary Medicinal 
Products 
EMEA/CVMP/248499/2007- Guideline on the evaluation of the benefit-
risk balance of veterinary medicinal 
products 
Adopted for consultation September 2007.   
(end of consultation March 2008) 
CONSULTATION 
EMEA/CVMP/2128/2007 e on procedures for re-
P opinions 
Adopted September 2007 Guidelin
examination of CVM
EMEA/358850/2007-CONSULTATION Adopted for ber 2007.  
(end of consultation: November 2007) 
 Concept paper on the classification of 
veterinary medicinal products authorised 
by the Community 
 consultation Septem
EMEA/CVMP/120559/2006 Questions and answers document 
regarding application of the so-called 
‘sunset clause’ to centrally authorised 
veterinary medicinal products  
Adopted October 2007 
 
 
 
 
  
EMEA annual report 2007 
EMEA/MB/17464/2008 2.4, CURRENT 
Page 132/138 
Committee for Orphan Medicinal Products (COMP) guidelines overview 
Scientific Committee Total number of 
adopted guidelines/ 
documents for 
which committee is 
responsible 
Number of concept 
papers/ guidelines/ 
documents 
initiated in 2007 
Number of concept 
papers/ guidelines/ 
documents in 
progress during 
2007 
Number of 
guidelines/ 
documents adopted 
in 2007 
Committee for Orphan Medicinal Produc 1 0 ts  5 1 
 
Subject of concept papers/guidelines/documents of significant scientific/therapeutic 
interest 
Scientific Committee 
Initiated Adopted 
Committee for Orphan Medicinal Produc
addendum to 
s 
gnation)  
Nts current COMP draft guideline on elementrequired to support the medical plausibility 
and the assumption of significant benefit for 
an orphan desi
Review of the designation criteria prior to 
marketing authorisation (
one 
 
Committee on Herbal Medicinal Products (HMPC) * 
Reference number Document title Status  
EMEA/HMPC/139800/2004 Rev.1 dicinal Products: Rules of Revision adopted May 2007 Committee on Herbal Me
Procedure 
EMEA/HMPC/107079/2007 ents ed for public consultation October 
2007 
Guideline on the assessment of genotoxic constitu
in herbal substances/preparations 
Releas
EMEA/HMPC/317913/2006 Reflection paper on the risks associated with 
furocoumarins contained in preparations of Angelica 
archangelica L. 
consultation 
January 2007 
Adopted October 2007 
Draft released for public 
EMEA/HMPC/102655/2007 Reflection paper on the adaptogenic concept  Released for public consultation July 
2007 
EMEA/HMPC/269258/2006 Rev.1 se reports connected to herbal  adopted May 2007 Assessment of ca
medicinal products containing Cimicifugae 
racemosae rhizoma (Black cohosh, root) 
Revision
 
* Including documents prepar munity monographs and 
Community list (MLWP) 
 
ity Drafting Group 
ed by the HMPC Working Party on Com
HMPC Qual
Reference number Document title Status  
EMEA/HMPC/CHMP/CVMP/28753
9/2005 
 
Guideline on declaration of herbal substances and 
herbal preparations in herbal medicinal 
products/traditional herbal medicinal products in the 
SPC 
Adopted May 2007 
EMEA/HMPC/CHMP/CVMP/21486
9/2006 
Guideline on quality of combination herbal medicinal 
products/traditional herbal medicinal products 
Released for public consultation March 
2007 
 
HMPC Organisational Matters Drafting Group 
Reference number Document title Status  
EMEA/HMPC/107399/2005 Rev.1 
 
Guideline on the documentation to be submitted for 
inclusion in the ‘Community list of herbal substances, 
preparations and combinations thereof for use in 
traditional herbal medicinal products’ 
Adopted July 2007 
EMEA/HMPC/107436/2005 Rev.2 Template for a Community herbal monograph Revision adopted January 2007 
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Reference number Document title Status  
 
EMEA/HMPC/126542/2005 Rev.1 
 
Timet
entry a
able for the establishment of a Community list 
nd/or a Community herbal monograph 
Revision adopted March 2007 
EMEA/HMPC/182352/2005 Rev.2 Procedure for the preparation of Community 
monograph for herbal medicinal products with well-
established medicinal use 
Revision adopted January 2007 
 
E 20/2005 Rev.2 
 
Procedure for the p munit
monograph for trad al 
MEA/HMPC/1823 reparation of Com
itional herbal medicin
y 
products 
Revision adopted January 2007 
E
 
Assessment report he develop
Community herbal m or inclusion of 
herbal substance(s) s) or comb
thereof in the Comm
Adopted January 2007 MEA/HMPC/418902/2005 template for t
onographs and f
ment of 
, preparation( inations 
unity list 
E
 
Procedure for the prepara
‘Community list of nces, prepa
and combinations thereof for use in tradition
medicinal products’
MEA/HMPC/57137/2007 tion of an entry to the 
herbal substa rations 
al herbal 
Adopted July 2007 
 
E Template for a Com ntry Revision adopted July 2007 MEA/HMPC/439705/2006 Rev.2 munity list e
E
 
Guideline on the us format in t
preparation of a reg ication for 
herbal medicinal pr
 public consultation May 2007 MEA/HMPC/71049/2007 e of the CTD 
istration appl
he 
traditional 
Release for
oducts 
E Procedure for calls data for us
HMPC assessment work 
07 MEA/HMPC/1004/2006 Rev.1 for scientific e in Revision adopted September 20
E Procedure on managem oposals from
interested parties fo  list entries
Community herbal monographs 
MEA/HMPC/328575/2007 ent of pr
r Community
 
 and 
Release for public consultation October 
2007 
E Inventory of herbal r assessme Adopted October 2007 MEA/HMPC/494079/2007  substances fo nt 
 
Paediatric Committee (PDCO) guidelines 
Reference number Document title Status  
E Guideline on the In  Medicinal
in the Term and Preter
MEA/267484/2007 vestigation of  Products Adopted 
m Neonates  
EMEA/495049/2007 Guidance on the content and the format of d
collected by the Me n all existi
medicinal products in the paediatric populat
ata to be Adopted 
mber States o ng uses of 
ion 
E Practical aspects on it an applic
paediatric investigation plan and requests fo
and deferral 
Adopted MEA/252191/2007  how to subm ation for 
r waiver 
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Annex 18 Arbitration and Community referrals overview 2007 
R P 
Procedures started 
eferrals made to the CHM
Type of referral Date of CHMP 
start of procedure 
International non-proprietary name (INN) 
Article 29(4) of Directive 2001/83/EC 24/01/2007 fentanyl 
Article 29(4) of Directive 2001/83/EC 22/02/2007 histrelin acetate 
Article 29(4) of Directive 2001/83/EC 22/03/2007 simvastatin, formoterol fumarate, fentanyl 
Article 29(4) of Directive 2001/83/EC 26/04/2007 clostridium botulinum type A neurotoxin comple
bicalutamide, hib/menC conjugate vacc
x, 
ine 
Article 29(4) of Directive 2001/83/EC 21/06/2007 nimesulide  
Article 29(4) of Directive 2001/83/EC 19/07/2007 budesonide 
Article 29(4) of Directive 2001/83/EC 20/09/2007 doxycycline 
Article 29(4) of Directive 2001/83/EC 18/10/2007 fentanyl citrate 
Article 29(4) of Directive 2001/83/EC rel/ethinylestradiol, ciclesonide 15/11/2007 levonorgest
Article 29(4) of Directive 2001/83/EC calcium 13/12/2007 atorvastatin 
Article 30 of Directive 2001/83/EC  22/03/2007 losartan potassium, losartan
potassium/hydrochlorothiazide, la
 
motrigine 
Article 30 of Directive 2001/83/EC  24/05/2007 venlafaxine 
Article 30 of Directive 2001/83/EC  21/06/2007 gemcitabine HCI 
Article 30 of Directive 2001/83/EC  19/07/2007 ciprofloxacin 
Article 30 of Directive 2001/83/EC  20/09/2007 risperidone, montelukast sodium 
Article 30 of Directive 2001/83/EC 18/10/2007 cetirizine 
Article 30 of Directive 2001/83/EC  15/11/2007 mirtazapine, sertraline 
Article 31 of Directive 2001/83/EC 21/06/2007 bromocriptine, cabergoline, 
cryptine, lisuride and pergolide dihydroergo
Article 31 of Directive 2001/83/EC 19/07/2007 methylphenidate 
Article 31 of Directive 2001/83/EC 20/09/2007 etoricoxib 
Article 31 of Directive 2001/83/EC 20/09/2007 norfloxacin 
Article 36 of Directive 2001/83/EC  20/09/2007 cetirizine dihydrochloride 
Article 107 of Directive 2001/83/EC 20/09/2007 clobutinol 
Article 107 of Directive 2001/83/EC 20/09/2007 carisoprodol 
Article 107 of Directive 2001/83/EC 15/11/2007 aprotinin 
Article 107 of Directive 2001/83/EC 15/11/2007 lumiracoxib 
Article 5(11) Of Commission Regulation (EC) N. 
1084/2003 
18/10/2007 drospirenone, ethinyl estradiol 
Article 6(12) Of Commission Regulation (EC) N. 
1084/2003 
24/05/2007 clomadinone acetate/ethinylestradiol 
Article 6(12) Of Commission Regulation (EC) N. 
1084/2003 
20/09/2007 etoricoxib 
Article 6(12) Of Commission Regulation (EC) N. 
1084/2003 
15/11/2007 moxifloxacin 
Article 20 of Council Regulation (EC) No 726/2004 19/06/2007 nelfinavir mesylate 
Article 22 of Council Regulation (EC) No 726/2004 25/01/2007 telithromycin 
Article 107 of Directive 2001/83/EC 24/05/2007 nimesulide 
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Procedures finalised 
Type of referral Date of CHMP 
opinion 
International non-proprietary name (INN) 
Article 29(4) of Directive 2001/83/EC  24/01/2007 ciprofloxacin lactate, alendronate 
Article 29(4) of Directive 2001/83/EC  26/04/2007 me axetil alteplase, cefuroxi
Article 29(4) of Directive 2001/83/EC  24/05/2007 histrelin acetate 
Article 29(4) of Directive 2001/83/EC  21/06/2007 lansoprazole 
Article 29(4) of Directive 2001/83/EC  19/07/2007 fentanyl, clostridium botulinum type A neurotoxin 
complex 
Article 29(4) of Directive 2001/83/EC  20/09/2007 bicalutamide 
Article 29(4) of Directive 2001/83/EC  15/11/2007 rol fumarate, 
onjugate vaccine 
ciprofloxacin, simvastatin, formote
fentanyl, hib/menC c
Article 30 of Directive 2001/83/EC  22/02/2007 lornoxicam  
Article 31 of Directive 2001/83/EC  24/05/2007 bicilutamide 
Article 31 of Directive 2001/83/EC  22/03/2007 mifepristone  
Article 31 of Directive 2001/83/EC  21/06/2007 piroxicam 
Article 31 of Directive 2001/83/EC  19/07/2007 veral pride i
Article 36 of Directive 2001/83/EC  18/10/2007 cetirizine dihydrochloride 
Article 5(11) Of Commission Regulation (EC) 
1084/2003  
N. adiol 13/12/2007 drospirenone, ethinyl estr
Article 6(12) Of Commission Regulation (EC) 
1084/2003  
N. thinylestradiol 13/12/2007 clomadinone acetate/e
Article 20 of Council Regulation (EC) No 726/2004 ylate 21/06/2007 nelfinavir mes
Article 22 of Council Regulation (EC) No 726/2004 7 22/03/200 telithromycin 
Article 107 of Directive 2001/83/EC 20/09/2007 nimesulide 
Article 107 of Directive 2001/83/EC 18/10/2007 clobutrinol 
Article 107 of Directive 2001/83/EC 15/11/2007 carisoprodol 
Article 107 of Directive 2001/83/EC 13/12/2007 lumiracoxib 
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Referrals made to the CVMP 
Type of referral Date of CVMP 
opinion 
 Product name  
 INN 
Referral for arbitration – Art. 33(4) Directive 17/1/2007 
2001/82/EC  Ivermectin  
 Equimectin 12mg/g   
Referral for arbitration – Art.40 Directive 2001/82/EC 17/01/2007  Suvaxyn Parvo E  
 Inactivated porcine parvovirus, strain S-80, 
Inactivated Erysipelothrix rhusiopathiae, strain B-
7 (serotype 2) 
Referral for arbitration – Art.40 Directive 2001/82/EC 17/01/200 n Ery 
hiae, strain B-
7  Suvaxy
 Inactivated Erysipelothrix rhusiopat
7 (serotype 2) 
Referral for arbitration – Art. 33(4) Directive 14/02/2007  Doxyprex  
e base as hyclate 2001/82/EC  Doxycyclin
Referral for arbitration – Art. 33(4) Directive 
2001/82/EC 
17/04/2007  Bovilis BVD 
6  Inactivated BVDV strain C-8
Referral for arbitration – Art. 33(4) Directive 18/04/2007 
2001/82/EC 
 Enurace 50 
 Ephedrine 
Referral for arbitration - Art. 33(4) Directive 
2001/82/EC 
11/07/200
(clock star
7  
t) 
 Ecomectin 18.7 
 Ivermectin  
mg/g 
Referral for arbitration – Art. 35 of Directive 
2001/82/EC 
12/12/200
associated names) 
 Trimethoprim and sulfadiazine  
7  Tribrissen oral paste for horses (including 
Referral under – Art. 35 of Directive 2001/82/EC 11/10/2007 (clock 
start)  
 Products containing toltrazuril for pultry  
 Toltrazuril  
Referral for arbitration – Art. 34(1) Directive 
2001/82/EC 
10/10/2007  Methoxasol-T 
 Trimethoprim and sulfamethoxazole 
Referral for arbitration – Art. 33(4) Directive 
2001/82/EC 
12/12/2007  Equibactin vet 
 Trimethoprim and sulfadiazine 
Referral for arbitration – Art. 33(4) Directive 
2001/82/EC 
12/12/2007 (clock  Solacyl 
start)   Sodium salicylate  
Referral under – Art. 35 of Directive  (clock  Oral  2001/82/EC 12/12/2007
start)  
solutions powders incicated for calves and 
pigs, containing sodium salicilate  
  Sodium salicylate
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oints 
risation (‘pharmacovigilance’) is an 
petent a
e conce ucts and 
coordinates action relating to the safety and quality o
For matters relating to pharmacovigilance for 
medicinal products for human use: Direct telephone: (44-20) 74 18 85 69  
ovigilance@emea.europa.eu 
For matters relating to pharmacovigilance for 
medicinal products for veterinary use:  81 
E-mail: vet-phv@emea.europa.eu 
For product defect and other quality-related E-mail: qualitydefects@emea.europa.eu. 
Fax: (44-20) 74 18 85 90 
o address the particular needs of smaller companies. 
ation with SMEs through dedicated personnel within the agency 
dural enquiries, monitor applications, and organise workshops and 
g ts on the content of this draft SME User Guide should also be 
forwarde
SME Off Melanie CARR 
  Direct telephone: (44-20) 74 18 85 75/84 63 
  Fax: (44-20) 75 23 70 40 
 E-mail: smeoffice@emea.europa.eu 
 
 arrangements laid down by 
atus 
ort to non-EU countries. 
r centrally 
icines for human or veterinary use:
E-mail: certificate@emea.europa.eu 
) 75 23 71 07 
 
Annex 19 EMEA contact p
Pharmacovigilance and product defect reporting 
The constant monitoring of the safety of medicines after autho
important part of the work of the national com
safety reports from within the EU and outsid
uthorities and the EMEA. The EMEA receives 
rning centrally authorised medicinal prod
f medicinal products. 
Sabine BROSCH  
E-mail: pharmac
Fia WESTERHOLM 
Direct telephone: (44-20) 74 18 85
matters: 
Out of hours telephone: (44-7880) 55 06 97 
 
SME Office 
The SME office has been set up within the agency t
The office aims to facilitate communic
ractical or procewho will respond to p
trainin  sessions for SMEs. Any commen
d to the SME office. 
ice contact point: 
 
Certificates of a medicinal product 
The EMEA issues certificates of a medicinal product in conformity with the
the World Health Organization. These certify the marketing authorisation and good manufacturing st
f medicinal products in the EU and are intended for use in support of marketing authorisation o
applications in and exp
For enquiries concerning certificates fo
authorised med Direct telephone: (44-20
Fax: (44-20) 74 18 85 95 
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EMEA PMF/VAMF certificates 
The EMEA issues plasma master file (PMF) and vaccine antigen master file (VAMF) certificates of a 
medicinal product in conformity with the arrangements laid down by Community legislation. The EMEA 
PMF/VAMF certification process is an assessment of the PMF/VAMF application dossier. The certificate 
of compliance is valid throughout the European Community. 
For enquiries concerning PMF certificates: Silvia DOMINGO ROIGÉ 
Direct telephone: (44-20) 74 18 85 52 
Fax: (44-20) 74 18 85 45 
E-mail: PMF@emea.europa.eu 
For enquiries concerning VAMF certificates: Ragini SHIVJI 
Direct telephone: (44-20) 74 18 86 98 
Fax: (44-20) 74 18 85 45 
E-mail: VAMF@emea.europa.eu 
 
Documentation services 
A wide range of documents has now been published by the EMEA, including press releases, general 
information documents, annual reports and work programmes.  
These and other documents are available: 
• on the Internet at: www.emea.europa.eu 
• by e-mail request to: info@emea.europa.eu 
• by fax to: (44-20) 74 18 86 70 
• by writing to: 
EMEA Documentation service 
European Medicines Agency  
7 Westferry Circus 
Canary Wharf 
UK – London E14 4HB 
 
European experts list 
Approximately 4 000 European experts are used by the EMEA in its scientific evaluation work. The list of 
these experts is available for examination on request at the EMEA offices. 
Requests should be sent in writing to the EMEA or by e-mail to: europeanexperts@emea.europa.eu 
 
Integrated quality management 
IQM adviser: Marijke KORTEWEG 
Direct telephone: (44-20) 74 18 85 56 
E-mail: iqmanagement@emea.europa.eu 
 
Press office 
Press officer: Martin HARVEY ALLCHURCH 
Direct telephone: (44-20) 74 18 84 27 
E-mail: press@emea.europa.eu 
 
 
